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Abstract
Toll-like receptor expression and signalling in rat trigeminal neurons:
Consequences for oral infection and mechanisms of orofacial pain.
Martin Paul Helley
The activation of Toll-like receptors (TLRs), expressed by peripheral sensory neurons,
represents an innate surveillance function of sensory neurons with important conse-
quences for neuronal function. Despite recent advances, many properties of neuronal
TLRs remain poorly understood, particularly within the trigeminal system. The main
objectives of this thesis, therefore, were to better characterise the expression and func-
tional consequences of activation of neuronal TLRs in the setting of orofacial pain. A de-
tailed, quantitative description of TLR4, TLR2 and TLR7 expression within neurochemi-
cally-identified sub-populations of trigeminal ganglion (TG) sensory neurons suggests
that these receptors are primarily expressed by nociceptor sub-populations. Acute ac-
tivation of these TLRs, in TG neurons, induced an increased gene expression of the
pro-inflammatory cytokines, TNFα and IL-1β. In an attempt to identify further novel
co-modulators of neuronal TLR activation, the expression of lysophosphatidylcholine
acyltransferase (LPCAT) isoforms, a phospholipid remodelling enzyme that is known
to mediate TLR4 activation in macrophages, are described within TG neurons. Un-
der naïve conditions, LPCAT1 was expressed by a range of sensory neuron sub-types
whereas LPCAT2 expression was confined to non-neuronal cells. Following nerve injury,
the expression of LPCAT2 was induced in a small proportion of TG neurons in vitro
whilst the expression of LPCAT1 remained unaltered. These results may support a role
for LPCAT2 in neuronal TLR activation following a priming stimulus, such as nerve
injury. Taken together, the results presented in this thesis support the hypothesis that
trigeminal nociceptors can directly detect and respond to pathogenic challenge and tissue
damage. The acute activation of TLRs, expressed by trigeminal nociceptors, results in
the up-regulation of pro-inflammatory cytokines which are known to activate and sensi-
tise neurons. The activation of neuronal TLRs may therefore contribute to the increased
neuronal excitability and pain that accompanies common orofacial disorders.
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Introduction
1
2
1. Introduction
1.1 Nociception and acute pain
The current International Association for the Study of Pain (IASP) definition of
pain is "an unpleasant sensory and emotional experience associated with actual or
potential tissue damage, or described in terms of such damage." (Merskey et al.
1994). The sensation of pain itself is a combination of nociception and the affec-
tive input from centres in the brain to add the emotive aspect of the sensation.
Nociception is defined as "the neural process of encoding noxious stimuli" and is
purely a cellular process (Merskey et al. 1994). These noxious stimuli are exclu-
sively detected by specialised high threshold primary sensory neurons termed no-
ciceptors. Under normal circumstances the acute activation of nociceptors causes
a brief, sharp pain that is coupled to the activatory stimulus. Acute physiological
or nociceptive pain is essential for normal development and identifying actual or
potential danger to prevent harm. The requirement for acute physiological pain
is demonstrated in individuals with mutations in the SCN9A gene coding for the
voltage-gated sodium channel NaV 1.7 that cause a condition known as congenital
insensitivity to pain (CIP) (Cox et al. 2006). CIP often leads to repeated injury
such as physical trauma and unintentional self injury during development and can
cause severe disability and death.
1.1.1 The detection of noxious stimuli
Most nociceptors are polymodal in nature meaning that a single cell can be acti-
vated by noxious stimuli of thermal, mechanical and chemical origins. This is due
to the unique arrangement of transduction channels on the peripheral terminals
of nociceptors that initiate the process of action potential generation in response
to specific stimuli (Basbaum et al. 2009). Whereas Aβ fibers, that respond to
innocuous low-threshold stimuli, are myelinated and large in diameter (6-12 µm),
3
1. Introduction
nociceptors have relatively small diameters and are either thinly myelinated or un-
myelinated. Nociceptors themselves can be further divided into several sub-classes
each with distinct anatomical and physiological properties. Aδ fibers are medium
diameter (1-5 µm), thinly myelinated afferents that conduct signals at a velocity
of 5-30 m/s to transmit well localised, fast signals that manifest as an acute, first
pain. These Aδ fibers can be further split into two sub-types - type I or type II Aδ
nociceptors. Type I Aδ nociceptors primarily respond to mechanical and chemical
stimuli and are heavily implicated in pain following tissue injury. Type II Aδ noci-
ceptors have a lower heat threshold than type I Aδ fibers and a higher mechanical
threshold. Therefore type II Aδ fibers primarily respond to noxious heat. The
other major class of nociceptors are small diameter (0.2-1.5 µm) unmyelinated C
fibers that transmit signals at a slower rate of 0.5-2 m/s manifesting as a poorly
localised, second pain. C fibers can be divided into peptidergic, non-peptidergic
and silent sub-types (Snider & McMahon 1998). The peptidergic/non-peptidergic
divide is based on the constitutive expression of particular neuropeptides as well as
further distinctive phenotypic markers. Peptidergic C fibers express Tropomyosin
receptor kinase A (TrkA) that responds to the neurotrophin nerve growth factor
(NGF) whereas non-peptidergic C fibers express c-Ret which responds to glial-
derived neurotrophic factor (GDNF) (see Woolf & Ma 2007). Non-peptidergic C
fibers also express high levels of the purinergic receptor P2X, ligand gated ion
channel, 3 (P2X3) and bind to the plant lectin isolectin B4 (IB4) (see Bradbury
et al. 1998. It is important to note that the above ’classical’ characterisation of
nociceptors primarily relates to those innervating the skin (cutaneous nocicep-
tors). Other types of nociceptors exist, such as those innervating joints or viscera,
that display slight differences to those described above. Many nociceptors inner-
vating joints and visceral tissues are classed as silent nociceptors (Grigg et al.
1986; Feng & Gebhart 2011). Under normal conditions these nociceptors are me-
chanically insensitive however they become responsive to mechanical stimulation
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following a priming stimulus such as inflammation or tissue damage (Michaelis
et al. 1996).
The transformation of thermal, chemical and mechanical stimuli into an electrical
signal is performed by a range of specific transduction channels expressed on the
peripheral terminals of the neuron. Transduction of heat is regulated by a range
of transient receptor potential (TRP) channels. TRP cation channel subfamily
V member 1 (TRPV1) is activated by noxious temperatures above 43 °C as well
as low pH and capsaicin which is a compound found in chilli peppers (Caterina
et al. 1997). TRPV1 was initially suggested to be the main thermal transduc-
tion channels however other TRP channels also act as thermal transducers. For
example, TRPV2 is activated by temperatures over 52 °C whereas TRPV3 and
TRPV4 respond to innocuous temperatures between 25°C and 35 °C (Guler et al.
2002; Leﬄer et al. 2007; Lumpkin & Caterina 2007; Rau et al. 2007). This al-
lows the host to discretely respond to a range of different temperatures. Recently
multiple TRP-independent thermosensation mechanisms have been suggested in-
volving the chlorine channel anoctamin 1 and Orai channels (Xiao et al. 2011; Cho
et al. 2012). The transduction of noxious cold stimuli is not as well understood
when compared to noxious heat. TRP cation channel, subfamily M, member 8
(TRPM8) is widely accepted to mediate the detection of cool stimuli (below 25
°C) and can also respond to temperatures in the noxious range although TRPM8
K.O. animals retain the ability to detect noxious cold (below 15 °C) due to a very
small percentage of neurons that remain responsive to cold (Bautista et al. 2007).
It has been suggested that TRP cation channel, subfamily A, member 1 (TRPA1)
responds to noxious cold as it is responsive to chemical cooling compounds such
as menthol however conflicting results have been reported from two independent
TRPA1 K.O. models (Bautista et al. 2006; Karashima et al. 2009).
A range of TRP channels are also implicated in chemical signal transduction.
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Collectively TRP channels may respond to environment chemicals in foods such
as chilli, garlic, mustard, horseradish, peppermint, oregano, sage and thyme
(Macpherson et al. 2005; Xu et al. 2006). TRPA1, for example, is becoming in-
creasingly prominent in the transduction of chemical signals as it can respond to a
wide range of different compounds found in food such as mustard oil, wasabi and
garlic (Bandell et al. 2004). It can also respond to a broad range of inflammation-
related chemicals (see Bautista et al. 2013) and more recently has been shown to
respond to lipopolysaccharide (LPS), a cell wall component of gram-negative bac-
teria which is a strong trigger of innate immunity (Meseguer et al. 2014). Further,
it is well accepted that nociceptors can detect a range of inflammatory mediators
including bradykinin, histamine, cytokines, chemokines, prostaglandins, protons,
neuropeptides and neurotrophins through the expression of specific surface re-
ceptors (see Hucho & Levine 2007). The detection of these factors can induce
spontaneous firing and action potential generation as well as the activation of
intracellular signalling pathways, including p38 mitogen-activated protein kinase
(MAPK), extracellular signal-regulated kinase (ERK)1/2 and c-Jun N-terminal
kinase (JNK), that are associated with the generation of inflammatory pain (de-
scribed in detail in section 1.2).
Noxious mechanical signal transduction remains a major uncertainty within the
field of sensory neuroscience. Certain candidate receptors have been identified that
are suggested to contribute towards noxious mechanical sensation such as pinching
and pressure (see Hu et al. 2006; Basbaum et al. 2009). These include TRPV2
and TRPV4 which respond to osmotic stretch (Guler et al. 2002; Muraki et al.
2003; Mochizuki et al. 2009), TRPA1 (Kwan et al. 2009) and two pore domain,
subfamily K (KCNK) potassium channels 2, 4 and 18 (Bautista et al. 2008).
Recently, two transmembrane proteins known as Piezo 1 and 2 (alternatively
Fam38A and B) have also been identified as possible candidate mechanical signal
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transducers. Evidence has been presented to suggest a role for these proteins
in innocuous mechanosensation however their involvement in the transduction of
noxious mechanical stimuli is unclear (see Wood & Eijkelkamp 2012).
1.1.2 Central processing of pain
The central branches of primary nociceptive afferents of the somatosensory system
enter the dorsal horn of the spinal cord and terminate mainly in laminae I, II and
V whereas low threshold afferents terminate in deeper laminae III, IV and V (Todd
et al. 2002). More specifically, Aδ fibers terminate in laminae I and V whereas
peptidergic C fibers terminate in lamina I and the dorsal region of lamina II and
non-peptidergic C fibers in lamina II (see Ribeiro-da Silva & De Koninck 2009).
Primary afferents terminating in lamina I synapse directly on to second order
sensory neurons whereas those that terminate in lamina II synapse indirectly to
second order neurons in the deeper laminae IV-VI via small interneurons. In
deeper laminae such as lamina V both noxious and innocuous input can therefore
synapse onto the same second order spinal neuron. These neurons are referred
to as wide dynamic range (WDR) neurons. WDR neurons respond to stimuli in
a graded manner and summate repetitive inputs to induce a short-term state of
sensitivity known as wind-up (Mendell & Wall 1965; Wall & Woolf 1986; Woolf
& Wall 1986).
Noxious stimuli detected by nociceptors that innervate cephalic tissues are pro-
cessed by the trigeminal system. Trigeminal primary sensory neurons, contained
within the trigeminal nerve (cranial nerve V), utilise slightly different ascending
pathways when compared to somatic afferents due to the proximity of the tissue to
the brain. Central branches of trigeminal primary afferents enter the central ner-
vous system (CNS) through the pons region of the mid-brain (Sessle 2000). These
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primary neurons descend along the spinal trigeminal tract to the trigeminal nu-
cleus within the medulla where they synapse with second order neurons. Second
order sensory neurons cross the mid-line and transmit information to somatotopi-
cally appropriate brain regions through various ascending pathways.
The most characterised ascending pathways of nociception are the spinothalamic
and trigemino-thalamic pathways associated with the somatosensory and trigem-
inal systems respectively. Other pathways have also been identified that termi-
nate in various other regions within the CNS such as the spinocervical, spinobul-
bar, spinopontine, spinomesencephalic, spinodiencephalic and spinothelencephalic
pathways (see Lima 2009). As the name suggests, a major target of the spinotha-
lamic and trigemino-thalamic pathways is the thalamus. The ventral posterior
lateral (VPL) nucleus and the ventral posterior medial (VPM) nucleus of the tha-
lamus receive information regarding sharp, fast pain from the somatosensory and
trigeminal systems respectively. Dull, slow pain information from the deep lami-
nae of the spinal cord is received by intralaminar nuclei of the thalamus and the
parabrachial nucleus of the brainstem (Bourgeais et al. 2001). Signals received
by thalamic nuclei are relayed onto various higher processing centres within the
brain, such as the primary somatic sensory cortex, the cingulate gyrus and the
insula allowing the stimulus to be perceived in multiple dimensions (Tracey &
Mantyh 2007). Each area of the body is somatotopically represented by a partic-
ular group of neurons in the primary somatic sensory cortex to allow for accurate
discrimination of sharp, fast pain in terms of location and intensity. Somatotopy
is dependent upon the density of innervation in the peripheral tissue. For exam-
ple the area of the somatic sensory cortex representing individual facial tissues
are much larger than that of the forearm. Neurons of the intralaminar and the
parabrachial nuclei relay information to the cingulate gyrus and insula within
the cerebral cortex via the amygdala, in the case of the parabrachial nucleus,
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to process the poorly localised sensations of slow pain such as dull burning and
deeper aching pain. The cingulate gyrus and insula regions are also partly re-
sponsible for adding emotional features to the perceived sensation (Bushnell et al.
2013). Ascending pathways also terminate in the periacqueductal gray and the
rostral ventral medulla in the brainstem to provide rapid feedback to the local
area where the initial stimulus was detected (Fields & Heinricher 1985; Fields
et al. 2005). These various ascending pathways and processing centres allow pain
to be perceived in multiple dimensions and allows for the generation of a complex
integrated signal to brings about multiple affector responses.
1.2 Chronic pain
Pain associated with an infection or injury is protective in the short term as it
alerts the host to the infection/injury and often limits the use of the affected tissue
to promote the healing process. In certain situations this acute pain does not re-
solve with the infection/injury and transitions into a state of chronic pain which
is maladaptive and significantly impacts on a patients quality of life. Whereas
acute physiological pain reflects the presence, intensity and duration of a stimulus,
chronic pain conditions cause an un-coupling of this stimulus-response relation-
ship so that the pain experienced is no longer a true reflection of the physiological
situation (see Woolf & Salter 2000). Chronic pain is an important co-morbidity
associated with many chronic disorders however it can also persist beyond the res-
olution of an initial insult and present as a pathology in itself. Approximately 20%
of the European population and 30% of the U.S. population suffer with chronic
pain (Breivik et al. 2006; Johannes et al. 2010). The total financial impact of
pain on society is estimated at $560-635 billion in the U.S.A. (Gaskin & Richard
2012). Apart from this financial impact, the physical and emotional toll on pa-
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tients is a significant burden that greatly impacts on quality of life as indicated
by the prevalence of psychological co-morbidities in chronic pain patients (Breivik
et al. 2006). Although much is known about individual mechanisms associated
with chronic pain the key mechanisms that mediate the transition to and mainte-
nance of chronic pain states remain unknown. Importantly, the efficacy of current
chronic pain treatments such as opioid analgesics are often sub-standard and in-
effective in the short term and potentially harmful and addictive in the long term
(Rapp et al. 1995). Therefore the development of safe and effective analgesics tar-
geted towards chronic pain states is a focus of the pain research community.
Chronic pain is often categorised as either inflammatory or neuropathic in origin.
Pain (dolor) is one of the cardinal signs of inflammation and is associated with in-
fection and tissue injury. Inflammatory pain serves a protective purpose during the
period of time where the initial infection is cleared and injured tissue is repaired.
However, in the case of chronic inflammatory pathologies, inflammatory pain per-
sists as long as the inflammatory response does and often increases in intensity.
A characteristic of inflammatory pain is an exaggerated response to noxious stim-
uli, known as hyperalgesia. Hyperalgesia may occur across a range of stimulus
modalities with mechanical and thermal hyperalgesia being commonly associated
with inflammation. Inflammatory pain is initiated by the chemical milieu that
develops at the local site of inflammation. Neuropathic pain is associated with
trauma/disease of the nervous system such as autoimmune disease, diabetes, viral
infection, channelopathies and nerve compression/trauma. This infection/injury
is often accompanied by inflammation however it is a sterile inflammation due
to the absence of an infection in the cause of physical trauma. Acute damage to
nerve fibres causes a large degree of spontaneous firing and ectopic action potential
generation that manifests as a sharp, pin-prick pain. Neuropathic pain involves
various peripheral mechanisms that are also associated with inflammatory pain
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but specifically induces a distinct set of central changes to the circuits of ‘pain
pathways’ to alter long-term neuronal excitability.
1.2.1 Peripheral mechanisms of chronic pain.
Neuronal plasticity is a critical survival mechanism that functions to tailor neu-
ronal function to environmental exposure. Peripheral sensitisation develops as
a result of the transcriptional/translational up-regulation of pro-algesic factors
such as cytokines and the post-translational sensitisation of multiple receptors
and channels in peripheral sensory neurons in response to changes in the local
micro-environment (see Bhave & Gereau 2004). Such a change in the local en-
vironment is commonly associated with inflammation and peripheral nerve in-
jury. A broad range of chemical factors including, but not limited to, tumour
necrosis factors alpha (TNFα), interleukin (IL)-1β, IL-6, chemokines, NGF, his-
tamine, prostaglandin E2 (PGE2), adenosine triphosphate (ATP) and protons are
produced by immune cells, non-neuronal cells within the nerve and damaged tis-
sue which activate specific receptors expressed by sensory neurons (see Hucho &
Levine 2007; Gold & Caterina n.d.). This ligand-receptor interaction is often suffi-
cient to directly activate the nociceptor but can also induce a long lasting periph-
eral sensitisation of nociceptors through various transcriptional, translational and
post-translational changes that affect protein production and receptor/channel ex-
pression (see Moalem & Tracey 2006). Sensitised nociceptors release factors from
their peripheral and central terminals as well as from their soma in the sensory
ganglia that can signal through autocrine and paracrine mechanisms to further
sensitise themselves and surrounding neurons. Multiple specific mechanisms are
involved in peripheral sensitisation which ultimately manifests as hyperalgesia and
a reduced activation threshold of nociceptors. Under normal circumstances the
plasticity associated with peripheral sensitisation would gradually return towards
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the physiological state as the inflammatory response resolves however in the case
of a chronic injury/inflammation peripheral sensitisation often persists. Specific
examples of inflammatory mediator-induced peripheral sensitisation are described
in the following paragraphs (see Fig. 1.1 for summary).
NGF is an inflammation- and tissue damage-associated neurotrophin that is re-
leased from keratinocytes, non-neuronal cells and invading immune cells. NGF
activates its receptor TrkA on peptidergic C fibres and signals through MAPK,
phosphoinositide 3-kinase (PI3K) and phospholipase C (PLC) pathways to induce
rapid changes in channel sensitivity in peripheral terminals in a protein kinase C
(PKC)-dependent manner (Chuang et al. 2001). NGF is also internalised and
is retrogradely transported to the nucleus of the nociceptor in the sensory gan-
glion to induce the transcriptional up-regulation of pro-nociceptive factors such
as calcitonin gene-related peptide (CGRP), substance P (SP), TRP channels and
the voltage gated sodium channel Nav1.8 (Bennett et al. 1998; Bennett 2001; Ji
et al. 2002). CGRP and SP are released by nociceptors both peripherally and
centrally and signal to neurons and non-neuronal cells through paracrine mecha-
nisms. Both are potent vasodilators and promote immune cell infiltration to the
local area (Brain et al. 1985; Bossaller et al. 1992) and can directly activate p38
MAPK, ERK and protein kinase A (PKA) signalling in non-neuronal cells within
sensory ganglia leading to the production of pro-inflammatory mediators (Cady
et al. 2011). Neuropeptides also directly activate and sensitise nociceptors in the
periphery and can also act centrally to modulate spinal mechanisms of nociception
(see Seybold 2009).
Exogenous application of the inflammatory cytokines TNFα and IL-1β are suffi-
cient to cause spontaneous firing of nociceptors (Fukuoka et al. 1994; Sorkin et al.
1997; Schafers et al. 2008) and induce hyperalgesia through direct and indirect
mechanisms (Junger & Sorkin 2000; Ozaktay et al. 2006). Neurons can directly de-
12
1. Introduction
tect these cytokines through the expression of the receptors interleukin-1 receptor
1 (IL1-R1), Tumour necrosis factor receptor (TNFR)1 and TNFR2. Acute acti-
vation of neuronal IL1-R1 and TNFR1 by IL-1β and TNFα, respectively, causes
a rapid facilitation of SP and CGRP release (Fukuoka et al. 1994; Opree & Kress
2000; Hou et al. 2003), induces prostaglandin production (Cunha et al. 1992),
sensitisation of TRPV1-dependent currents (Nicol et al. 1997; Obreja et al. 2002)
and also reduces the slow inactivation of tetrodotoxin (TTX)-resistant NaV chan-
nels in a p38 MAPK-dependent manner to increase neuronal excitability (Jin &
Gereau 2006; Binshtok et al. 2008; Czeschik et al. 2008). TNFR2 is not normally
activated in neurons and only contributes to neuronal sensitisation following nerve
injury (Schafers et al. 2008). Transcriptional changes are mediated by the activa-
tion of signalling pathways such as nuclear factor kappa-light-chain-enhancer of
activated B cells (NF-κB), p38 MAPK, ERK, JNK and PI3K (Pollock et al. 2002;
Wei et al. 2007) whereas post-translational changes are suggested to be mediated
by PKA- and PKC-dependent phosphorylation of receptors/channels (see Uceyler
et al. 2007). TNFα and IL-1β can also indirectly sensitise neurons by activating
positive feedback pathways in immune and non-neuronal cells to further promote
the production of pro-inflammatory and pro-nociceptive mediators. For example,
TNFα and IL-1β promote the production of NGF, prostaglandins, bradykinin and
further promote their own synthesis by immune cells which can directly sensitise
neurons (see Moalem & Tracey 2006). TNFα may also be produced by satellite
cells in the sensory ganglion to promote a more general inflammation in the ner-
vous system (Dubovy et al. 2006). This can then lead to a more diffuse systemic
hyperalgesia as observed with many systemic infections.
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Figure 1.1 – Peripheral sensitisation of nociceptors following inflammation. Inflammation and tissue damage leads to an increased
production of pro-inflammatory mediators such as NGF, ATP, cytokines, bradykinin, histamine and prostaglandins by immune
and non-neuronal cells. Specific receptors are expressed by peripheral nociceptors that recognise many of these factors and
their activation initiates intracellular signalling cascades, including p38 MAPK, ERK1/2, JNK, PI3K and PLC pathways. The
activation of these pathways promotes a transcriptional up-regulation of multiple channels, receptors and neuropeptides as well as
a re-distribution of pre-existing channels to the peripheral terminals. Further, the activation of these receptors is often sufficient to
induce the spontaneous firing of nociceptors. An increase in intracellular calcium leads to the activation of kinases, such as PKA,
PKC and CamKII, and results in the phosphorylation of channels/receptors which ultimately reduces the activation threshold of
the nociceptor. Multiple pro-inflammatory factors, such as CGRP and SP, are also released from the nociceptor terminal which
can further promote the inflammatory response. Collectively these mechanisms reduce the activation threshold and therefore
increase the excitability of the nociceptor both in the short term and long term to initiate/maintain a state of increase pain
sensitivity.
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The transcriptional and translational changes induced by pro-inflammatory me-
diators, described above, can cause the up-regulation of channel/receptor expres-
sion in peripheral neurons. This includes, but is not limited to, TRPV1 (Ji et al.
2002), TRPA1 (Diogenes et al. 2007), P2X3 (Fabbretti et al. 2006) and NaV 1.8
(Jin & Gereau 2006) channels and is often accompanied by a redistribution of
existing channels towards the peripheral terminal of the neuron. The activation
thresholds of these channels can also be reduced by protein kinase-dependent
post-translational modifications which are activated by calcium signalling. Cer-
tain lipid mediators and protons can also directly alter channel/receptor kinetics
by acting as allosteric modulators (Jordt et al. 2000; Cao et al. 2013). The spe-
cific pathways and kinases activated are receptor-specific however MAPK and
PLC signalling and PKA, PKC and Calcium/calmodulin dependent protein ki-
nase II (CamKII) activation are frequently implicated in channel up-regulation
and sensitisation (Bhave et al. 2002; 2003; Jung et al. 2004; Jin & Gereau 2006;
Varga et al. 2006).
Positive feedback mechanisms are key to the development of peripheral sensitisa-
tion and many current treatments for inflammatory pain reflect this. Non-steroidal
anti-inflammatory drugs (NSAIDs) targeting cyclooxygenase-2 (COX-2) and also
TNFα and NGF signalling-specific inhibitors are often prescribed in an attempt to
interrupt this vicious cycle thereby reducing the degree of inflammation and asso-
ciated pain (Sommer et al. 2001; Atzeni et al. 2005; Hefti et al. 2006). However the
modulation of nociceptor plasticity to confer pain hypersensitivity is not limited to
peripheral primary afferents. The activation of sensitised peripheral nociceptors
not only produces changes in cellular processes at the peripheral terminal but also
at the central synapse with second order sensory neurons. Activation of sensitised
peripheral nociceptors can promote the release of neurotransmitters (e.g. gluta-
mate) and neuropeptides (e.g. SP and CGRP) from central terminals to sensitise
16
1. Introduction
second order neurons in the dorsal horn/trigeminal nucleus (see Latremoliere &
Woolf 2009).
1.2.2 Central mechanisms of chronic pain.
The sensitisation of second order spinal neurons is known as central sensitisa-
tion. This confers long term alteration in pain hypersensitivity associated with
inflammatory and neuropathic pain. The onset of central sensitisation alters the
central circuitry responsible for spinal nociception to such an extent that innocu-
ous stimuli that do not normally activate nociceptive pathways are now able to
produce a painful response. This is a phenomenon known as allodynia and, along
with hyperalgesia, are frequently associated with chronic inflammation, peripheral
neuropathies and central pain pathologies (Jensen & Finnerup 2014). It should
be noted that central sensitisation can occur without peripheral involvement in
the case of injuries to the CNS. Although peripheral and central sensitisation
share some common clinical symptoms the molecular mechanisms responsible for
their manifestation are distinct. Whereas peripheral sensitisation is restricted to
neurons innervating the site of inflammation/injury and resolves as inflamma-
tion is cleared, central sensitisation can also induce hypersensitivity referred to
uninjured tissue. Central sensitisation often develops in an activity-dependent
manner but can also persist after the initial insult has disappeared. Multiple
mechanisms contribute to central sensitisation, however the sensitisation of N-
methyl-D-aspartate receptors (NMDAR), activation of glial cells and the loss of
inhibitory connections (disinhibition) are suggested to be most prominent (see
Fig 1.2 for summary). Glutamate is the main neurotransmitter at the excitatory
synapse between primary afferents and second order neurons within the CNS. Un-
der normal conditions glutamate rapidly activates α-amino-3-hydroxy-5-methyl-
4-isoxazolepropionic acid receptor (AMPAR) to initiate the generation of action
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potentials in post-synaptic spinal neurons. Repeated stimulation, associated with
inflammatory and neuropathic pain, causes the activation of an additional gluta-
mate channel called NMDAR which is silent under normal conditions due to the
presence of a Mg2+ block. A summation of excitatory input promotes the increased
release of CGRP and SP by pre-synaptic neurons. This increased neuropeptide
release causes a temporal summation of neuropeptide-induced potentials in the
post-synaptic neuron. This, in turn, promotes the removal of the Mg2+ block
allowing NMDAR to be activated by subsequent glutamate (Mayer et al. 1984).
This activation of NMDAR is critical in the development and maintenance of
central sensitisation (Woolf & Thompson 1991). Once active, depolarisation of
post-synaptic neurons through NMDA receptors causes an increase in intracellular
calcium which can further modulate NMDAR sensitivity to ultimately strengthen
synapses. The activation of calcium-dependent MAPK pathways, PKA, PKC,
PI3K and Src kinase further alters NMDAR properties (see Basbaum et al. 2009;
Latremoliere & Woolf 2009). The phosphorylation of AMPAR and NMDAR by
these kinases causes an increase in channel density at the synaptic membrane and
responsiveness to subsequent glutamate (Carvalho et al. 2000; Lau & Zukin 2007).
The increased excitability of the second order spinal neuron means that it can now
be activated by inputs that are normally sub-threshold (Ma & Woolf 1996).
Just as excitatory synapses are strengthened in chronic pain states, inhibitory
synapses are often lost through a process known as disinhibition (Moore et al.
2002). Inhibitory interneurons within the dorsal horn or trigeminal nucleus release
inhibitory neurotransmitters such as glycine and γ-aminobutyric acid (GABA) to
tightly regulate spinal neuron activation. This regulatory signal is critical in
order to couple the response to a given stimulus. Disinhibition occurs following
peripheral and central neuropathies and has been shown to contribute towards the
development of mechanical allodynia (Keller et al. 2007). It is not known whether
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disinhibition involves the death or reduced activity of regulatory interneurons and
whether the cellular mechanisms induced by nerve injury are primarily active in
the interneuron itself or neighbouring neurons. Regardless of these unanswered
questions, disinhibition remains a key component of central sensitisation.
The communication between glial cells and neurons is also altered in the setting
of chronic inflammation and nerve injury. Astrocytes and microglia normally pro-
vide homeostatic support to neurons however an altered state of communication
can promote glial activation and, in turn, contributes towards neuronal sensiti-
sation (see Watkins et al. 2001). Microglia are tissue resident macrophages in
the CNS and are central to the orchestration of a central neuroinflammatory re-
sponse. Microglia are rapidly activated within the dorsal horn following nerve
injury (Jin et al. 2003) and inflammation (Fu et al. 1999) and begin to release
pro-inflammatory mediators such as TNFα and IL-1β (see Hanisch 2002), the
actions of which have been previously described. Astrocytes are also activated in
chronic pain states although their specific contributions to pain hypersensitivity
are unknown. It is suggested that astrocytes may be more involved with the main-
tenance of chronic pain rather than initiation due to their delayed yet prolonged
activation in persistent pain models (Zhuang et al. 2005). More recent focus has
centred around the involvement of peripheral and central neuroimmune signalling
in chronic pain states. Following the onset of inflammation, the communication
between neurons, non-neuronal and immune cells is altered both in the periph-
eral area of inflammation as well as within the sensory ganglia and the CNS (see
Marchand et al. 2005; Scholz & Woolf 2007). Inflammatory mediators such as cy-
tokines, chemokines, neuropeptides, lipid mediators, ATP and neurotransmitters
all act through specific receptors expressed by neurons, glial cells and immune
cells to promote peripheral and central sensitisation through previously described
mechanisms.
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Figure 1.2 – Mechanisms of central sensitisation. (1) Repeated activation of primary afferents leads to the increased release of
excitatory neurotransmitters such as glutamate, SP and CGRP at the central synapse within the dorsal horn or trigeminal nucleus.
An increase in excitatory post-synaptic potentials promotes the removal of the Mg2+ block and subsequent activation of the
normally silent glutamate receptor NMDAR. Receptor activation results in an increased level of intracellular calcium and activation
of calcium-dependent pathways including MAPKs, PI3K and PLC. These pathways ultimately induce a transcriptional up-
regulation of multiple factors to promote increased neuronal excitability. The activation of kinases also leads to post-translational
modifications to channels/receptors that further promote excitability. (2) The release of neurotransmitters from the pre-synaptic
terminal is sufficient to stimulate and activate glial cells. Activated glial cells produce factors such as pro-inflammatory cytokines,
chemokines, ATP, brain-derived neurotrophic facotr (BDNF) and PGE2 which can act through receptors on the pre- and post-
synaptic terminals to promote an increase in synaptic strength and neuronal excitability. (3) Under normal circumstances,
inhibitory interneurons release GABA and glycine to produce a descending inhibitory tone that regulates the pain response.
Following injury, this descending inhibition can be lost, through a process known as disinhibition, resulting in an increased
excitability of central neurons. Collectively these mechanisms act to induce a long-term sensitisation of central nociceptors so
that the response to noxious stimuli is exaggerated (hyperalgesia) and previously innocuous stimuli are now able to induce a
painful response (allodynia).
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1.3 Orofacial pain
The studies that underpin the understanding of the above peripheral and central
mechanisms of neuronal sensitisation were mainly performed on neurons from
the somatosensory system. When discussing orofacial pain it is important to
consider the potential differences in these mechanisms due to the slight anatomical
and physiological differences between the trigeminal and somatosensory systems
(summarised by Bereiter et al. 2009). Orofacial pain is classified as pain that
localises to an area superior to the neck, anterior to the ears and inferior to the
orbitomeatal line whereas craniofacial pain is a broader term that includes pain
localised to the head, face and neck. According to the American Academy of
Orofacial Pain, the current scope of orofacial pain includes temporomandibular
joint (TMJ) disorders, masticatory musculoskeletal pain, cervical musculoskeletal
pain, neurovascular pain, neuropathic pain, orofacial dystonias, headache and
more systemic disorders that cause poorly localised orofacial pain (see Leeuw
& Klasser 2013). The most common orofacial pain conditions are considered
to be toothache (caries), TMJ disorders (TMDs) and trigeminal neuropathies
however pain can also accompany late-stage periodontal disease. According to
previous epidemiological studies it is estimated that approximately 22% of the
U.S. general population had encountered some form of orofacial pain within 6
months prior to questioning (Hargreaves & Cohen 2010) and 7% of the U.K.
population suffered with chronic orofacial pain of some nature (Aggarwal et al.,
2006). As with any chronic pain condition, chronic orofacial pain patients often
develop psychological co-morbidities and experience a significant reduction in their
quality of life (Korszun 2002).
The current understanding and characterisation of the peripheral and central
mechanisms of orofacial pain is very much dependent on the specific location
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of the primary afferent. For example, primary afferents innervating the facial skin
and tooth pulp are relatively well characterised when compared to those inner-
vating the periodontal tissues. The pulp is densely innervated and is particularly
sensitive to changes in the local environment, possibly due to it being contained
within a thick, protective layer of dentine. Pulp inflammation, as is seen with
carious tooth decay, can promote the peripheral sensitisation of primary afferents
through well characterised mechanisms. Specialist techniques such as microdial-
ysis and pulpal perfusion have been used in past studies to investigate the effects
of multiple factors on pulpal afferents (see Khan & Hargreaves 2010). For exam-
ple, the application of capsaicin to the pulp induces the release of CGRP (Bowles
et al. 2003), SP (Khan & Hargreaves 2010), PGE2 and NGF (Chidiac et al. 2001).
Further, an infiltration and activation of immune cells within the pulp results in
the production of various inflammatory mediators that can activate and sensi-
tise nociceptors (see Jain et al. 2013). A role for various inflammatory mediators
have also been demonstrated in models of deep orofacial pain. For example, in-
creased levels of SP, CGRP, serotonin (5-HT), TNFα, IL-1β and PGE2 have been
identified in the arthritic TMJ and are associated with spontaneous pain, hyper-
algesia and allodynia (see Kopp 2001). The peripheral sensitisation of neurons
innervating the TMJ and lip/whisker pad, in the setting of chronic inflammation,
results in an increased neuronal excitability and reduced threshold of activation.
This has been shown to involve a potentiation of TTX-R sodium currents and
alteration of potassium currents (Takeda et al. 2006; Morgan & Gebhart 2008).
It should be noted however that no change in sodium currents were observed in
TMJ inflammation (Flake & Gold 2005).
Peripheral injury to the trigeminal nerve is associated with increased spontaneous
and mechanically-induced firing as well as an alteration in the expression of var-
ious receptors and channels including TRPV1 (Biggs et al. 2007) and multiple
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NaV channels (Davies et al. 2006) at the injury site. Nerve injury is also sufficient
to induce a range of changes in neuropeptide expression within the injured nerve
(Bird et al. 2003). An increased rate of neuronal activation following injury has
also been demonstrated to be further increased by the presence of the neuropep-
tides SP, CGRP and vasoactive intestinal peptide (VIP) (Loescher et al. 2001;
Robinson et al. 2004). Interestingly some of the mechanisms associated with the
development of pain following trigeminal nerve injury are distinct from those as-
sociated with spinal nerve injury. For example, differences in the time course of
spontaneous firing, neuropeptide expression and degree of sympathetic sprouting
within the sensory ganglion have been reported (see Fried et al. 2001).
The peripheral sensitisation of orofacial primary afferents following inflammation
and nerve injury is also associated with alterations in channel expression (Biggs
et al. 2007), neuropeptide production (Elcock et al. 2001) and intercellular com-
munication within the trigeminal ganglion (TG). This can promote the activation
of satellite cells and subsequent release of pro-inflammatory mediators (Freeman
et al. 2008; Vause & Durham 2009). This is indeed the case in TMD pain where an
increased level of activation of glia and immune cells within the trigeminal ganglion
has been demonstrated (Villa et al. 2010). The production of pro-inflammatory
mediators including IL-1β and SP as well as the activation of PKC within the
trigeminal ganglia can promote the sensitisation of neighbouring neurons through
paracrine mechanisms and can therefore contribute to the spread of orofacial pain
(Safieh-Garabedian et al. 1995; Takeda et al. 2005; Freeman et al. 2008).
In addition to the above peripheral mechanisms, a range of central changes have
been identified in multiple orofacial pain models. The acute activation of central
neurons of the trigeminal system following peripheral exposure to inflammatory
irritants and neuropeptides has been demonstrated by the increased expression of
cFos (Hathaway et al. 1995; Worsley et al. 2007; Bowler et al. 2013). The central
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sensitisation of nociceptors and WDR neurons within the subnucleus oralis and
ventrobasal thalamus following peripheral application of irritants has also been
reported (Kaneko et al. 2005; Zhang et al. 2006; Kawamura et al. 2010). This
central sensitisation also occurs in the case of chronic inflammation and nerve
injury and can last for prolonged periods (Dubner & Ren 2004; Yamazaki et al.
2008; Tsuboi et al. 2011). Various mechanisms have been shown to contribute to
the observed activation and sensitisation of central neurons including NMDAR,
nitric oxide (NO), protein kinase and P2XR signalling (Allen et al. 2011; Sessle
2011). Taking P2XR as a specific example, the application of P2XR agonists to
the tooth pulp and TMJ is sufficient to induce mechanical hyperalgesia, allodynia
and increase peripheral receptive fields (Hu et al. 2002; Chiang et al. 2005) and
these can be blocked by the application of receptor antagonists (Adachi et al.
2010; Watanabe et al. 2010). Alterations is descending regulatory mechanisms
are also altered in chronic orofacial pain. Specifically, TMDs have been associated
with a loss of descending inhibition (disinhibition) as well as an increased level of
descending facilitatory signals (Sarlani et al. 2004; King et al. 2009).
Glial cell activation within trigeminal central structures have also been shown to
play a major role in the development and maintenance of chronic orofacial pain
states. Peripheral inflammation and nerve injury are associated with the increased
activation of microglia and astrocytes (Yeo et al. 2001; Xie et al. 2007; Okada-
Ogawa et al. 2009; Villa et al. 2010). Blocking this activation of microglia and
astrocytes has been shown to partially reduce the development and maintenance
of hyperalgesia and allodynia (Xie et al. 2007; Shimizu et al. 2009; Itoh et al.
2011). A delayed inhibition of astrocyte activity, 7 days after the development
of pulpitis, is also sufficient to reduce central sensitisation and mechanical hy-
peralgesia (Tsuboi et al. 2011). The role of P2X4 and P2X7, expressed by glial
cells within the subnucleus caudalis, has also been demonstrated to mediate the
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increased activity and production of ATP and pro-inflammatory cytokines associ-
ated with the development of central sensitisation (Chiang et al. 2005; Itoh et al.
2011).
Various chronic orofacial pain states therefore share common mechanisms with
those associated with the development of peripheral and central sensitisation in
the somatosensory system. However it is important to note that a number of
pain states also display distinct differences when compared to those of the so-
matosensory system. As mentioned above, previous studies have mainly focussed
on primary afferents innervating the pulp, TMJ, masseter muscles and cutaneous
facial skin. These afferents are therefore relatively well characterised compared to
those innervating other orofacial tissues such as the periodontal tissues. Gingivitis
and periodontitis are prevalent conditions that are associated with inflammation
within periodontal tissues. The presence of an inflammatory response is suffi-
cient to induce a range of peripheral and central changes in neuronal function,
as previously described. However the effect of inflammatory mediators on sen-
sory neurons, specifically innervating periodontal tissues such as the gingiva and
periodontal ligament, for example, have not been investigated.
1.4 Periodontal disease
The microbiome present within the oral cavity is second in complexity only to
the colon. Over 700 prevalent species of commensal microbes have been iden-
tified within the healthy oral flora (Dewhirst et al. 2010; Ge et al. 2013). The
majority of these are bacterial species, however viruses, protozoa, archaea and
fungii are also present (see Wade 2013). The presence of this flora is central to
normal homeostasis within the oral cavity as its mere presence normally prevents
the invasion of and colonisation by pathogenic species, possibly due to the lack of
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available binding sites in the cavity (Vollaard & Clasener 1994). This is reflected
in the aetiology of periodontal disease. This initially establishes as gingivitis with
plaque formation by opportunistic aerobic species and then develops into peri-
odontal disease associated with a more complex plaque composition dominated
by anaerobic species. This gradual formation of a complex pathological plaque is
dependent upon the early opportunistic microbial species which provide binding
sites for more pathogenic microbial species. Whilst many orofacial disorders are
often considered less of a priority when compared to other human disease states,
an association between dysregulation of the oral microbiome and increased risk of
developing systemic disease such as cardiovascular disease, diabetes and rheuma-
toid arthritis has recently been uncovered (Genco & Van Dyke 2010; Lundberg
et al. 2010; Lalla & Papapanou 2011).
Gingivitis is one of the most prevalent bacterial human disease with approxi-
mately 90% of adults affected (see Coventry et al. 2000). Dental plaque formation
begins with the selective adsorption of salivary glycoproteins such as α-amylase,
immunoglobulin (Ig) A, mucin, acidic proline-rich protein and cystatins onto the
tooth surface to form the salivary pellicle (Murray et al. 1992; Ahn et al. 2002).
This pellicle provides binding sites for primary colonising species such as Strepto-
coccus, Actinomyces, Fusobacterium, Treponema and Synergistetes species (Nyvad
& Kilian 1987; Zijnge et al. 2010). Interactions between early colonising species
can produce an environment that promotes the additional recruitment and attach-
ment of other species to the immature plaque (see Kolenbrander et al. 2006).
Early, immature plaque can induce a low grade immune response that produces an
inflammatory exudate contained within the gingival crevicular fluid (GCF). The
GCF also promotes plaque development and the induction of gingivitis (Peters
et al. 2012). Plaque formation in gingivitis is supra-gingival and is relatively easy
to control. Good oral hygiene is normally sufficient to break down the plaque and
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maintain it in an immature state. However, if good oral hygiene is not practised, in
susceptible individuals the plaque is allowed to develop; numbers of Gram-negative
anaerobic species increase in proportion and produce virulence factors that result
in tissue damage and an the activation of a local immune response.
The continued presence of a complex plaque causes a chronic low grade inflamma-
tion and subsequent damage to local tissue. Interestingly it is the host response
that primarily causes the irreversible tissue damage (Eskan et al. 2012). The gin-
gival pocket, the space between the gingiva and the tooth structures, increases in
depth and the plaque is therefore allowed to migrate to sub-gingival structures.
This environment is highly supportive of anaerobic species which dominate sub-
gingival plaques from periodontitis patients (Ximenez-Fyvie et al. 2000). Contin-
ued protease production by plaque bacteria causes a gradual progression of tissue
damage from the gingiva to the supporting tooth structures such as the periodon-
tal ligament and the alveolar bone. Resorption of the alveolar bone causes the
tooth to loosen and become increasingly mobile until it is eventually lost (see
Pihlstrom et al. 2005).
Periodontitis associated with dental plaque can be classified as either chronic or
aggressive with the latter being associated with a more rapid rate of progression,
increased severity and earlier onset (see Armitage 1999). Both forms of the dis-
ease can be further categorised as generalised or localised with the latter being
specific to the tissues surrounding individual teeth rather than the whole mouth
or a large proportion of the gingiva. Chronic periodontal disease presents with
inflamed gums that are tender and often bleed, receding gums, loose and sensitive
teeth, halitosis and also painful mastication. Systemic manifestations may also
accompany both forms of the disease that are mainly related to mental well-being
(Page et al. 1983). These symptoms also present with aggressive forms of the
disease however severity and disease progression are greatly elevated. The chronic
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disease is most prevalent in middle aged adults whereas the aggressive form is
often seen in juveniles (Armitage 1999). Both chronic and aggressive periodonti-
tis present with phases of active tissue damage and periods of remission that can
last for years. Factors that mediate this switch to and from an active state are
currently unknown. During remission periods, symptoms of the disease do not
present even though deep gingival pockets are maintained. Currently the disease
is managed by improved dental hygiene including the use of specific toothpaste
or mouthwash, mechanical scaling of plaque, the use of anti-bacterial or anti-
inflammatory medication and surgical intervention to promote bone regeneration
however ultimately it is an irreversible condition that will lead to tooth loss (see
Roshna & Nandakumar 2012).
A recent oral microbiome sequencing study showed that the levels of approxi-
mately 200 species were significantly altered in sub-gingival plaques (Ge et al.
2013). Early studies into the microbiome associated with chronic periodontitis
grouped various bacterial species into different colour-assigned groups (Socransky
et al. 1998). These were characterised based on the similarity between species
and also their correlation with clinical symptoms of the disease. Three bacterial
species, Porphyromonas gingivalis, Treponema denticola and Tannerella forsythia,
are identified as key pathogenic species associated with the disease and are fre-
quently identified in the majority of chronic periodontitis patients. These are
classified as ‘red complex’ bacteria and are thought to play a key orchestrating
role in tissue destruction and disease progression due to their correlation with in-
creased bleeding upon probing (Socransky et al. 1998). This is primarily elicited
by their ability to activate host responses but also through multiple virulence
factors including proteinases, cell wall expressed polysaccharides, hemin-binding
proteins and fimbriae (Holt & Ebersole 2005). Other secondary colonising species
are primarily located within the green and orange complexes whereas primary
29
1. Introduction
colonisers are mainly located in the yellow and purple complexes. Aggressive pe-
riodontitis however is primarily associated with the overwhelming presence of Ag-
gregatibacter actinomycetemcomitans, an invasive Gram-negative facultative rod
as well as Porphyromonas gingivalis (Zambon et al. 1988; Schacher et al. 2007).
Current theories regarding the development of periodontal disease centre around
the ‘keystone pathogen’ theory (Hajishengallis et al. 2012). It is suggested that P.
gingivalis triggers a dysbiotic relationship between the host and the oral flora that
allows the plaque to develop and it is this overall shift in microbial activity that
promotes the pathology associated with the disease. This theory is supported by
the fact that the presence of P. gingivalis alone is not sufficient to cause periodon-
titis in a germ-free mouse model (Hajishengallis et al. 2011).
The change in composition of the oral flora associated with periodontitis is suffi-
cient to activate a host immune response. The activation of macrophages and neu-
trophils promote bacterial clearance through the production of cytokines, phago-
cytosis and oxidative killing mechanisms (see Cekici et al. 2014). The production
of cytokines promotes blood vessel dilation, increased permeability and the sub-
sequent infiltration of immune cells into the local tissues. It is this inflammatory
response that causes the majority of host tissue damage that is observed in chronic
periodontitis (see Taubman et al. 2005). The immune response generated in peri-
odontitis is often insufficient for full clearance of the infection. Therefore, in sus-
ceptible individuals, a chronic, relapsing and remitting pathology can develop that
is associated with a progressive destruction of periodontal tissues. This is, in part,
due to the multiple host evasion mechanisms employed by pathogenic bacterial
species such as P. gingivalis to promote its survival and the subsequent develop-
ment of a mature plaque (see Hajishengallis & Lamont 2014 for a detailed review).
The increased production of pro-inflammatory mediators, including TNFα, IL-1β,
IL-6 and PGE2 (see Yucel-Lindberg & Bage 2013 for detailed review), in chronic
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periodontitis patients would predict that a peripheral sensitisation of sensory neu-
rons innervating periodontal tissue may also develop. These inflammatory medi-
ators are known to contribute towards the peripheral and central sensitisation of
sensory neurons however this has not been demonstrated within the setting of
periodontitis.
1.5 Toll-like receptors
As previously mentioned, the presence of a mature plaque is sufficient to activate
the host immune response via multiple innate receptor families. One major class of
receptors that are implicated in the pathogenesis of periodontitis are the Toll-like
receptors (TLRs). TLRs are categorised as a class of pattern recognition receptors
(PRRs) that detect specific pathogen-associated (PAMPs) and damage-associated
molecular patterns (DAMPs) released by damaged/stressed host cells to mediate
the activation of an innate immune response (Takeda & Akira 2005). The Toll
protein and its signalling pathway were first identified in Drosophila melanogaster
and were demonstrated to be involved in the immune response to fungal infection
(Lemaitre et al. 1996). A mammalian homolog of the Toll receptor, subsequently
named the Toll-like Receptor, was discovered (Medzhitov et al. 1997) and to date
13 TLRs have been identified, 11 of which are confirmed to be present in humans
(Bowie & O’Neill 2000; Akira et al. 2006). TLRs are expressed on various innate
and adaptive immune cells, such as macrophages, dendritic cells, regulatory T
cells, B cells, mast cells, natural killer cells, neutrophils, basophils and utilise
receptor dimerisation to obtain pathogen specificity allowing a tailored, pathogen-
specific response (Takeda & Akira 2005). Activation of TLRs typically results in
the production of multiple pro-inflammatory mediators, such as cytokines and
chemokines, which exert a wide range of functions to orchestrate the innate and
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adaptive immune response.
1.5.1 Ligand binding
TLRs are type I transmembrane receptors that contain an extracellular leucine-
rich-repeat (LRR) domain for ligand binding. As previously mentioned each TLR
recognises a specific set of PAMPs and DAMPs (Table 1.1). This receptor speci-
ficity is essential in order to ascertain what type of pathogen has invaded the host
system and to generate an efficient innate response to facilitate clearance of the
infection. If a host cell has become damaged through infection or injury its con-
tents can spill out into the extracellular matrix and elicit effects on neighbouring
cells many of which can promote further tissue damage. It is therefore impor-
tant to alert the immune system to these damaged cells and one mechanism by
which this can be achieved is through TLR activation. The activation of TLRs
by endogenous ligands has a different functional outcome when compared to ac-
tivation by exogenous ligands. Activation by exogenous ligands primarily drives
a pro-inflammatory response whereas endogenous ligands do not induce such a
strong response and there is more emphasis on tissue repair (Miyake 2007). The
discovery that TLRs can sense tissue damage is a significant development as it
highlights a role for TLRs in pathophysiological states other than infection (Okun
et al. 2011).
The sub-cellular location of TLRs reflect the location at which they will encounter
their specific ligands; TLR1, 2, 4 ,5 ,6 and 10 are located on the cell membrane
whilst TLR3, 7, 8 and 9 are present on the intracellular endosomal membranes as
they recognise nucleic acids of both bacterial, viral and host origin (see Kawai &
Akira 2007b). TLR activation upon ligand recognition relies on receptor dimerisa-
tion. TLR3, 4, 5, 7, 8 and 9 form homodimers whereas TLR2 forms a heterodimer
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Table 1.1. Summary of TLR ligands (* denotes TLRs identified in mice only.)
TLR Exogenous ligand Endogenous
ligand
References
TLR2 Peptidoglycan HMGB1 Schwandner et al. 1999
Yu et al. 2006
Phospholipomannan HSP70 Asea et al. 2002
Vabulas et al. 2002
tGPI-mucin Hyaluronic acid Coelho et al. 2002
Shimada et al. 2008
Haemagglutinin α-synuclein Bieback et al. 2002
Kim et al. 2013
Porins Massari et al. 2002
Lipoarabinomannan Means et al. 1999
Glucuronoxylomannan Yauch et al. 2004
Atypical lipopolysaccharide Darveau et al. 2004
TLR2/1 Triacyl lipoproteins Omueti et al. 2005
TLR2/6 Diacyl lipoprotein Omueti et al. 2005
lipoteichoic acid Kang et al. 2009
zymosan Gantner et al. 2003
TLR3 dsRNA dsRNA Alexopoulou et al. 2001
TLR4 Lipopolysaccharide HSP60 Poltorak et al. 1998
Ohashi et al. 2000
Fusion protein (RSV) HSP70 Kurt-Jones et al. 2000
Asea et al. 2002
Envelope protein (MMV) Fibrinogen Rassa et al. 2002
Smiley et al. 2001
Glucuronoxylomannan HMGB1 Yauch et al. 2004
Yu et al. 2006
Glycosylinositolphospholipids Fibronectin Okamura et al. 2001
Debierre-Grockiego et al.
2007
Environmental Nickel Hyaluronic acid Schmidt et al. 2010
Termeer et al. 2002
Heparin
sulphate
Johnson et al. 2002
TLR5 Flagellin Hayashi et al. 2001
TLR7 ssRNA microRNAs Diebold et al. 2004
Fabbri et al. 2012
TLR8 ssRNA microRNAs Heil et al. 2004
Fabbri et al. 2012
TLR9 CpG-containing DNA Hemmi et al. 2000
Haemozoin Coban et al. 2010
Table continued on next page.
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continued from previous page.
TLR10 Listeria Regan et al. 2013
Influenza A Lee et al. 2014
TLR11* Uropathogenic bacteria Zhang et al. 2004
Profilin-like protein Yarovinsky et al. 2005
TLR12* Profilin-like protein Koblansky et al. 2013
TLR13* rRNA Oldenburg et al. 2012
End of table.
with either TLR1 or 6 to distinguish between triacyl and diacyl lipoproteins, re-
spectively (see Kawasaki & Kawai 2014). It should be noted however that previous
studies have also demonstrated that TLR4 may form a heterodimer with TLR1,
2 and 5 (Spitzer et al. 2002; Mizel et al. 2003; Wang et al. 2014). TLR10 is
thought to form a heterodimer with TLR1 or 2 although the specific ligands re-
main unknown (Akira et al. 2006). Certain TLRs also rely on co-receptors for
ligand recognition. For example TLR4 and TLR2 associate with the co-receptor
CD14 and TLR4 also recruits myeloid differentiation factor (MD)- 2 in order to
fully activate the receptor (Wright et al. 1990).
Certain TLRs are known to translocate to specific membrane micro-domains
known as lipid rafts following activation (Triantafilou et al. 2002). Intracellular
signalling pathways also cluster at these domains and can be activated follow-
ing receptor translocation. The exact mechanisms that mediate the translocation
of TLRs to lipid raft domains are poorly understood however it has previously
been suggested that a lysophospholipid recycling enzyme, known as lysophos-
phatidylcholine acyltransferase (LPCAT), may be involved. LPCATs are known
to regulate the lysophospholipid/phospholipid ratio of the cell membrane and can
therefore alter certain membrane properties and functions such as fluidity and
associated lateral movement of membrane proteins (Drecktrah et al. 2003). In-
deed, Jackson et al. 2008 displayed how LPCAT inhibition in innate immune cells
prevented the translocation of TLR4 into lipid raft domains and subsequently
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reduced the inflammatory response in response to LPS. A recent study has now
shown that it is specifically the isoform LPCAT2, and not LPCAT1, that medi-
ates the activation of TLR4 and TLR2 through a physical interaction with the
receptors (Abate & Jackson 2015).
1.5.2 TLR signalling
TLRs contain an intracellular signalling domain termed the Toll/IL-1R homology
(TIR) domain which undergoes conformational changes after ligand binding to
promote the recruitment of adapter proteins (Bowie & O’Neill 2000). The adapter
proteins which are recruited differ between each TLR dimer but include myeloid
differentiation primary response gene 88 (MyD88), MyD88 adapter-like (MAL),
TIR-domain-containing adapter protein (TIRAP), Toll-receptor-associated acti-
vator of interferon (TRIF), TRIF-related adapter molecule (TRAM) and sterile
α and TIR motif-containing protein (SARM) (Akira & Takeda 2004). The differ-
ent combination of adapter molecules determines which transcription factors are
activated and what type of response is generated. There are two classic signalling
pathways that can be activated following TLR activation; the MyD88-dependent
and –independent (TRIF-dependent) pathways (Fig. 1.3). All TLRs, except
TLR3 which exclusively signals through the TRIF-dependent pathway, utilise the
MyD88 adapter molecule. TLR4 is unique as it is capable of signalling through
both pathways (Kawai & Akira 2007b). TLR2 and 4 are reliant on an additional
adaptor protein, TIRAP, in order to recruit MyD88 (Horng et al. 2001) and TLR4
also requires TRAM to activate the TRIF-dependent pathway (Kawai & Akira
2007b). The MyD88-dependent pathway primarily results in the rapid activation
of NF-κB, a transcription factor that governs the expression of pro-inflammatory
genes, whereas the TRIF-dependent pathway activates the transcription factor in-
terferon regulatory factor (IRF) 3 responsible for the induction of type I interferon
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(IFN) genes to produce an anti-viral response (Kaisho & Akira 2006).
1.5.2.1 MyD88-dependent pathway
The binding of MyD88 to the TIR domain of the TLR induces conformational
changes to promote the recruitment of interleukin-1 receptor-associated kinase
(IRAK) family members such as IRAK1, IRAK2 and IRAK4 through death do-
main interactions. Phosphorylation causes the IRAKs to dissociate and interact
with TNF receptor associated factor (TRAF) 6 which, in turn, forms a complex
with ubiquitin-conjugating protein (Ubc) 13 and TGF-β activated kinase (TAK)
1 (Chen 2005). This complex is responsible for the activation of both the MAPK
pathway and the IκB kinase (IKK) complex. The activation of the MAPK path-
way leads to the activation of the transcription factor activator protein 1 (AP-1),
composed of a group of proteins belonging to the c-Fos, c-Jun, activating tran-
scription factor (ATF) and Jun dimerisation protein (JDP) families, which con-
trols cellular processes such as apoptosis, differentiation and proliferation (Ame-
yar et al. 2003) as well as the production of pro-inflammatory mediators. The
activated IKK complex, consisting of subunits IKKα, IKKβ and IKKγ/NEMO,
induces the degradation of IκB via phosphorylation subsequently allowing for the
nuclear translocation of NF-κB to drive the production of inflammatory cytokines
such as TNFα, IL-1β and IL-6 (see Kawai & Akira 2007a).
1.5.2.2 TRIF-dependent pathway
The discovery that MyD88-deficient mice display normal activation of IRF3 and
IFNβ induction following exposure to TLR3 and TLR4 ligands led to the identi-
fication of TRIF and the MyD88-independent pathway (Yamamoto et al. 2002).
TRIF is recruited to the TIR domain of TLR3 and TLR4, via TRAM in the
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Figure 1.3. Summary of TLR signalling pathways. TLR4, 5, 11 and 12 as well as TLR2/1
and TLR2/6 heterodimers are expressed at the cell membrane whereas TLR3, 7, 8 and 9 are
expressed intracellularly on the endosomal membrane. TLR4 is unique in the fact that it can
also localise to endosomal membranes. Following ligand-induced dimerisation and activation
of receptors, the TIR domains of the receptors engage a range of adapter proteins including
MyD88, TRIF, TRAM and TIRAP. Association of these adapter proteins to the TIR domains
allows the activation of downstream signalling cascades through a series of interactions between
IRAK and TRAF molecules. These ultimately lead to the activation of transcription factors
such as NF-κB, IRFs and the AP-1 group (c-Fos, c-Jun, ATF). The majority of TLRs, with
the exception of TLR3, signal through the MyD88-dependent pathway which primarily results
in the production of pro-inflammatory cytokines. TLR3, and TLR4, signal through the TRIF-
dependent pathway which induces the production of an anti-viral response through type I IFN
production. It should be noted that TRIF-dependent signalling is able to induce a delayed
production of pro-inflammatory cytokines through interactions involving TRAF6 and RIP1.
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case of TLR4, and forms a complex with non-canonical IKKι/IKK and TANK-
binding kinase 1 (TBK1). This complex phosphorylates IRF3 allowing it to form
a dimer which drives the expression of type I IFN genes and the subsequent anti-
viral response after nuclear translocation (Sharma et al. 2003; Fitzgerald et al.
2003).
Interestingly, MyD88 deficient mice remain able to activate NF-κB albeit with
delayed kinetics suggesting that the TRIF-dependent pathway is also capable of
activating NF-κB (Kawai et al. 1999). The mechanism by which TRIF goes on
to activate IRF3 or NF-κB is governed by which end of the molecule is phospho-
rylated. Both the N-terminal and C-terminal portions of the molecule activate
the NF-κB promoter but only the N-terminal activates the IRF3 promoter (Ya-
mamoto et al. 2002). The N-terminal portion of TRIF interacts with TRAF6
(Sato et al. 2003), which is involved in NF-κB activation. The C-terminal portion
of TRIF associates with receptor-interacting serine-threonine kinase 1 (RIP1), a
deficiency in which causes impaired NF-κB activation in response to TLR3 ligands
(Meylan et al. 2004). Therefore both TRAF6 and RIP1 are responsible for the
TRIF-dependent activation of NF-κB through interactions on the N-terminal and
C-terminal portion of TRIF, respectively.
1.5.2.3 Negative regulation
TLR signalling forms an integral part of the inflammatory response by driving the
production of many pro-inflammatory mediators. The uncontrolled production of
these mediators can cause serious tissue damage and contribute towards chronic
pathophysiologies such as rheumatoid arthritis (Feldmann et al. 2001). Therefore
it is essential to tightly control the degree of TLR signalling and subsequent in-
flammatory response through multiple mechanisms of negative regulation. This in-
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cludes intracellular inhibitors that target specific tiers of TLR signalling pathways
from TIR domain interactions to transcription factor activity (see Kawai & Akira
2007b). The activation of and communication between these regulators is key
to coordinating a controlled pathogen-specific innate response. It should also be
noted that each individual inflammatory and pain-associated molecule, produced
downstream from TLR activation, possesses distinct positive and negative feed-
back mechanisms which act to further complicate the scene. The combination of
positive and negative feedback signals for all factors involved ultimately converge
to generate either a pro-inflammatory/pro-nociceptive or anti-inflammatory/anti-
nociceptive response.
1.6 Toll-like receptor signalling in chronic pain
Prolonged inflammation at various sites within the nervous system contributes to
the pathology associated with many neurological disorders including chronic pain
(see Nicotra et al. 2012), neurodegeneration (Meraz-Rios et al. 2013), stroke (Jin
et al. 2010), spinal cord injury and neuropsychiatric illness (Najjar et al. 2013). As
TLRs generate a pro-inflammatory response in immune cells it was hypothesised
that they may also mediate this inflammatory damage within the nervous system.
Indeed, multiple lines of evidence have shown that TLR activation contributes to
inflammation-induced damage associated with neurodegeneration (Walter et al.
2007; Richard et al. 2008), autoimmunity (see Fischer & Ehlers 2008) and stroke
(Lehnardt et al. 2007). TLRs also play a key role in the induction and mainte-
nance of chronic pain states (see Nicotra et al. 2012). The link between TLRs
and chronic pain was first shown in a series of association studies investigating
TLR4 expression levels in models of neuropathic and inflammatory pain. TLR4
messenger ribonucleic acid (mRNA) is elevated in the spinal cord, brainstem and
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forebrain following nerve transection (Raghavendra et al. 2003) and the peripheral
application of CFA (Raghavendra et al. 2004). As well as TLR4, CD14 mRNA
is up-regulated in the spinal cord following nerve transection and this induction
follows a time course that correlates with the development of allodynia, peak-
ing at 14 days post-injury (DeLeo et al. 2004). TLR4 knock out (K.O.) mice,
CD14 K.O. mice and rats that receive a TLR4 antisense oligodeoxynucleotide
display a reduced behavioural sensitivity and decreased expression of spinal mi-
croglial markers and cytokines following L5 nerve transection (Tanga et al. 2005;
Cao et al. 2009). Two similar studies also used small interfering RNA (siRNA)
against TLR4 to demonstrate its involvement in the development of cancer pain
and chronic constriction injury-induced pain (Lan et al. 2010; Wu et al. 2010).
Pharmacological blocking of TLR4 is also able to prevent and reverse preclini-
cal neuropathic pain models (Bettoni et al. 2008; Hutchinson et al. 2007; 2008;
2010).
These findings have been extended to demonstrate the involvement of other TLRs
in chronic pain. TLR2 mRNA is up-regulated following nerve injury (Shi et al.
2011) and TLR2 activation is shown to partially mediate glial cell activation and
production of inflammatory cytokines following nerve injury. TLR2 K.O. mice
display reduced capacity to develop mechanical allodynia and thermal hyperalge-
sia (Kim et al. 2007; Shi et al. 2011). TLR3 has also been shown to activate spinal
glia and promote the development of tactile allodynia following peripheral nerve
damage (Obata et al. 2008). Although the involvement of TLR7 and TLR9 in
chronic pain have not been investigated using animal models their activation on
microglia and astrocytes causes an increase in multiple pro-inflammatory media-
tors that are known to affect neuronal excitability (Bowman et al. 2003; Butchi
et al. 2010; El-Hage et al. 2011). Interestingly, peripheral blood mononuclear
cells from chronic pain patients display increased responsiveness to TLR7 ligand
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stimulation, as well as TLR2 and TLR4 (Kwok et al. 2012).
The focus for these prior studies was the involvement of TLRs expressed by im-
mune and glial cells. Indeed, the activation of TLRs expressed by microglia and
astrocytes induces the production of multiple pro-inflammatory mediators (Car-
pentier et al. 2005; Jack et al. 2005; El-Hage et al. 2011), many of which are known
to affect neuronal excitability. However, there is now a growing body of evidence
to suggest that TLRs are also expressed by neurons in multiple locations through-
out the peripheral nervous system (PNS) and CNS. This implies that pathogens
could activate or modulate the nociceptive pathway by a far more direct mecha-
nism. It is suggested, therefore, that TLRs can have both a direct and indirect
actions on nociceptive neurons to alter pain processing pathways although the
specific mechanisms are largely unknown.
1.6.1 TLR expression in the nervous system
Various past studies have characterised the expression of TLRs in the different cell
types of the CNS and PNS and it has become clear that each cell type displays a
unique assortment of TLRs that display differing levels of expression. Microglia
express a full compliment of TLRs (Bsibsi et al. 2002; Olson & Miller 2012; Jack
et al. 2005). This is not surprising given the resident tissue macrophage activity
of microglia. Comparatively, the expression of TLRs in astrocytes and oligoden-
drocytes is more restricted than that of microglia. The most prominent TLR
expressed by astrocytes is TLR3 whereas TLR1-9 and 11 have also been detected,
although there is some variation between studies (Bsibsi et al. 2002; Bowman
et al. 2003; Farina et al. 2005; Jack et al. 2005; Mishra et al. 2006). Activation
of TLRs in astrocytes is shown to mediate the production of pro-inflammatory
and neuroprotective mediators (Bsibsi et al. 2006; Kim et al. 2008). Oligodendro-
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cytes primarily express TLR2 and TLR3 and the activation of these mediates cell
survival (Bsibsi et al. 2012).
Within the PNS, Schwann cells primarily express TLR2, 3 and 4 (Oliveira et al.
2003; Lee et al. 2007; Cheng et al. 2007; Goethals et al. 2010) however low level
mRNA expression of all other TLRs (from 1-9) has recently been demonstrated
(Goethals et al. 2010). Studies concerning satellite glial cells within peripheral
ganglia however are distinctly lacking. Recently it has been shown that satellite
cells express TLR2 (Kim et al. 2011) and TLR4 (Tse et al. 2014b; Wu et al.
2015) under certain circumstances and the activation of TLR4 by paclitaxel in-
duces TNFα production (Wu et al. 2015). The expression of TLRs in PNS res-
ident macrophages has not been studied although it is likely that they would
express a full complement of TLRs given their importance in the innate immune
response.
Prehaud et al., 2005 were the first to demonstrate TLR expression in CNS neurons
by showing the human cell line NT2-N expressed TLR3 and activation resulted in
the induction of an anti-viral response (Lafon et al. 2006). Cortical neurons have
since been shown to express TLR2, 3, 4 and 8 (Ma et al. 2006; Cameron et al.
2007; Tang et al. 2007; 2013). TLR1-9 mRNA is also expressed in hippocampal
neurons, with TLR4 displaying the greatest level of expression (Hu et al. 2013),
and TLR4 activation induces an inflammatory response (Hu et al. 2013; Zhao
et al. 2014).
Primary sensory neurons are perhaps the most characterised cell type within the
PNS with respect to TLR expression. Two previous studies have utilised real-
time PCR to detect the expression of a broad range of TLRs in sensory neurons,
with varying results. Goethals et al., 2010 report that embryonic murine dorsal
root ganglion (DRG) sensory neurons express TLR2-6 and 8 mRNA with TLR3-
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5 displaying the highest levels of expression. Ochoa-Cortes et al., 2010 however
detect TLR1-9 mRNA, with TLR1 and 4-6 displaying relatively high levels of
expression, in murine colonic DRG neurons. The expression of TLR4 has been
demonstrated in TG (Wadachi & Hargreaves 2006; Ferraz et al. 2011; Diogenes
et al. 2011; Vindis et al. 2014; Lin et al. 2015) and DRG neurons (Acosta &
Davies 2008; Goethals et al. 2010; Due et al. 2012; Tse et al. 2014a; 2014b). More
specifically, TLR4 co-localises with markers of peptidergic and non-peptidergic
populations within the rat DRG (Due et al. 2012) and the rat and human TG
(Wadachi & Hargreaves 2006; Diogenes et al. 2011; Ferraz et al. 2011; Lin et al.
2015). TLR4 expression has also been identified in the peripheral terminals of
human TG sensory neurons innervating the tooth pulp (Wadachi & Hargreaves
2006; Ferraz et al. 2011; Lin et al. 2015) and in various locations of the enteric
nervous system (Barajon et al. 2009). Information regarding the expression of
other cell surface TLRs on sensory neurons is limited. Human and mouse DRG
neurons have also been shown to express TLR3, 7 and 9 (Qi et al. 2011). TLR3 and
TLR7 co-localise with TRPV1 and gastrin-related peptide (GRP) populations, as
well as TRPA1 for TLR7 only (Liu et al. 2010; Liu et al. 2012; Qi et al. 2011;
Park et al. 2014). TLR3 and 7 are also expressed in neurons of the enteric nervous
system (Barajon et al. 2009). Interestingly, a recent study has demonstrated
that TLR5 is expressed by sensory neurons in the DRG (Xu et al. 2015). This
expression occurs mainly in large diameter neurons that express neurofilament 200
kDa heavy molecular weight subunit (NF200) thus highlighting a need for more
detailed characterisation of previously identified neuronal TLRs. Although mRNA
expression of TLR1, 2, 6 and 8 has been reported (Goethals et al. 2010; Ochoa-
Cortes et al. 2010) no subsequent study has identified protein expression.
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1.6.2 TLR signalling in neurons
Whilst microglia (Jung et al. 2005) and astrocytes (Krasowska-Zoladek et al. 2007;
Gorina et al. 2011) signal through both the MyD88-dependent and -independent
pathways, the pathways activated downstream from neuronal TLR activation are
largely unknown. A role for MyD88 signalling in CNS neuronal TLR signalling has
only been demonstrated following TLR7 activation (Liu et al. 2013). Similarly
a role for TRIF-dependent signalling has not been directly proven although it
is suggested given that the neuronal cell line NT2-N produced IFNβ following
TLR3 activation (Prehaud et al. 2005; Lafon et al. 2006). The signalling pathways
implicated downstream from neuronal TLR activation within the CNS seem to be
dependent on the nature of the activatory stimulus and the specific type of neuron.
For example whilst hippocampal neurons utilise NFκB signalling following TLR4
activation to generate a pro-inflammatory response (Hu et al. 2013; Zhao et al.
2014) the activation of TLRs in cortical neurons, following oxygen deprivation
and ischemic injury, mediates cell death independently of NFκB (Ma et al. 2006;
Cameron et al. 2007; Tang et al. 2007; Leow-Dyke et al. 2012; Tang et al. 2013).
Therefore it is suggested that cortical neurons may utilise non-canonical pathways
following TLR activation.
The understanding of TLR-associated intracellular pathways activated in primary
sensory neurons is limited. Although the presence of MyD88 has been identified
in peptidergic DRG neurons (Ochoa-Cortes et al. 2010; Li et al. 2014) and it is
known to play an instrumental role in IL-1R signalling (Davis et al. 2006), only
one previous study has directly demonstrated that the MyD88-dependent path-
way is activated following TLR activation. Following LPS-binding to TLR4 a
rapid activation of NFκB, as well as ERK1/2 and p38 MAPK, drives the tran-
scriptional up-regulation of multiple pro-inflammatory factors (Tse et al. 2014a).
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The presence of the TRIF has also been identified in both small, peptidergic and
non-peptidergic DRG neurons (Li et al. 2014) although the functionality of the
TRIF-dependent pathway has not yet been demonstrated and, following TLR4
activation, no IFNβ production is observed (Tse et al. 2014a). The intracellular
signalling pathways utilised by other neuronal TLRs have not been investigated
although a functional interaction between TLR7 and TRPA1, independent from
MyD88, MAPK and protein kinase signalling, has been demonstrated suggesting
that non-canonical pathways may also be implicated in peripheral sensory neurons
(Park et al. 2014). It is also suggested that intracellular signalling may not always
be required for neuronal TLRs to affect physiological processes as direct activation
of sensory neurons has been identified following TLR3, 4 and 7 activation (Due
et al. 2012; Liu et al. 2012; Park et al. 2014).
1.6.3 Biological roles of neuronal TLRs
Given the primary role of TLRs in immune cells there is also a probability that
neuronal TLRs may be at least partly responsible for the direct detection of infec-
tion/injury within the nervous system. Indeed, the direct activation of neuronal
TLRs within the CNS have been implicated in the induction of an inflammatory
response, neuronal survival and also neuronal development/growth. For example,
the activation of TLR4 in cortical and hippocampal neurons induces the tran-
scriptional upregulation of pro-inflammatory mediators such as TNFα, IL-1β,
IL-6, regulated on activation, normal T cell expressed and secreted (RANTES)
and chemokine CXC motif ligand (CXCL) 1 (Hu et al. 2013; Leow-Dyke et al.
2012; Zhao et al. 2014). In addition, ischemic injury upregulates the expression
of TLR2, 4 and 8 and the activation of these TLRs promotes apoptosis (Tang
et al. 2007; 2013). A range of endogenous molecules are known to activate these
receptors and it is thought that some of these may mediate the observed neuronal
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cell death following energy deprivation and ischemic injury. Certain neuronal
TLRs are also capable of regulating neuronal growth under physiological condi-
tions. The activation of TLR3, 7 and 8 all reduce neurite outgrowth in cortical
and hippocampal neurons suggesting that they negatively regulate neuron growth
in the developing and adult brain (Ma et al. 2006; Cameron et al. 2007; Liu et al.
2013; 2015).
Direct activation of peripheral sensory neurons has been observed following the
activation of TLR3, 4 and 7, as characterised by the presence of inward currents
and an increase in intracellular calcium (Due et al. 2012; Liu et al. 2012; Park
et al. 2014). The effects of TLR7 activation have also been shown to be depen-
dent upon an association with TRPA1; removing either TLR7 or TRPA1 from
the equation prevented the observed responses (Park et al. 2014). The majority
of previous studies have demonstrated the ability of neuronal TLR activation to
induce transcriptional and post-translational changes that are known to increase
neuronal excitability through mechanisms of peripheral sensitisation. Activation
of TLR3, 4, 7 and 9 induces the expression of pro-inflammatory and pro-algesic
mediators such as cytokines (TNFα, IL-1α and IL-1β), chemokines (CC motif
ligand (CCL) 5 and CXCL10), PGE2, COX-2 and nociceptin (Acosta & Davies
2008; Ochoa-Cortes et al. 2010; Qi et al. 2011; Tse et al. 2014a). The activation of
neuronal TLR4 by endogenous DAMPs has been shown to promote nociception
associated with inflammation and tissue damage (Ohara et al. 2013; Miller et al.
2014; Lin et al. 2015). It has also been shown that the activation of neuronal
TLR3, 4, 7/8 and 9 induces the transcriptional up-regulation and sensitisation of
TRPV1 channels through post-translational modifications (Qi et al. 2011; Ferraz
et al. 2011; Diogenes et al. 2011). LPS-dependent activation of TLR4 in TG neu-
rons triggers an influx and intracellular accumulation of calcium ions as well as the
sensitisation of TRPV1 and TRPV1-dependent release of CGRP (Diogenes et al.
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2011; Ferraz et al. 2011). Therefore LPS, from odontogenic infections such as P.
gingivalis, can directly sensitise nociceptors leading to a hypersensitivity to pain.
DRG neuron stimulation with TLR3, TLR7/8 and TLR9 ligands also cause an
up-regulation of TRPV1 as well as a redistribution of the receptor from neuronal
cell bodies to sensory nerve endings (Qi et al. 2011); something which has been
reported to be involved in the development of hyperalgesia in vivo (Ji et al. 2002).
TRPV1 was also sensitised and an increased calcium influx occurred upon activa-
tion. The role of TRPV1 in neuronal plasticity is well documented and the above
experimental evidence showing TRPV1 sensitisation following neuronal TLR acti-
vation provides a key insight into a possible mechanism of TLR-mediated neuronal
plasticity that could also be relevant to other signal transduction molecules. The
activation of TLR3, but not TLR7, is also necessary for eliciting mechanical,
thermal, inflammatory or neuropathic pain in mice whereas both are shown to be
important in the induction of an itch response (Liu et al. 2010; 2012). TLR3 K.O.
mice display impaired spinal cord synaptic transmission and central sensitisation.
Interestingly, the activation of TLR3 and TLR7 have also been shown to medi-
ate pruritis (an itch response). The mechanisms of nociception and pruritis are
strikingly similar and both share certain common signalling pathways and cellular
receptors/channels.
1.7 Hypothesis and aims
The expression of neuronal TLRs on trigeminal sensory neurons represents a po-
tential mechanism for the detection of pathogens that is independent from the
innate immune response. However it is important to characterise the expres-
sion of TLRs within specific sub-populations of sensory neuron in order to better
understand the potential consequences of receptor activation. For example, the
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activation of TLRs expressed by nociceptors may have implications for the devel-
opment of pain hypersensitivity and the orchestration of a local immune response.
Therefore it is hypothesised that the activation of trigeminal neuronal TLRs by
a range of exogenous ligands, including those associated with periodontitis, is
sufficient to bring about alterations in neuronal function that may promote the
development and maintenance of a heightened pain response. The specific aims
of the thesis are as follows:
• To provide a detailed description of a range of TLR expression within
neurochemically-identified sub-populations of sensory neurons within the
trigeminal ganglion and to compare this with their distribution within so-
matic ganglia.
• To investigate TLR-dependent induction of cytokine gene expression in
trigeminal ganglion sensory neurons.
• To investigate the potential role for the phospholipid-modifying enzyme LP-
CAT in the activation of neuronal TLRs.
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2. Materials and methods
2.1 Materials & methods
2.1.1 Materials
Table 2.1 details the supplier and catalogue/model number of the reagents, materi-
als, equipment and analysis software that were used in the experiments performed
in this thesis, with the exception of antibodies that are detailed in tables 2.3, 2.4,
2.5, 2.6 and 2.7.
2.2 Animal care
Male Sprague Dawley rats (Charles River, UK) were group-housed in a temper-
ature and humidity controlled environment with a 12 h light/dark cycle (lights
on at 8:00 A.M.) with food and water available ad libitum. Adult animals, >3
months of age, weighing 250-350 g were used in all experiments. All experiments
adhered to guidelines described by Schedule 1 of the UK 1986 Animals (Scientific
Procedures) Act. Death was confirmed by the permanent cessation of the heart
beat before proceeding with dissection. Table 2.2 details the number of animals
used in each experiment.
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Table 2.1. Details of the reagents, materials, equipment and software used in the following
methods.
Reagent Supplier Catalogue
Number
β-mercaptoethanol Sigma-Aldrich M6250
B-27 supplement ThermoFisher Scientific 17504
Biotinylated protein ladder New England Biolabs 7727S
Bovine serum albumin Sigma-Aldrich A8531
Cell culture water Sigma-Aldrich W3500
CLI-095 InvivoGen tlrl-cli95
Collagenase Type II Worthington Biochemical LS004204
DAPI Sigma-Aldrich 32670
Dispase Type II Sigma-Aldrich D4693
DMEM Lonza BE12-708F
Donkey serum Sigma-Aldrich D9663
dPBS ThermoFisher Scientific 14190
E. coli LPS (0111:B4) Sigma-Aldrich L2630
Ethanol Sigma-Aldrich E7023
Ethylene glycol Sigma-Aldrich 324558
Euthatal (sodium pentobarbital) Merial -
Fast SyBr Green master mix ThermoFisher Scientific 4385612
Foetal calf serum ThermoFisher Scientific 10500
FluorSave mounting reagent VWR 345789
GlutaMAX ThermoFisher Scientific 35050-061
Guanidine hydrochloride Fisher Scientific 10543325
Guanidium thiocyanate Fisher Scientific BP221
HBSS ThermoFisher Scientific 14170
HEPES Sigma-Aldrich H0887
Table continued on next page.
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continued from previous page.
Imiquimod InvivoGen tlrl-imqs
L-cysteine Sigma-Aldrich C7352
L-glutamine Lonza 17-60
L15 culture medium Invitrogen 11415049
Laminin Sigma-Aldrich L2020
Luminata Crescendo HRP substrate Millipore WBLUR0100
Methanol Fisher Scientific 10000280
Micro BCA protein assay ThermoFisher Scientific 23235
Milk powder Marvel -
Neurobasal-A culture medium Invitrogen 10888022
Nuclease-free water ThermoFisher Scientific AM9938
NuPAGE antioxidant Invitrogen NP0005
NuPAGE LDS sample buffer Invitrogen NP0007
NuPAGE MOPS SDS running buffer Invitrogen NP0001
NuPAGE Novex Bris-Tris gels 4-12% Invitrogen NP0321BOX
NuPAGE sample reducing agent Invitrogen NP0009
NuPAGE transfer buffer Invitrogen NP00061
OCT compound VWR 361603E
Pam3 CSK4 InvivoGen tlrl-pms
Papain Sigma-Aldrich P4762
Paraformaldehyde Sigma-Aldrich 158127
PBS tablets Oxoid BR0014G
Penicillin & streptomycin ThermoFisher Scientific 15140-122
Percoll Sigma-Aldrich P4937
Phorbol myristate acetate Sigma-Aldrich P1585
PhosSTOP Roche Applied Science 4906845001
Poly-D-lysine Sigma-Aldrich P6407
Table continued on next page.
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continued from previous page
P. gingivalis LPS1435 Astarte Biologics 7010
P. gingivalis LPS1690 Astarte Biologics 7000
Protease inhibitor Fisher Scientific 12801640
Qubit microRNA assay kit Life Technologies Q32852
Recombinant human TNFα Miltenyi Biotec. 130-094-014
RepelCote VS VWR 632474U
RNAqueous Micro RNA kit Life Technologies AM1931
Sarkosyl salt Fisher Scientific BP234
SeeBlue standard Invitrogen LC5625
Sodium azide Sigma-Aldrich 13412
Sodium bicarbonate Sigma-Aldrich S8761
Sodium chloride Sigma-Aldrich 71376
Sodium citrate Fisher Scientific BP327
Sodium dodecyl sulfate Sigma-Aldrich 71725
Sodium phosphate dibasic Sigma-Aldrich S3264
Sodium phosphate monobasic Sigma-Aldrich S0751
Sucrose Sigma-Aldrich S0389
SuperScript VILO cDNA synthesis kit Life Technologies 11754
TaqMan fast advanced master mix ThermoFisher Scientific 4444557
Tris base Fisher Scientific 10103203
Triton X-100 Sigma-Aldrich T8787
Trypsin inhibitor Sigma-Aldrich T6522
TWEEN-20 Sigma-Aldrich P9614
Vitamin D3 Sigma-Aldrich D1530
Material Supplier Catalogue
Number
0.5 mL tubes Fisher Scientific 11508232
Table continued on next page.
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continued from previous page
1.5 mL tubes Fisher Scientific 11569914
6 well plate Fisher Scientific 10396482
15 mL tubes Fisher Scientific 11542293
50 mL tubes Fisher Scientific 11512303
96 well MicroAmp plate ThermoFisher Scientific 4316813
Cell scraper Greiner Bio-One 541070
Cover glass Fisher Scientific 12313138
Gel-loading tips Alpha Laboratories LW1100
Glass pipette Fisher Scientific FB50253
MicroAmp optical adhesive film ThermoFisher Scientific 4311971
Microplate sealing tape ThermoFisher Scientific 15036
Nuclease-free 0.2 mL tubes Greiner Bio-One 683201
Nuclease-free 0.5 mL tubes Greiner Bio-One 682201
Nuclease-free 1.5 mL tubes Fisher Scientific 10398031
Nuclease-free filter tips Greiner Bio-One 771288, 774288,
739288, 740288
Nunc-Immuno 96 well plate Sigma-Aldrich M9410
PAP pen Vector Laboratories H-4000
PVDF membrane ThermoFisher Scientific 88518
Qubit assay tubes (1.5 mL) ThermoFisher Scientific Q32856
SuperFrost microscope slide VWR 631-0446
Equipment Suppler Model Number
Centrifuge Eppendorf 5415 R
Centrifuge Eppendorf 5810 R
ChemiDoc-it2 imager UVP 515
Cryostat Leica Biosystems CM1100
Hotplate Labnet AccuBlock
Table continued on next page.
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continued from previous page
Incubator Sanyo MCO 17AIC
Inverted microscope Olympus CK30
Microcentrifuge ThermoFisher Scientific Heraeus Fresco21
NanoDrop ThermoFisher Scientific NanoDrop 2000
Nikon epifluorescence microscope Nikon Eclipse 80i
Orbital shaker Stuart Scientific SO3
Plate reader Molecular devices VersaMax
Powerpack Invitrogen ZOOM
QuantStudio Applied Biosystems 12k flex
Qubit fluorometer ThermoFisher Scientific 2.0
Roller mixer Stuart Scientific SRT6
Sonicator Sonics VCX130
Veriti thermal cycler Applied Biosystems Veriti
Vortex Velp Scientifica ZXclassic
Water purification system Millipore Simplicity UV
XCell SureLock mini cell ThermoFisher Scientific EI0002
Software Developer Version
Excel Microsoft 2010
NIS-elements Nikon BR 3.0
PCR miner Sheng Zhao & Russell
Fernald
4.0
QuantStudio software Applied Biosystems 1.1
SigmaPlot Systat software 13.0
SoftMax Pro Molecular devices 5.4
SPSS IBM 21
VisionWorks UVP LS
End of table.
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Table 2.2. Breakdown of animal usage per experiment.
Experiment Animals Used
TLR expression in sensory neurons.
TLR expression and co-expression with neurochemical markers 3
TLR-associated molecule gene expression profile 3
PAMP-induced cytokine production by sensory neurons.
TLR-associated molecule & cytokine gene expression in vitro 6
E. coli LPS-induced cytokine gene expression 8
P. gingivalis LPS-induced cytokine gene expression 12
Pam3CSK4-induced cytokine gene expression 6
Imiquimod-induced cytokine gene expression 6
LPCAT expression in sensory neurons.
LPCAT expression and co-expression with neurochemical markers 3
LPCAT gene expression in vitro 9
LPCAT immunocytochemistry 6
Total 62
2.3 Immunohistochemistry (IHC)
2.3.1 Tissue processing
Age-matched animals were euthanized by intraperitoneal (I.P.) injection of a lethal
dose of sodium pentobarbital and transcardially perfused with 0.1 M phosphate
buffered saline (PBS) (pH 7.4) followed by 4% w/v paraformaldehyde in 0.1 M
phosphate buffer (pH 7.4). TG, L4/L5 DRG, maxillary nerve, incisors, lung and
59
2. Materials and methods
spleen were dissected and post-fixed in 4% w/v paraformaldehyde in 0.1 M phos-
phate buffer for 2 h at 4 °C before cryoprotection in 20% w/v sucrose solution
overnight at 4 °C. Rat incisors were cracked open to isolate tooth pulp prior to
post-fixation. The following day, tissue samples were frozen in OCT compound,
using liquid nitrogen, and stored at -80 °C until sectioning. Tissue samples were
then cryo-sectioned at 9 µm, sequentially thaw-mounted onto SuperFrost Plus
slides and stored at -20 °C in cryoprotection solution (30% w/v sucrose, 30% v/v
ethylene glycol in 0.1 M PBS). Sequential sectioning using multiple slides ensured
that sections across the whole ganglion were represented on each slide. For ex-
ample, section 1-10 were mounted onto slides 1-10, respectively. Then section
11-20 were mounted onto slides 1-10 as before. This was repeated until 6-8 tissue
sections were mounted onto each slide.
2.3.2 Staining procedure
For expression and co-expression experiments, tissue from 3 individual animals
was used and 3 slides of tissue from each source, TG and DRG, were selected
per animal. Therefore, for each target protein, roughly 54-72 tissue sections were
stained per tissue type.
Slides were chosen at random, placed in a Coplin jar on an orbital shaker and
washed 3 x 10 min in 0.1 M PBS. A PAP pen was used to create a hydrophobic
barrier around the tissue sections to ensure that liquid did not wick off the slides.
Permeabilisation and non-specific blocking stages were combined by incubating
sections in 10% v/v donkey serum (in 0.1 M PBS, 0.2% v/v Triton-X-100 and
0.1% v/v sodium azide) for 1 h in a humidity chamber at room temperature.
Following further 3 x 10 min washes in 0.1 M PBS, sections were incubated with
primary antibodies in a humidity chamber for 24 h at 4 °C, with the exception of
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the TLR4 primary antibody which was incubated for 48 h. For dual-labelled co-
expression experiments, sections were incubated with primary antibodies against
target antigens in conjunction with either TRPV1, P2X3, NF200 or β-III tubulin;
see Table 2.3 for more information on primary antibodies used for IHC. Primary
antibodies were pooled together before incubation to allow for an even distribution
of the two primary antibodies. Following incubation, sections were washed 3 x 10
min in 0.1 M PBS and then incubated with appropriate combinations of species-
matched secondary antibodies depending on the primary antibodies used; see
Table 2.4 for more information on secondary antibodies used for IHC. Secondary
antibodies were again pooled together before application and tissue sections were
incubated for 3 h at room temperature in a dark humidity chamber. For all of the
following steps, measures were taken to minimise the amount of light the sections
were exposed to. Sections were washed 3 x 10 min in 0.1 M PBS and incubated
with 4’, 6-diamidino-2-phenylindole (DAPI) (100 ng/mL, in 0.1 M PBS) for 1 h
in a humidity chamber at room temperature to stain nuclear chromosomal DNA.
One final 10 min wash in 0.1 M PBS was performed before sections were air-dried
and a cover slip applied using FluorSave mounting reagent. Slides were left to
dry overnight in the dark before being sealed with nail varnish and stored at 4 °C
until required for imaging.
2.3.3 Image acquisition & analysis
Images were captured using a Nikon Eclipse 80i epifluorescence microscope equipped
with a Nikon DS-Qi1Mc camera using NIS-Elements software. All images were
taken using 20X or 60X objectives coupled with a 10X eyepiece. Neuronal soma
were identified morphologically as well as by the presence of a DAPI stain; neu-
ronal nuclei generally appear more rounded and slightly darker than those of non-
neuronal cells. Only neuronal profiles with a visible nuclear DAPI counterstain
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were included in the counting process. For expression and co-expression analysis,
3 images were taken from each tissue section on the slide to ensure that a realistic
representation of expression throughout the tissue section as a whole was given.
This was repeated on each tissue section (6-8 per slide) so that in total roughly
54-72 images were captured and quantified per ganglion. Image analysis and
quantification was performed on monochrome images by a single investigator who
was blinded to the slide identity. A threshold for positive counting was set using
mean fluorescence intensity units, determined by two independent investigators
for each antibody. Subjective visual criteria were first used to determine positive
and negative immunoreactivity (IR) for each target protein. A threshold was then
determined by considering the fluorescence intensity units from these positive and
negative cells. This was performed for each independent experiment to account
for variability in staining due to experimental conditions. Co-expression of tar-
gets with phenotypic markers was determined by positive identification of mark-
ers in individual images obtained by switching between fluorescein isothiocyanate
(FITC) and tetramethylrhodamine (TRITC) filters. Following identification of
positive profiles in individual images, co-expression was confirmed in merged im-
ages. Co-expression was expressed as a percentage of target markers expressing
phenotypic markers and vice-versa.
2.3.4 Statistical analysis
Data are displayed as mean ± standard error of the mean (SEM), n=3. Com-
parisons between groups were made using a Student’s t-test, as appropriate, per-
formed on IBM SPSS statistics software (1 animal = 1 unit for statistical analysis).
Differences were considered statistically significant when p < 0.05.
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2.4 Immunocytochemistry (ICC)
Staining on cultured cells was performed as for immunohistochemistry except for
the following variations. Culture medium was aspirated and cells, grown on glass
coverslips, were washed briefly in 0.1 M Dulbecco’s PBS (dPBS). Cells were then
fixed by incubation with 4% w/v paraformaldehyde in 0.1 M phosphate buffer
for 1 h at room temperature. All staining was performed in 6 well plates. Once
stained, coverslips were removed from wells, briefly air-dried and inverted onto
a drop of FluorSave mounting medium on a SuperFrost microscope slide. Slides
were dried, sealed and stored as previously described.
2.5 Antibody characterisation
Tables 2.3 and 2.4 detail the primary and secondary antibodies used for IHC ex-
periments, respectively. A series of quality control experiments were performed
to verify the specificity of the antibodies used. The antibodies/antisera used for
the neurochemical markers have been categorised elsewhere (Vulchanova et al.
1997; Guo et al. 1999; Michael & Priestley 1999; Kiasalari et al. 2010). These
antibodies/antisera performed as previously described when in our hands. Pri-
mary rat spleen tissue was used as a positive control for the TLR and LPCAT2
antibodies because of the high proportion of immune cells found in the spleen.
Primary lung tissue was used as a positive control for the LPCAT1 antibody due
to the high expression of LPCAT1 in lung alveolar cells (Nakanishi et al. 2006).
To test the specificity of the TLR2 primary antibody pre-incubation with 10 µg
of blocking peptide (Santa Cruz Biotechnology., sc-12504 P) for 2 h at room tem-
perature was performed before staining tissue sections as described previously.
No blocking peptides were available for the TLR4, TLR7, LPCAT1 and LPCAT2
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Table 2.3. Details of primary antibodies used for IHC/ICC.
Antigen Host Species
Reactivity
Supplier (Cat. Number) Working
Dilution
TLR2 Goat Mouse, Rat Santa Cruz Biotechnology
(sc-12504)
1:200
TLR4 Rabbit Human, Mouse,
Rat
Abcam (ab13556) 1:200
TLR7 Rabbit Human, Mouse,
Rat
Imgenex (IMG-581A) 1:500
LPCAT1 Rabbit Human, Mouse,
Rat
ProteinTech (16112-1-AP) 1:200
LPCAT2 Rabbit Human, Rat Novus Biologicals
(NBP1-88921)
1:200
Neurochemical Marker
NF200 Mouse Wide species
range
Sigma-Aldrich (N0142) 1:4000
TRPV1 Guinea-Pig Rat Neuromics (GP14100) 1:200
P2X3 Guinea-Pig Human, Mouse,
Rat
Novus Biologicals
(NB100-1658)
1:1000
β-III
Tubulin
Mouse Wide species
range
Abcam (ab7751) 1:500
primary antibodies used here. For the TLR4 and TLR7 antibodies we performed
staining on tissue known to be negative for the antigen in question. Peripheral rat
red blood cells were used as negative controls for both TLR antibodies. LPCAT
expression has been identified in a wide range of tissue and cell types. Therefore,
in the absence of a suitable negative control sample, the specificity of the LPCAT
antibodies were tested by western blotting. Single, specific bands were observed
for both antibodies at the expected molecular weights. Non-specific binding of the
rabbit primary antibodies was also tested for by using a rabbit polyclonal IgG iso-
type control (abcam, ab27478). To test the specificity of the secondary antibodies
TG sections were incubated with secondary antibodies in the absence of primary
antibodies. Unstained TG sections were used to observe any auto-fluorescence
within the tissue. See individual experimental chapters for the results of antibody
characterisation experiments.
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Table 2.4. Details of secondary antibodies used for IHC/ICC.
Host Species
Reactivity
Fluorochrome Supplier (Cat. Number) Working
Dilution
Donkey Goat Alexa Fluor 488 Abcam (ab150129) 1:500
Donkey Rabbit Alexa Fluor 488 Abcam (ab150073) 5µg/mL
Donkey Mouse Alexa Fluor 555 Life Technologies (A-31570) 5µg/mL
Donkey Guinea-Pig Alexa Fluor 594 Jackson Immuno Research
(706-585-148)
1:500
2.6 Western blotting
2.6.1 Tissue processing
Age-matched animals were euthanised by I.P. injection of a lethal dose of sodium
pentobarbital and transcardially perfused with 0.1 M PBS (pH 7.4) and TG, L4/5
DRG and cortex were rapidly removed. Tissue was cut up into small pieces and
placed in a suitable volume of radioimmunoprecipitation assay (RIPA) buffer (50
mM Tris, 150 mM sodium chloride, 0.1% v/v SDS, 1% v/v Triton-X 100, 1% v/v
protease inhibitor, 5% v/v phosphatase inhibitor) (50 µL per TG/DRG pair and
200 µL per piece of cortex tissue). Tissue was sonicated on ice (3 bursts of 11 s
with 30 s breaks in between bursts) and incubated on ice for 30 min with regular
trituration. Lysates were collected by centrifugation at 5,000 x g for 2 min at 4 °C
and stored at -80 °C until required. RAW 264.7 lysates were harvested directly
from the culture dish. Media was aspirated and cells were washed once with 0.1
M PBS and incubated with RIPA buffer on ice for 30 min. Lysates were collected
as above.
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2.6.2 Sodium dodecyl sulphate polyacrylamide gel elec-
trophoresis (SDS-PAGE)
The total protein content of lysates were quantified using the Micro BCA Protein
Assay Kit, according to manufacturers instructions, in a 96 well plate format.
Samples were prepared at a concentration of 1 µg/µL by adding 12.5 µL of Nu-
PAGE LDS sample buffer, 5 µL of NuPAGE sample reducing agent and adjusting
the final volume to 50 µL with MilliQ water. Samples were denatured by heating
at 70 °C for 10 min and placed on ice until loading the gel. 10 µL of biotinylated
protein ladder was heated at 90 °C for 4 min and then combined with 10 µL of See-
Blue and kept on ice ready for loading. NuPAGE Novex 4-12% bis-tris gels were
rinsed with deionised water, the comb was gently removed and the wells were
washed 3x with running buffer. The gel was inserted into the XCell SureLock
Mini-cell and the outer chamber was filled with NuPAGE MOPS SDS running
buffer (prepared from 20X stock using deionised water). A smaller volume (200
mL) of running buffer with 2.5% v/v NuPAGE sample reducing agent was used
to fill the inner chamber of the mini-cell. 20 µg (20 µL) of each sample was loaded
into the appropriate wells and 20 µL of biotinylated protein ladder/SeeBlue mix
was loaded into the end well. Proteins were separated by running the gel at 200
V for approximately 50 min.
2.6.3 Transfer onto PVDF membrane
NuPAGE transfer buffer was prepared in deionised water from 20X stock and
samples were transferred onto a polyvinylidene fluoride (PVDF) membrane using
a wet transfer method performed on an XCell II Blot Module. Membranes were cut
to size and activated by immersion in methanol for 15 s followed by 2 min in MilliQ
water. Filter papers, membranes and blotting pads were then soaked in NuPAGE
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transfer buffer (10% v/v methanol, 1% v/v NuPAGE antioxidant in deionised
water). If two gels were being transferred together then the methanol percentage
was increased to 20% v/v. The transfer assembly was created by placing a filter
paper on the back of the gel and the activated membrane on the front followed
by a filter paper on top of this. A roller was used to remove trapped air from
the assembly. Two blotting pads were placed on either side of the assembly. The
finished assembly was placed into the transfer module making sure of the correct
orientation to ensure that proteins would be transferred onto the membrane. The
transfer module was placed in the mini-cell and filled with transfer buffer. The
outer chamber was also filled with transfer buffer and the transfer was run at 30
V for 90 min. Once the transfer was finished the membrane was placed protein-
side up in MilliQ water. Transfer quality was assessed by observing the SeeBlue
marker on the membrane and no longer in the gel.
2.6.4 Western blotting
Membranes were blocked with 5% w/v milk powder in PBS 0.1% v/v Tween-20
for 1 h at room temperature on an orbital shaker. Once blocked the membranes
were transferred to a 50 mL Falcon tube with the protein side forming a lumen and
incubated with primary antibody overnight at 4 °C on a rotator mixer (see table
2.5 for information on primary antibodies). The membranes were then washed 4
x 5 min with 0.1 M PBS, 0.1% v/v Tween-20 on an orbital shaker and incubated
with horseradish peroxidase (HRP) linked secondary antibodies (pooled solution
of antibodies targeting the primary antibodies of the protein of interest and the
biotin marker, see table 2.6 for more details) for 30 minutes at room temperature
on an orbital shaker. The membranes were again washed 4 x 5 min with 0.1 M
PBS, 0.1% v/v Tween-20 before being developed by incubating with Luminata
Crescendo HRP substrate for 5 minutes, protected from light.
67
2. Materials and methods
Table 2.5. Details of primary antibodies used for western blotting.
Antigen Host Species
Reactivity
Supplier (Cat. Number) Working
Dilution
LPCAT1 Rabbit Human, Mouse,
Rat
ProteinTech (16112-1-AP) 1:1000
LPCAT2 Rabbit Human, Rat Novus Biologicals
(NBP1-88921)
1:1000
β-III
Tubulin
Rabbit Human, Mouse,
Rat
Sigma-Aldrich (T2200) 1:1000
Table 2.6. Details of secondary antibodies used for western blotting.
Host Target Tag Supplier (Cat. Number) Working
Dilution
Goat Rabbit IgG HRP-linked Abcam (ab6721) 1:2500
Goat biotin HRP-linked Abcam (ab19221) 1:2000
2.6.5 Image acquisition
Imaging was performed on a ChemiDoc-it2 imaging system using VisionWorksLS
Acquisition and Analysis software.
2.6.6 Membrane stripping and re-probing
Membranes were stripped to allow for subsequent re-probing for other targets.
Membranes were washed 2 x 5 min with 6 M guanidine hydrochloride, 0.1 M
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β-mercaptoethanol in 0.1 M PBS, 0.2% v/v Triton-X 100, 0.1% v/v Tween-20
followed by 4 x 5 min washes in 0.1 M PBS, 0.05% v/v Tween-20. Membranes
were then re-probed following the same procedure as described above.
2.7 RAW 264.7 cell culture
The RAW 264.7 cell line is an adherent monocyte/macrophage cell line that is
frequently used in immunological studies. As macrophages express a full com-
plement of TLR associated molecules, RAW 264.7 cells were used as a positive
control for western blotting and qPCR (see Appendix E). RAW 264.7 cells were
plated out into 6 well plates at a seeding density of 5×105 cells per well and incu-
bated overnight to allow for cells to adhere to the coverslips. Cells were cultured
and maintained as an adherent monolayer in DMEM culture medium (10% foetal
calf serum, 1mM L-glutamine) at 37 °C, 5% CO2.
Cultured RAW 264.7 cells were a kindly supplied by Wondwossen Abate and
Hanaa Alrammah.
2.8 Primary neuron cell culture
2.8.1 Trigeminal ganglion dissociation
The protocol used for TG dissociation in this study was adapted from Malin et.
al. 2007 (more information on the adaptions and optimisation of neuronal culture
methods can be found in Appendix C). Briefly, age-matched Sprague-Dawley rats
were euthanized by exposure to rising concentrations of CO2. Animals were tran-
scardially perfused with chilled Hank’s buffered salt solution (HBSS, Calcium and
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Magnesium-free), TG were rapidly removed and cut into 10-12 small pieces. Tis-
sue was incubated with 1.5 mL of pre-warmed papain solution (60 units papain,
1mg L-cysteine, 3 µL sodium bicarbonate (NaHCO3) in HBSS) for 30 min at 37
°C with gentle mixing halfway. Tissue was pelleted by centrifugation at 800 x g
for 5 min and the supernatant discarded. The tissue was resuspended in 3 mL
of pre-warmed collagenase/dispase solution (12 mg collagenase type II and 14 mg
dispase type II in HBSS) and incubated for 30 min at 37 °C with gentle mixing
halfway. 3 mL of pre-warmed trypsin inhibitor (1 mg/mL in HBSS) was added to
stop enzymatic digestion and tissue was then pelleted by centrifugation at 800 x
g for 5 min. A single cell suspension was created by trituration (6-8 times) with
a sterile fire-polished, silicon-coated glass pipette in pre-warmed L15 medium (10
mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), 1% v/v Peni-
cillin/Streptomycin (Pen/Strep)) until the mixture appeared cloudy with small
chunks of tissue still visible. This cell suspension was then passed through a
30/60% v/v Percoll gradient at 1800 x g for 10 min in order to remove the ma-
jority of non-neuronal cells, axonal and cellular debris. The neuron-enriched cell
layer and the majority of the 30% Percoll layer (see Fig 2.1) were harvested and
diluted in 10 mL of L15 medium. This cell suspension was then centrifuged at
1800 x g for 6 min, the supernatant discarded, and the pellet resuspended in 75
µL/coverslip pre-warmed Neurobasal-A (NBA) medium (2% v/v B-27, 0.5 mM
GlutaMAX, 1% v/v Pen/Strep).
2.8.2 Cell plating
Glass coverslips were detergent-cleaned and hot-oven sterilised before use. The
day before culture, coverslips were placed in a 6 well plate and coated in poly-
D-lysine and laminin (both 20 µg/mL in HBSS) and incubated overnight at 4
°C. Before plating, coverslips were warmed to room temperature and washed 2x
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Figure 2.1. Cell suspension separation following Percoll spin. Following 10 min centrifugation
at 1800 x g, a thin layer of axonal/cellular debris is located on top of the 30% Percoll layer.
Neurons are primarily located at the 30%/60% Percoll interface but can also be located in the
30% Percoll layer.
with cell culture water. Cells were plated out onto a suitable number of coverslips
depending on the experiment (2 coverslips per animal for ICC, 3 coverslips per
animal for qPCR). Coverslips were air-dried and 75 µL of cell suspension was
added to each coverslip in a doughnut shape. This prevented the majority of cells
from grouping together in the middle of the coverslip. Cells were incubated for
2-3 hours in a 37 °C, 5% CO2 incubator. Wells were then flooded with 3 mL of
NBA medium (2% v/v B-27, 0.5 mM GlutaMAX, 1% v/v Pen/Strep) per well.
The success of the cell culture was dependent upon the cell plating density. Cells
plated at too high/low density would not display the expected level of neurite
outgrowth.
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Figure 2.2. Phase micrograph of a typical TG neuronal cell culture 48 h post-plating. Note the
bright neuronal soma and extensive neurite outgrowth. Scale bar 50 µm.
2.8.3 Cell culture conditions
Primary neurons were maintained in NBA medium (2% v/v B-27, 0.5 mM Gluta-
MAX, 1% v/v Pen/Strep) at 37 °C, 5% CO2 for a maximum of 2 days. No media
changes were required during this period.
2.8.4 Treatment with TLR agonists
Following 48 h in vitro, cells were exposed to a range of TLR agonists for sub-
sequent real-time polymerase chain reaction (qPCR) experiments. Cell culture
media was removed and replaced with fresh, pre-warmed NBA media (2% v/v
B-27, 0.5 mM GlutaMAX, 1% v/v Pen/Strep) containing either 1 µg/mL E. coli
LPS, 1 µg/mL P. gingivalis LPS1690, 1 µg/mL P. gingivalis LPS1435, 500 ng/mL
of the synthetic triacylated lipopeptide Pam3 CSK4 or 5 µg/mL of the imida-
zoquinoline amine analogue imiquimod. Control groups were exposed to NBA
medium (2% v/v B-27, 0.5 mM GlutaMAX, 1% v/v Pen/Strep) alone. Cells were
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incubated for 2 h at 37 °C, 5% CO2 prior to sample collection.
For TLR4 antagonism experiments cells were pre-treated with 1 µg/mL of the
cyclohexene derivative CLI-095 in NBA medium (2% v/v B-27, 0.5 mM Gluta-
MAX, 1% v/v Pen/Strep) for 2 h prior to exposure with E. coli LPS. The same
concentration of CLI-095 was maintained during LPS exposure.
2.9 THP-1 cell culture and differentiation
THP-1 cells were used as a control cell line for P. gingivalis LPS isoform exposure.
THP-1 cells were maintained as a suspension in Roswell Park Memorial Institute
(RPMI)-1640 media (supplemented with 2 mM L-glutamine, 1% v/v Pen/Strep
and 10% v/v foetal calf serum) at 37 °C, 5% CO2. Cells were sub-cultured at a
ratio of 1:5 every 3 days.
THP-1 cells were differentiated into adherent M1 and M2 macrophages by treat-
ment with phorbol myristate acetate (PMA) and vitamin D3, respectively. THP-1
cells were differentiated into pro-inflammatory M1-like macrophages over a period
of 3 days. THP-1 cells were incubated with 25 ng/mL of PMA (in culture medium)
for 2 days before being further maintained overnight more days in fresh media.
THP-1 cells were differentiated into anti-inflammatory M2-like macrophages over
a period of 7 days. THP-1 cells were incubated with 10 µM of vitamin D3 (in
culture medium) for 4 days, culture media was then replenished and cells were
again incubated with 10 µM of vitamin D3 for a further 3 days. Culture medium
was then removed and cells exposed to 1 µg/mL of each individual P. gingivalis
LPS isoform (in culture medium) for 4 h. Following treatment with P. gingivalis
LPS isoforms, supernatants were harvested and stored at -20 °C until required for
ELISA.
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Differentiated M1 and M2 macrophages were kindly supplied by Alexander Stra-
chan.
2.10 Enzyme-linked immunosorbent assay
(ELISA)
A 96 well plate was pre-coated with 4 µg/mL of capture antibody in 0.1 M PBS
(mouse anti-human TNFα) overnight at 4 °C. Plates were blocked with 2% w/v
bovine serum albumin (BSA) in 0.1 M PBS for 1 hour at room temperature.
Meanwhile, a series of standards ranging from 13 - 10,000 pg/mL of human re-
combinant TNFα were prepared. Plates were washed 3x with 0.01% v/v Tween-20
in distilled water and 50 µL of either test sample or standard was added to each
well. Plates were then incubated for at least 1.5 h at room temperature. Plates
were washed 3x with 0.01% v/v Tween-20 in distilled water and incubated with 0.5
µg/mL of detection antibody (mouse anti-human TNFα) in 0.1 M PBS, 1% w/v
BSA for 1 h at room temperature. Plates were again washed 3x with 0.01% v/v
Tween-20 in distilled water and incubated with 50 µL biotinylated-streptavidin
HRP in 0.1 M PBS, 1% w/v BSA for 1 h at room temperature. Plates were
washed 3x with 0.01% v/v Tween-20 in distilled water and 100 µL/well of TMB
substrate reagent was added to allow colour to develop at room temperature.
The reaction was stopped by adding 50 µL of 1.8 M sulphuric acid (H2SO4) to
each well. The absorbance at 450 nm was then read on a VersaMax plate reader.
The concentration of unknown samples was extrapolated from a standard curve
created on SoftMax Pro software.
ELISA was kindly performed by Alexander Strachan.
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Table 2.7. Details of antibodies used for ELISA.
Antigen Host Species
Reactivity
Conjugate Supplier (Cat.
Number)
Working
Dilution
TNFα Mouse Human None BD biosciences
(551220)
4 µg/mL
TNFα Mouse Human Biotin BD biosciences
(554511)
0.5 µg/mL
Biotin Streptavidin - HRP R and D
systems
(Dy998)
1:250
2.11 Real-time polymerase chain reaction
(qPCR)
2.11.1 RNA isolation
All reagents used were of RNA grade and all plastics were RNase/DNase free.
Total mRNA from dissociated TG neurons and spleen tissue was isolated us-
ing RNAqueous-Micro kit according to the manufacturer’s instructions. Cells,
grown on glass coverslips, were lysed with 100 µL lysis buffer (4 M guanid-
ium thiocyanate, 0.024 M sodium citrate, 0.49% w/v sarkosyl, 0.13% w/v β-
mercaptoethanol in nuclease-free water) per coverslip. Coverslips were scraped
and the lysates transferred to 0.5 mL tubes on ice. Typically 3 coverslips were
pooled together at this stage to form one sample. Lysates were briefly vortexed
and a half volume of 100% ethanol was added (e.g. 50 µL ethanol added to 100
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µL lysate). Samples were briefly vortexed and kept on ice whilst loading onto the
filter. 150 µL of sample at a time was loaded onto the filter by centrifuging at
16,000 x g for 10 s. Filters were then washed 1x with wash solution 1 and 2x
with wash solution 2/3 by centrifugation at 16,000 x g for 10 s. The filter was
dried by centrifugation at 16,000 x g for 1 min before the bound RNA was eluted
by incubating the filter with 10 µL of pre-warmed (70 °C) elution solution for 1
min and centrifugation at 16,000 x g for 30 s. This elution step was performed
twice to yield a final elute of 20 µL. Isolated RNA was treated with DNase I (1
µL DNase I and 2 µL DNase buffer per 20 µL of sample) for 20 min at 37 °C to
remove any genomic deoxyribonucleic acid (DNA) contamination. The DNase I
enzyme was inactivated by adding inactivation reagent (2 µL per 20 µL sample),
incubating for 2 min with a brief vortex halfway and centrifugation at 16,000 x g
for 1.5 min.
Total RNA concentration of samples was determined using a Qubit 2.0 Fluorom-
eter with the Qubit microRNA Assay Kit. Typically, cultured neurons from one
animal produced samples with a RNA concentration of approximately 10 ng/µL.
Sample purity was assessed by measuring 260/280 and 260/230 absorbency ratios
using a nanodrop 2000. Only samples with a 260/280 ratio of >1.8 were used for
reverse transcription.
2.11.2 Reverse transcription
First-strand complementary DNA (cDNA) was synthesised from 100 ng RNA
using the SuperScript VILO cDNA Synthesis Kit, which contained SuperScript III
reverse transcriptase, performed on a Veriti thermal cycler. Reaction conditions:
25 °C for 10 min, 42 °C for 2 h, 85 °C for 5 min. cDNA was stored at -20 °C until
used for qPCR.
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2.11.3 qPCR
Relative quantification was achieved with qPCR using probe-based detection chem-
istry (see table 2.8 for specific probe information). For the gene expression profile
(see Chapter 3) glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used
as a sole endogenous control gene. For the PAMP-induced cytokine gene expres-
sion experiments (see Chapter 5) GAPDH, β-actin (ACTB) and 18s were all used
as endogenous control genes. All qPCR experiments used TaqMan Fast Advanced
Master Mix, containing AmpliTaq Fast DNA Polymerase, and were performed in
triplicate on a QuantStudio 12k Flex system with a Fast 96-well Block using 2.5
ng (1 µL) of template cDNA in a total reaction volume of 10µL per well (see
Appendix D for optimisation experiments). Reaction conditions: 50 °C for 2 min,
95 °C for 20 s, 40 cycles of 95 °C for 1 s and 60 °C for 20s. An initial no reverse
transcription (RT) control for each sample type was performed to assess the ef-
fectiveness of the DNAse treatment used which returned an undetectable result.
No template controls were also included in every run and returned undetectable
results.
2.11.4 Data analysis
A gene expression profile from each tissue type was created using ∆ copy threshold
(CT ) values, with GAPDH set at 100. Analysis of gene expression data between
tissue types was performed using the 2−∆∆CT method (Livak & Schmittgen 2001)
with target gene expression in each sample normalised against the endogenous
control gene GAPDH.
For PAMP-induced cytokine gene expression experiments data were analysed us-
ing the Pfaﬄ method (Pfaﬄ 2001). Target gene expression in each sample was
77
2. Materials and methods
Table 2.8. Details of primer and probe sets used for qPCR
Target Company Reference/Catalogue
Number
TLR4 Life Technologies (TaqMan) Rn00569848_ m1
MD-1 (LY86) Life Technologies (TaqMan) Rn01434815_ m1
MD-2 (LY96) Life Technologies (TaqMan) Rn01448830_ m1
CD14 Life Technologies (TaqMan) Rn00572656_ m1
MyD88 Life Technologies (TaqMan) Rn01640049_ m1
TRAM Life Technologies (TaqMan) Rn02082474_ s1
TNFα Life Technologies (TaqMan) Rn01525859_ g1
IL-1β Life Technologies (TaqMan) Rn00580432_ m1
IL-6 Life Technologies (TaqMan) Rn01410330_ m1
IFNβ Life Technologies (TaqMan) Rn00569434_ s1
LPCAT1 Life Technologies (TaqMan) Rn01756070_ m1
LPCAT2 Life Technologies (TaqMan) Rn01531165_ m1
GAPDH Primer Design (geNORM) ge-DD-12
ACTB Primer Design (geNORM) ge-DD-12
18s Primer Design (geNORM) ge-DD-12
normalised to the geometric mean of the endogenous control genes. Amplifica-
tion efficiencies and CT values were calculated on the basis of all fluorescent data
points using real time PCR miner online software (Zhao & Fernald 2005).
2.11.5 Statistical analysis
Data are displayed as mean± SEM, n=3. Comparisons between groups were made
using a one-way analysis of variance (ANOVA) with either Tukey’s or Dunnett’s
post hoc tests or Student’s t-test, as appropriate, using SPSS statistics software
(1 animal/culture preparation = 1 unit for statistical analysis). Differences were
considered statistically significant when p < 0.05.
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Toll-like Receptor 4, 2, 7 &
associated receptor component
expression in trigeminal & dorsal
root ganglion sensory neurons.
Published in part as:
Helley, M.P., Abate, W., Jackson, S.K., Bennett, J.H., Thompson, S.W. (2015)
The expression of Toll-like receptor 4, 7 and co-receptors in neurochemical sub-
populations of rat trigeminal ganglion sensory neurons. Neuroscience 310, 686-
698. (see Appendix A).
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3. TLR expression in sensory neurons.
3.1 Introduction
Since the discovery by Wadachi & Hargreaves (2006) of TLR4 expression on
trigeminal sensory neurons, a range of functional TLRs have been shown to be
expressed by neurons in both the peripheral and central nervous system (see sec-
tion 1.6.1 for a detailed description). TLR signalling has been identified as a
critical component in the development of multiple pain states although this is
thought to be mediated by non-neuronal cells such as microglia and infiltrating
immune cells (see Nicotra et al. 2012). The discovery that sensory neurons express
TLRs and subsequent research has uncovered a mechanism for direct interaction
between pathogen and sensory neurons with implications for both nociception
and the inflammatory response. Sensory neurons are now considered therefore
to possess an innate surveillance function whereby they can directly detect and
respond to PAMPs and DAMPs. Given the range of various TLR ligands, of both
exogenous and endogenous origin, neuronal TLR signalling has the potential to
play a major role in the development and maintenance of chronic inflammatory
and neuropathic pain. Despite the identification of TLR expression in periph-
eral sensory neurons a detailed description of their expression within functional
sub-populations is lacking, particularly within the trigeminal system.
Historically, sensory neurons have been divided into various sub-populations based
upon their anatomy, physiology and neurochemistry in order to better understand
their function and phenotype. It is now widely accepted that multiple types of
sensory neuron exist within a sensory ganglion each with distinct properties that
contribute to the phenotype of the cell (see Julius & Basbaum 2001). Given
this heterogeneity in phenotype, it is important to carefully consider the methods
used to characterise neuronal phenotype within the sensory neuron population as
a whole. In the present study, TRPV1, P2X3 and NF200 are used as neurochem-
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ical markers of neuronal sub-populations in order to characterise the expression
patterns of TLR2, TLR4 and TLR7 within sensory ganglia. TRPV1 is a ther-
mal transduction channel that is expressed by a large small-/medium-diameter
C- and Aδ-fibres of both peptidergic and, to a lesser extent, non-peptidergic sub-
populations within the DRG and TG (Caterina et al. 1997; Tominaga et al. 1998).
TRPV1 sensitisation is a key mechanism for the development and maintenance of
both inflammatory and neuropathic pain given that a range of pro-inflammatory
factors can sensitise the channel (see Levine & Alessandri-Haber 2007 for an in
depth review of TRPV1). P2X3 is an ATP-sensitive purinergic receptor that is
expressed by small diameter, non-peptidergic C- and Aδ-fibres (Bradbury et al.
1998; Dunn et al. 2001). P2X3-mediated activation has been demonstrated in
various models of inflammatory and neuropathic pain (Barclay et al. 2002; Jarvis
et al. 2002; McGaraughty et al. 2003). NF200 is often used as a marker of myeli-
nated neurons given that all A fibres display NF200-IR whereas C-fibres do not
(Lawson & Waddell 1991).
TLR4 expression has previously been shown to co-localise to a proportion of pep-
tidergic and non-peptidergic populations within the rat DRG (Due et al. 2012)
and the rat and human TG (Wadachi & Hargreaves 2006; Diogenes et al. 2011;
Lin et al. 2015). TLR4 mRNA has also been identified in sensory neurons of
the rat and mouse DRG (Acosta & Davies 2008; Goethals et al. 2010; Tse et al.
2014a; 2014b). In the DRG, the reported percentage of TLR4-positive neurons
in vivo is approximately 30% (28-34%, Due et al. 2012; Tse et al. 2014b) and in
vitro ranges between 45-60% of total neurons (Acosta & Davies 2008; Tse et al.
2014a). Whilst it has been shown that 19% of neurons in the maxillary region of
the TG and 29% of neurons innervating the gingivomucosa express TLR4, mainly
in small- to medium-sized neurons (Vindis et al. 2014), there is currently no quan-
titative data for TLR4 expression within the TG as a whole. TLR4 expression
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has also been identified in the peripheral terminals of human TG sensory neurons
innervating the tooth pulp (Wadachi & Hargreaves 2006) and in various locations
of the enteric nervous system (Barajon et al. 2009).
Previous studies have identified the expression of TLR7 in small/medium sized
DRG neurons and co-expression with TRPV1, TRPA1 and gastrin-releasing pep-
tide (GRP) has been observed (Barajon et al. 2009; Liu et al. 2010; Park et al.
2014) although no quantitative analysis has been performed. TLR7 has also been
identified in the enteric nervous system (Barajon et al. 2009). TLR7 mRNA has
been identified in DRG neurons (Liu et al. 2010) although a separate study did
not replicate these findings (Goethals et al. 2010).
Information regarding TLR2 expression in the peripheral sensory neurons is severely
limited. Murine DRG sensory and motor neurons reportedly express TLR2 mRNA
(Goethals et al. 2010; Ochoa-Cortes et al. 2010) however a separate study suggests
that TLR2 protein expression is absent in neurons and is limited to satellite cells
within the murine DRG (Kim et al. 2011).
There is also some debate regarding the composition of the TLR4 receptor complex
expressed by sensory neurons. In innate immune cells a functional TLR4-signalling
complex consists of TLR4, CD14 and MD-2 (Akira & Takeda 2004). Both TG
and DRG neurons express CD14 mRNA and protein (Wadachi & Hargreaves
2006; Acosta & Davies 2008; Ochoa-Cortes et al. 2010; Tse et al. 2014a; 2014b).
DRG neurons reportedly express MD-1 mRNA and protein but little MD-2 and
no RP105 mRNA or protein (Acosta & Davies 2008). Upon activation, neuronal
TLR4 is reported to form an atypical co-receptor complex with CD14 and MD-1
(Acosta & Davies 2008). MD-1 classically interacts with the TLR4 homologue,
radioprotective 105 (RP105) to regulate TLR4 signalling (Ohto et al. 2011). More
recent studies however have shown that DRG neurons do indeed express MD-2
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and RP105 mRNA and protein in addition to MD-1 mRNA and protein (Ochoa-
Cortes et al. 2010; Tse et al. 2014a; 2014b). Additionally it was shown that the
majority of TLR4-positive neurons co-localise with CD14 and MD-2, rather than
MD-1 (Tse et al. 2014a).
Whilst it has been shown that nociceptors express a range of TLRs, a detailed
quantitative analysis of TLR expression within multiple sensory neuron sub-
populations has not been performed, particularly within the TG. Further de-
scribing the expression of TLR2, 4 and 7 within primary sensory neuron popula-
tions is a pre-requisite for further functional analysis of receptor activation and
the role of these ligands within the trigeminal system as a whole. In the cur-
rent set of experiments it is hypothesised that nociceptors possess the required
molecular components to directly detect and respond to ligands of bacterial, viral
and endogenous origin. Using well-defined neurochemical markers, a quantitative
analysis of TLR4, TLR2 and TLR7 expression within sensory ganglion neuron
sub-populations is performed. The expression of TLRs in peripheral nerve fibres
within the tooth pulp and maxillary nerve tissue is also demonstrated. Finally,
previous studies have provided conflicting results when describing TLR accessory
molecule expression within sensory neurons. Therefore a gene expression profile
of TLR signalling-associated components within the TG is described.
3.2 Results
3.2.1 Antibody characterisation
When performing any immunofluorescence analysis of protein expression it is es-
sential to correctly characterise the antibodies used. Therefore a series of control
experiments were performed to validate the antibodies used in this study (see
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section 2.4). Multiple TLR2-IR, TLR4-IR and TLR7-IR cells were observed in
spleen tissue (Fig. 3.1). No TLR4-, TLR2- or TLR7-specific staining was ob-
served in red blood cells; only a low level of non-specific staining was observed
(Fig. 3.3). When the TLR2 antibody was pre-incubated with a blocking peptide,
no positive staining was observed in the TG; only a low level of non-specific stain-
ing was observed (Fig. 3.4). TG tissue stained with an IgG isotype control did
not display any specific, positive staining (Fig. 3.5). The above results demon-
strate the specificity of the TLR primary antibodies used in these experiments.
No positive staining was observed for all secondary antibodies when primary an-
tibodies were omitted from the staining procedure (Fig. 3.6). This demonstrates
the specificity of the secondary antibodies that were used. Finally, a minimal level
of autofluoresence was detected in the TG and DRG (Fig. 3.7). Taken together,
these control experiments verify that any positive staining observed in subsequent
experiments is a true reflection of antigen expression within the tissue and is not
due to non-specificity of the antibody.
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Figure 3.1. TLR expression in spleen tissue as a positive control. Images show fluorescent micrographs of spleen tissue
stained with antibodies against TLR4 (A-B), TLR2 (C-D) and TLR7 (E-F). Multiple positively stained profiles were
identified for TLR4 (A), TLR2 (C) and TLR7 (E). Images B, C and F show an overlap of the respective TLR-IR plus
DAPI staining. Areas contained within the indicated borders (dashed lines) have been magnified in Fig. 3.2. Scale
bar 100 µm.
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Figure 3.2. Images show selected areas of Fig. 3.1 that have been magnified to give a more detailed representation
of TLR staining within the spleen. Similarly to the previous figure, multiple positively stained profiles were identified
for TLR4 (A), TLR2 (C) and TLR7 (E). Images B, C and F show an overlap of the respective TLR-IR plus DAPI
staining. Scale bar 100 µm.
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Figure 3.3. TLR expression in red blood cells as a negative control. Images show fluorescent
micrographs of rat red blood cells stained with antibodies against TLR4 (B), TLR2 (C) and
TLR7 (D). Phase contrast microscopy was used to identify red blood cells (A). No positive
staining was observed in red blood cells for any of the TLR antibodies used (B-D). Scale bar 50
µm.
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Figure 3.4. TLR2 staining in TG after pre-incubation with blocking peptide. Images show
fluorescent micrographs of rat TG stained with a pre-adsorbed antibody against TLR2 (A).
The TLR2 antibody was incubated with 10 µg of blocking peptide for 2 h at room temperature
before staining tissue as previously described. Dual-labelling was performed with NF200 (B) to
show a selection of neuronal profiles in more detail. An overlay of combined images with a DAPI
counterstain is also included (C). No specific TLR2-IR and a minimal amount of non-specific
background staining was observed (A). Scale bar 50 µm.
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Figure 3.5. IgG isotype control staining in TG. Images show fluorescent micrographs of TG
tissue stained with an IgG isotype control. A low level of non-specific background staining was
observed (A). A DAPI counterstain was also included to identify neuronal profiles (B). Scale
bar 50 µm.
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Figure 3.6. Secondary antibody control staining in spleen tissue. Images show fluorescent micro-
graphs of spleen tissue stained with secondary antibodies in the absence of primary antibodies
in order to observe non-specificity of secondary antibodies. Minimal levels of non-specific back-
ground staining was observed for DαRb AF488 (A), DαM AF555 (B), DαG AF488 (D) and
DαGP AF594 (E). Scale bar 50 µm.
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Figure 3.7. Autofluorescence in rat sensory ganglia. Images show fluorescent micrographs of
un-stained rat TG (A) and DRG (B) in order to determine the level of autofluorescence within
the tissue. A minimal level of autofluorescence was observed under the TRITC channel for both
tissues. Scale bar 50 µm.
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Figure 3.8. Images show fluorescent micrographs of TG and DRG stained with antibodies specific for TLR4, TLR2 and
TLR7. Multiple neuronal profiles display intracellular granular TLR4-IR within the TG (green, A) and DRG (green,
B), arrows show selected examples of positive neurons. A proportion of non-neuronal cells that were morphologically
identified as satellite cells also display TLR4-IR within both TG and DRG, selected examples indicated by arrowheads
(A, B). Multiple neuronal profiles also display TLR2-IR within the TG (green, C) and DRG (green, D), arrows show
selected examples of positive neurons. A proportion of non-neuronal cells that do not resemble satellite cells display
strong TLR2-IR, selected examples indicated by arrowheads (C, D). TLR7-IR was also identified within the TG (green,
E) and DRG (green, F), arrows show selected examples. All non-neuronal cells within the tissue were negative for
TLR7. Areas contained within the indicated borders (dashed lines) have been magnified in Fig. 3.9. Scale bar 50 µm.
Images representative of three biological replicates.
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Figure 3.9. Images show selected areas of Fig. 3.8 that have been magnified to give a more detailed representation
of TLR staining patterns within the TG (A, C, E) and DRG (B, D, F). Similarly to the previous figure, arrows show
selected examples of neurons that display positive IR for TLR4 (A-B), TLR2 (C-D) and TLR7 (E-F). Arrowheads
show selected examples of non-neuronal cells that display positive IR for TLR4 (A-B) and TLR2 (C-D). Scale bar 50
µm. Images representative of three biological replicates.
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3.2.2 TLR4 expression & co-expression within the adult
mammalian TG & DRG
Single labelling IHC was performed on rat TG and DRG to observe the cell-specific
pattern of expression of TLR4. A quantitative analysis of TLR4 expression within
the sensory neuron population as a whole was then performed by expressing TLR4-
IR neurons as a percentage of total neuronal profiles. A positive intracellular,
granular staining pattern for TLR4 was detected in multiple neuronal profiles
within the TG and DRG (Fig. 3.8A-B). The majority of non-neuronal cells in
the ganglia were negative for TLR4 although a small proportion of fusiform cells
enveloping neuronal soma that were morphologically identified as satellite cells did
display weak TLR4-IR (Fig. 3.8A-B). TLR4-IR was identified in 29.27 ± 3.39%
and 32.04 ± 2.91% of total neuronal profiles in the TG and DRG, respectively.
The difference in TLR4 expression between the TG and DRG was not statistically
significant (Student’s t-test).
Dual-labelling IHC of TLR4 with the neurochemical markers TRPV1, P2X3 and
NF200 was performed to provide an in-depth description of TLR4 expression with
respect to different functional sensory neuron sub-populations. A quantitative
analysis of co-localisation was performed by expressing co-labelled neurons as a
percentage of marker positive neurons. In the TG, TLR4-IR was identified in 53.7
± 0.9%, 76.6 ± 0.4% and 3.5 ± 0.7% of TRPV1-, P2X3- and NF200-IR neurons,
respectively (Fig. 3.10). Within the DRG, TLR4-IR was identified in 56.1 ± 1.4%,
81.9 ± 0.6% and 4 ± 1.3% of TRPV1-, P2X3- and NF200-IR positive neurons,
respectively (Fig. 3.11). The difference in TLR4 co-localisation with neurochem-
ical markers between the TG and DRG was not statistically significant (Stu-
dent’s t-test). However, TLR4 co-localised more frequently with P2X3-positive
neurons compared to TRPV1-positive neurons (TLR4/TRPV1 co-expression vs.
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TLR4/P2X3 co-expression, p < 0.0001 for TG and DRG, Student’s t-test).
Alternatively, co-labelled neurons were expressed as a percentage of TLR4-IR
neurons. This provides a description of neurochemical marker expression within
the total TLR4-positive neuron population. In the TG, 57.8 ± 0.9%, 58.2 ± 2%
and 9.2 ± 1.5% of TLR4-IR neurons co-expressed the markers TRPV1, P2X3 and
NF200, respectively. In the DRG, 68.2 ± 4.7%, 76.5 ± 2.5% and 6.9 ± 2.1% of
TLR4-IR neurons co-expressed TRPV1, P2X3 and NF200 respectively (see table
3.1 for summary).
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Figure 3.10. Fluorescence micrograph of rat TG dual-labelled for TLR4-IR (green, A, D, G) plus either TRPV1-
(red, B), P2X3- (red, E) or NF200-IR (red, H). The combined images (C, F, I) show co-localisation of TLR4-IR
with neurochemical markers. A substantial proportion of TLR4-IR neurons co-express TRPV1-IR, examples of co-
expressing neurons are indicated by filled arrows (A, B) and by asterisks in the combined image (C). Not all TRPV1-IR
neurons express TLR4, examples indicated by open arrows (A, B, C). A substantial proportion of TLR4-IR neurons
also co-express P2X3-IR, examples of co-expressing neurons are indicated by filled arrows (D, E) and by asterisks in
the combined image (F). Also however, not all P2X3-IR neurons express TLR4, examples indicated by open arrows
(D, E, F). There was minimal co-localisation between TLR4-IR and NF200-IR, examples of co-expressing neurons are
indicated by filled arrows (G, H) and by asterisks in the combined image (I). The majority of NF200-IR neurons did
not express TLR4-IR, examples indicated by open arrows (G, H, I). Scale bar 50µm. Images representative of three
biological replicates.
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Figure 3.11. Fluorescence micrograph of rat DRG dual-labelled for TLR4-IR (green, A, D, G) plus either TRPV1-
(red, B), P2X3- (red, E) or NF200-IR (red, H). The combined images (C, F, I) show co-localisation of TLR4-IR
with neurochemical markers. A substantial proportion of TLR4-IR neurons co-express TRPV1-IR, examples of co-
expressing neurons are indicated by filled arrows (A, B) and by asterisks in the combined image (C). Not all TRPV1-IR
neurons express TLR4, examples indicated by open arrows (A, B, C). A substantial proportion of TLR4-IR neurons
also co-express P2X3-IR, examples of co-expressing neurons are indicated by filled arrows (D, E) and by asterisks in the
combined image (F). There was minimal co-localisation between TLR4-IR and NF200-IR, examples of co-expressing
neurons are indicated by filled arrows (G, H) and by asterisks in the combined image (I). The majority of NF200-IR
neurons did not express TLR4-IR, examples indicated by open arrows (G, H, I). Scale bar 50µm. Images representative
of three biological replicates.
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3.2.3 TLR2 expression & co-expression within the adult
mammalian TG & DRG
Single labelling IHC was performed on rat TG and DRG to observe the cell-specific
pattern of expression of TLR2. A quantitative analysis of TLR2 expression within
the sensory neuron population as a whole was then performed by expressing TLR2-
IR neurons as a percentage of total neuronal profiles as defined using a DAPI
counterstain. TLR2-IR was identified in multiple neuronal profiles within the TG
and DRG (Fig. 3.8C-D). The majority of non-neuronal cells within the ganglia
were negative for TLR2 although a small number of cells displayed very strong
TLR2-IR (Fig. 3.8C-D). TLR2 was expressed by 32.6 ± 3.5% and 42.5 ± 5.1% of
total neuronal profiles in the TG and DRG, respectively. The difference in TLR2
expression between the TG and DRG was not statistically significant (Student’s
t-test).
Dual-labelling IHC of TLR2 with the neurochemical markers TRPV1, P2X3 and
NF200 was performed to provide an in-depth description of TLR2 expression
with respect to different functional sensory neuron sub-populations. A quantita-
tive analysis of co-localisation was performed by expressing co-labelled neurons
as a percentage of marker positive neurons. In the TG, TLR2 was expressed by
65.6 ± 4.9% and 66.1 ± 4.5% of TRPV1 and P2X3 positive neurons, respec-
tively (Fig. 3.12A-F). TLR2 did not co-localise with NF200 positive neurons
(Fig. 3.12G-I). In the DRG, TLR2 was expressed by 83.5 ± 1.9% and 87.2 ±
1.5% of TRPV1 and P2X3 positive neurons, respectively (3.13A-F). The differ-
ence in TLR2 co-localisation with each marker between the TG and DRG was
statistically significant (TRPV1 TG vs. DRG, p < 0.05; P2X3 TG vs. DRG, p <
0.05, Student’s t-test). Again, in the DRG, TLR2 did not co-localise with NF200
(Fig. 3.13G-I).
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Alternatively, co-labelled neurons were expressed as a percentage of TLR2-IR
neurons. This provides a description of neurochemical marker expression within
the total TLR2-positive neuron population. In the TG, 67.6 ± 2.6% and 49.8 ±
1.9% of TLR2-positive neurons co-expressed TRPV1 and P2X3, respectively. In
the DRG, 79.1 ± 2.9% and 64.6 ± 2.1% of TLR2-positive neurons co-expressed
TRPV1 and P2X3, respectively (see table 3.1 for summary).
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Figure 3.12. Fluorescence micrograph of rat TG dual-labelled for TLR2-IR (green, A, D, G) plus either TRPV1-
(red, B), P2X3- (red, E) or NF200-IR (red, H). The combined images (C, F, I) show co-localisation of TLR2-IR
with neurochemical markers. A substantial proportion of TLR4-IR neurons co-express TRPV1-IR, examples of co-
expressing neurons are indicated by filled arrows (A, B) and by asterisks in the combined image (C). Not all TRPV1-IR
neurons express TLR2, examples indicated by open arrows (A, B, C). A substantial proportion of TLR2-IR neurons
also co-express P2X3-IR, examples of co-expressing neurons are indicated by filled arrows (D, E) and by asterisks in the
combined image (F). There was minimal co-localisation between TLR2-IR and NF200-IR, examples of co-expressing
neurons are indicated by filled arrows (G, H) and by asterisks in the combined image (I). The majority of NF200-IR
neurons did not express TLR2-IR, examples indicated by open arrows (G, H, I). Scale bar 50µm. Images representative
of three biological replicates.
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Figure 3.13. Fluorescence micrograph of rat DRG dual-labelled for TLR2-IR (green, A, D, G) plus either TRPV1-
(red, B), P2X3- (red, E) or NF200-IR (red, H). The combined images (C, F, I) show co-localisation of TLR2-IR
with neurochemical markers. A substantial proportion of TLR4-IR neurons co-express TRPV1-IR, examples of co-
expressing neurons are indicated by filled arrows (A, B) and by asterisks in the combined image (C). Not all TRPV1-IR
neurons express TLR2, examples indicated by open arrows (A, B, C). A substantial proportion of TLR2-IR neurons
also co-express P2X3-IR, examples of co-expressing neurons are indicated by filled arrows (D, E) and by asterisks in the
combined image (F). There was minimal co-localisation between TLR2-IR and NF200-IR, examples of co-expressing
neurons are indicated by filled arrows (G, H) and by asterisks in the combined image (I). The majority of NF200-IR
neurons did not express TLR2-IR, examples indicated by open arrows (G, H, I). Scale bar 50µm. Images representative
of three biological replicates.
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3.2.4 TLR7 expression & co-expression within the adult
mammalian TG & DRG
Single labelling IHC was performed on rat TG and DRG to observe the cell-specific
pattern of expression of TLR7. A quantitative analysis of TLR7 expression within
the sensory neuron population as a whole was then performed by expressing TLR7-
IR neurons as a percentage of total neuronal profiles as defined using a DAPI
counterstain. Similarly to both TLR4 and TLR2, TLR7-IR was identified in
multiple neuronal profiles within the TG and DRG (Fig. 3.8E-F). However, unlike
TLR4 and TLR2, TLR7 staining was restricted to neurons and was excluded
from all non-neuronal cells within the ganglia. TLR7 was expressed by 32.4 ±
1.8% and 35 ± 3.9% of total neuronal profiles in the TG and DRG, respectively.
The difference in TLR7 expression between the TG and DRG is not considered
statistically significant (Student’s t-test).
Dual-labelling IHC of TLR7 with the neurochemical markers TRPV1, P2X3 and
NF200 was performed to provide an in-depth description of TLR7 expression
with respect to different functional sensory neuron sub-populations. A quantita-
tive analysis of co-localisation was performed by expressing co-labelled neurons as
a percentage of marker positive neurons. In the TG, TLR7 was expressed by 75.7
± 2.5% and 61.6 ± 2.1% of TRPV1 and P2X3 positive neurons respectively (Fig.
3.14A-F). TLR7 did not co-localise with NF200 positive neurons (Fig. 3.14G-I).
Within the DRG, TLR7 was expressed by 78.6 ± 2.6% and 54.8 ± 9.4% of TRPV1
and P2X3 positive neurons respectively (Fig. 3.15A-F). Again, TLR7 and NF200
expression were mutually exclusive (Fig. 3.15G-I). The difference in co-expression
of TLR7 with neurochemical markers between the TG and DRG is not consid-
ered statistically significant (Student’s t-test. However TLR7 co-localised more
frequently with TRPV1-positive neurons compared to P2X3-positive neurons in
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both tissues (TLR7/TRPV1 co-expression vs. TLR7/P2X3 co-expression, p <
0.05 for TG, Student’s t-test. The difference was not statistically significant in
the DRG (p = 0.07)).
Alternatively, co-labelled neurons were expressed as a percentage of TLR7-IR
neurons. This provides a description of neurochemical marker expression within
the total TLR7-positive neuron population. In the TG, 43.4 ± 8.1% and 34.8 ±
3.1% of TLR7-positive neurons also expressed TRPV1 and P2X3, respectively. In
the DRG, 43.2 ± 10.5% and 32.2 ± 4.8% of TLR7-positive neurons also expressed
TRPV1 and P2X3, respectively.
Table 3.1 and Fig. 3.16 provide a full summary of TLR4, TLR2 and TLR7 co-
expression with neurochemical markers within the TG and DRG.
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Figure 3.14. Fluorescence micrograph of rat TG double labelled for TLR7-IR (green, A, D, G) plus either TRPV1-
(red, B), P2X3- (red, E) or NF200-IR (red, H). The combined images (C, F, I) show co-localisation of TLR7-IR
with neurochemical markers. A substantial proportion of TLR7-IR neurons co-express TRPV1-IR, examples of co-
expressing neurons are indicated by filled arrows (A, B) and by asterisks in the combined image (C). Some neurons
expressing low levels of TRPV1-IR neurons do not display TLR7-IR, examples indicated by open arrows (A, B, C). A
substantial proportion of TLR7-IR neurons also co-express P2X3-IR, examples of co-expressing neurons are indicated
by filled arrows (D, E) and by asterisks in the combined image (F). Also however, not all P2X3-IR neurons display
TLR7-IR, examples indicated by open arrows (D, E, F). There was minimal co-localisation between TLR7-IR and
NF200-IR, examples of co-expressing neurons are indicated by filled arrows (G, H) and by asterisks in the combined
image (I). The vast majority of NF200-IR neurons did not express TLR7-IR, examples indicated by open arrows (G,
H, I). Scale bar 50µm. Images representative of three biological replicates.
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Figure 3.15. Fluorescence micrograph of rat DRG double labelled for TLR7-IR (green, A, D, G) plus either TRPV1-
(red, B), P2X3- (red, E) or NF200-IR (red, H). The combined images (C, F, I) show co-localisation of TLR7-IR
with neurochemical markers. A substantial proportion of TLR7-IR neurons co-express TRPV1-IR, examples of co-
expressing neurons are indicated by filled arrows (A, B) and by asterisks in the combined image (C). Some neurons
expressing low levels of TRPV1-IR neurons do not display TLR7-IR, examples indicated by open arrows (A, B, C). A
substantial proportion of TLR7-IR neurons also co-express P2X3-IR, examples of co-expressing neurons are indicated
by filled arrows (D, E) and by asterisks in the combined image (F). There was minimal co-localisation between TLR7-
IR and NF200-IR, examples of co-expressing neurons are indicated by filled arrows (G, H) and by asterisks in the
combined image (I). The majority of NF200-IR neurons did not express TLR7-IR, examples indicated by open arrows
(G, H, I). Scale bar 50µm. Images representative of three biological replicates.
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Figure 3.16. A graphical summary showing the percentage of neurochemical marker-positive
neuronal populations that express TLR4, TLR2 or TLR7. *, p < 0.05. Data are presented as
mean ± S. E. M., n = 3.
3.2.5 TLR expression in peripheral nerve fibres innervat-
ing orofacial tissues.
Dual-labelling IHC was performed in order to investigate the expression of TLRs
along the peripheral maxillary nerve and nerve terminals of TG sensory neurons
within maxillary incisor dental pulp, using β-III-tubulin as a marker of periph-
eral neuron terminals/axons. A high degree of non-specific binding of the TLR4
antibody was observed in peripheral tissues and it was therefore difficult to draw
any valid conclusions about TLR4 expression in peripheral nerve fibres. Multiple
peripheral nerve axons within the tooth pulp display both TLR2- and TLR7-IR
(Fig. 3.17A-C and Fig. 3.17D-F, respectively). Multiple axons within the max-
illary nerve also display TLR2- and TLR7-IR (Fig. 3.18A-C and Fig. 3.18D-F,
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Figure 3.17. TLR2 (A-C) and TLR7 (D-F) expression in nerve fibres innervating the rat dental
pulp. Images show fluorescent micrographs of rat incisor tooth pulp co-stained with antibodies
against either TLR2 (A) or TLR7 (D) and β-III-tubulin (B, E). Combined images (C, F) also
include a DAPI counterstain. Both TLR2-IR and TLR7-IR were detected within multiple nerve
fibres. Scale bar 50 µm. Images representative of three biological replicates.
respectively). Collectively these images suggest that TLR2 and TLR7 are indeed
expressed by trigeminal sensory neurons within peripheral tissues.
3.2.6 Expression of TLR4 signalling-associated molecules
in TG sensory neurons
A gene expression profile for a selection of TLR signalling-associated components
was compiled by performing qPCR on acutely dissociated TG sensory neurons.
Specifically, the gene expression of TLR4 and three TLR4 accessory molecules,
MD-1, MD-2 and CD14, as well as two intracellular signalling molecules that
represent two pathways of the TLR intracellular signalling cascade, MyD88 and
TRAM, was evaluated. The MyD88 pathway is active downstream from all other
TLRs (including TLR2 and TLR7), with the exception of TLR3 which signals
solely via the MyD88-independent pathway. TLR4 is unique in the fact that it
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Figure 3.18. TLR2 (A-C) and TLR7 (D-F) expression in nerve fibres contained within the
maxillary nerve. Images show fluorescent micrographs of rat maxillary nerve co-stained with
antibodies against either TLR2 (A) or TLR7 (D) and β-III tubulin (B, E). Combined images
(C, F) also include a DAPI counterstain. Both TLR2-IR and TLR7-IR were detected within
multiple nerve fibres. Scale bar 50 µm. Images representative of three biological replicates.
can activate both pathways following receptor activation. For reference purposes,
the pain-associated genes for TRPV1, P2X3 and TrkA were also included. The
expression of these target genes relative to the housekeeping gene GAPDH (set
at 100) is shown for TG sensory neurons (Fig. 3.19A) and control (spleen tissue,
Fig. 3.19B), respectively. All target genes were expressed in TG sensory neurons
(CT < 35) albeit at lower levels than TRPV1, P2X3 and TRKA expression, re-
spectively (Fig. 3.19A). Gene expression levels of the TLR-associated components
within TG sensory neurons were also compared to that of primary spleen tissue
which is known to contain a broad range of TLR-expressing immune cells. All
genes were expressed at lower levels in TG sensory neurons than in spleen tissue
(Fig. 3.19C). MD-1 was expressed 290.1 ± 36.3 fold lower in TG sensory neurons
compared to primary spleen tissue although this was not surprising given the high
B lymphocyte content of spleen tissue (Cesta 2006). TLR4 gene expression was
the most comparable between the different tissue types with a 9.1 ± 1.1 fold lower
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expression in TG sensory neurons. The remaining targets were expressed 9.8 ±
2.1 (TRAM), 13 ± 2.1 (MD-2), 24.5 ± 3.1 (MyD88) and 40 ± 8.2 (CD14) fold
lower in TG sensory neurons than the spleen.
3.3 Discussion
Previous studies have shown both TLR4 and TLR7 to be expressed by putative
nociceptive neurons within mammalian sensory ganglia (Wadachi & Hargreaves
2006; Liu et al. 2010; Qi et al. 2011; Due et al. 2012; Park et al. 2014; Lin
et al. 2015) whereas TLR2 expression is restricted to non-neuronal cells (Kim
et al. 2011). In the current study, it is demonstrated that TLR4, TLR2 and
TLR7 are all expressed by sensory neurons within the TG and DRG. Further, the
expression of these TLRs specifically localised to functional sub-populations of
nociceptive neurons. Co-localisation of TLR4 and TLR7 with TRPV1 has been
shown previously (Wadachi & Hargreaves 2006; Park et al. 2014; Lin et al. 2015),
however this is the first quantitative description of their expression within adult
mammalian sensory ganglia in relation to functional neuronal phenotype.
The degree of TLR4 expression for both TG and DRG falls within the range of ex-
pression of TLR4 previously observed in DRG sections (28-34% of total neurons)
(Due et al. 2012; Tse et al. 2014b). Certain properties of sensory neurons, in-
cluding the expression and co-expression between phenotypic markers, have been
shown to vary between the TG and DRG (see Bereiter et al. 2009) however there
was no significant difference in expression levels of TLR4 or TLR7 between the
tissue types. TLR2 was however expressed by a larger proportion of neurons in
the DRG compared to the TG (approximately 10%), although this was not con-
sidered statistically significant. Previous studies have reported that non-neuronal
cells in peripheral ganglia do not express TLR4 (Due et al. 2012; Tse et al. 2014a)
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Figure 3.19. TLR4 signalling-associated component gene expression in dissociated TG sensory
neurons (A) and spleen tissue (B) as determined by qPCR. All genes are expressed relative to
GAPDH levels (set at 100). Three pain-associated genes are also included in (A) for reference
purposes. All targets were expressed in sensory neurons (CT <35). All TLR-associated genes
were expressed at noticeably lower levels than each of the three pain-associated genes, respec-
tively. The difference in gene expression between TG sensory neurons and spleen tissue was
calculated using the ∆∆CT method (C). All targets were expressed in TG sensory neurons at
lower levels compared to spleen tissue. Data are displayed as mean ± S.E.M., n = 3 individual
cell preparations.
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however here we show that a proportion of satellite cells do indeed display TLR4-
IR. This observation has been confirmed in a recent study that also identified
TLR4-IR in satellite cells within the TG (Lin et al. 2015). Although Tse et al.,
2014a, 2014b found that non-neuronal cells within the DRG did not express TLR4
under normal conditions they subsequently showed that they do indeed begin to
express TLR4 once contact with neurons is removed in vitro. Therefore it seems
as though non-neuronal cells express TLR4 in an inducible manner and therefore
may play a role in neuroimmune signalling within the PNS.
TLR4, TLR2 and TLR7 are expressed by both heat- and ATP-responsive noci-
ceptors in the TG and DRG due to a high degree of co-expression with TRPV1
and P2X3, respectively. Interestingly there was a noticeable difference in co-
localisation levels of certain TLRs with the different markers. Co-expression data
shows that TLR4 more readily co-localised with P2X3- compared to TRPV1-
expressing neurons in the TG and DRG. Conversely, TLR7 more readily co-
localised with TRPV1- compared to P2X3-expressing neurons in the TG and
DRG. The amount of co-localisation of TLR2 with TRPV1- and P2X3-expressing
neurons is comparable in the TG and DRG although the percentage of co-localisat-
ion with both markers is statistically higher in the DRG. The degree of co-
localisation with either marker also varies when comparing between the three
TLRs. In the TG, TLR7 displayed a greater percentage of co-localisation to
TRPV1-positive neurons when compared to TLR2 and, similarly, TLR2 dis-
played a greater percentage when compared to TLR4 (TLR7>TLR2>TLR4).
When comparing co-localisation of TLRs with P2X3 the observed pattern is
TLR4>TLR2≈TLR7. In the DRG a different pattern is observed. With respect
to co-localisation with TRPV1-positive neurons, TLR2 displayed a comparable
amount of co-localisation to TLR7 and both of these TLRs displayed larger de-
gree of co-localisation compared to TLR4 (TLR2≈TLR7>TLR4). When compar-
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ing co-localisation with P2X3 the observed pattern is TLR2≈TLR4>TLR7. The
functional significance of these observations are currently unknown although Park
et al. (2014) have recently shown that TLR7 interacts with TRPA1, expressed by a
proportion of TRPV1-positive neurons, to directly activate sensory neurons. With
respect to TLR2, these comparisons correspond to the observation that TLR2 is
expressed by a greater number of total neurons in the DRG. It is worth noting
here that there is a degree of co-expression between TRPV1- and P2X3-expressing
populations reported in previous literature (Guo et al. 1999; Ichikawa & Sugimoto
2004; Kim, Chung, Jo, Kim, Bae, Jung, Kim & Oh 2011) and therefore a degree of
overlap in the current co-expression data must be considered. It has been shown
that P2X3 activity can mediate subsequent TRPV1 sensitisation (Saloman et al.
2012). Therefore, given the high degree of co-expression with each marker de-
scribed here, it is probable that a proportion of TLR-positive neurons co-express
both TRPV1 and P2X3. We found minimal co-localisation between TLR4, TLR2
and TLR7 with NF200 suggesting that these TLRs selectively localise to C-fibre
nociceptors, but not low-threshold non-nociceptive sensory neurons. Preferen-
tial and direct activation and/or sensitisation of nociceptors by pathogens and
damage-released endogenous molecules via TLR4, TLR2 and TLR7 is therefore
highly likely.
There is now extensive evidence for the involvement of neuroimmune signalling
in the development and maintenance of chronic pain states (reviewed by Nicotra
et al. 2012). TLRs are an important class of receptor in the complex intercellular
signalling network that develops in the setting of chronic pain. TLR4 is the most
widely studied member of the receptor family in this setting and it is rapidly
up-regulated following the onset of inflammatory and neuropathic pain (DeLeo
et al. 2004; Raghavendra et al. 2004). TLR4 deletion (Tanga et al. 2005; Agalave
et al. 2015) and pharmacological inhibition are both able to prevent (Bettoni
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et al. 2008) and reverse behavioural hypersensitivity (Hutchinson et al. 2007;
2008; 2010; Lan et al. 2010; Wu et al. 2010) and decrease the production of
pro-inflammatory mediators in models of neuropathic pain (Tanga et al. 2005;
Lan et al. 2010). Importantly, the involvement of TLR4 in the development and
maintenance of chronic pain has also been demonstrated in a human model. A low
intravenous dose of LPS sensitised nociceptors to a subsequent capsaicin challenge
and participants experienced an increase in capsaicin-dependent flare, allodynia
and hyperalgesia; although the effect of LPS on neurons in this study is likely
to be mainly indirect (Hutchinson et al. 2013). Findings from past studies have
been extended to include the contribution of TLR2 and TLR3 to central nervous
system preclinical pain models (Kim et al. 2007; Obata et al. 2008; Mei et al.
2011). TLR3 (Liu et al. 2012) and TLR7 (Park et al. 2014) activation has also
been shown to directly activate peripheral sensory neurons in the murine DRG.
Early research in this field has focussed mainly on TLR4 however more TLRs are
emerging as important mediators of pain hypersensitivity. Whilst the role, for
example, of TLR7 in clinical pain models has yet to be studied, peripheral blood
mononuclear cells from chronic pain patients display increased responsiveness to
TLR7 ligand stimulation, as well as TLR2 and TLR4 (Kwok et al. 2012).
From the results presented in this chapter it can be inferred that, in several
of these settings, TLR activation is likely to occur directly on sensory neurons
and is not necessarily dependent on the activation of the innate immune sys-
tem. The ability of neurons to directly detect and respond to pathogenic ligands
independently from the innate immune system represents a rapid response mecha-
nism that has significant consequences for nociceptor activation, sensitisation and
altered neuronal-non-neuronal cell communication. Following TLR4 activation,
for example, peripheral sensory neurons display increased excitability (Ochoa-
Cortes et al. 2010; Due et al. 2012), sensitisation of TRPV1 and potentiation of
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TRPV1-dependent neuropeptide production (Diogenes et al. 2011; Ferraz et al.
2011). Various pro-inflammatory mediators are also induced downstream from
acute TLR4 activation (Ochoa-Cortes et al. 2010; Tse et al. 2014a). Neuronal
TLR7 activation induces rapid inward currents and action potentials to increase
neuronal excitability through mechanisms involving TRPA1 (Liu et al. 2010; 2012;
Park et al. 2014). An up-regulation and sensitisation of TRPV1 and induction of
pro-inflammatory mediators is also observed following neuronal TLR7 activation
(Qi et al. 2011). It is likely that these pro-inflammatory mediators can signal
through autocrine and/or paracrine mechanisms to activate nociceptors, further
alter transcriptional/translational expression of various factors and contribute to
the local inflammatory response (see Sommer & Kress 2004; Binshtok et al. 2008;
Milligan & Watkins 2009; Uceyler et al. 2009 for focussed reviews). Therefore the
activation of neuronal TLRs may also be relevant for the acute pain response. As
previously mentioned, the expression of TLR2 has not been previously identified
in peripheral sensory afferents and therefore the functional implications down-
stream from neuronal TLR2 activation is unknown. In chapter 4 of this thesis
we demonstrate that neuronal TLR2 is functional and capable of generating a
response following ligand exposure. Despite this, a significant amount of work is
required to fully understand the properties of neuronal TLR2 and its ability to
modulate nociceptor physiology.
The expression of TLRs in TG neurons within peripheral tissues has great im-
plications for oral pathology. The various densely innervated, specialised sensory
organs innervated by the trigeminal nerve combined with the plethora of invasive
pathogens implicated in infections of the oral cavity would suggest that direct
pathogen-neuron interactions are a frequent occurrence in multiple disease set-
tings. TLR4 expression has been identified in tooth pulp previously (Wadachi &
Hargreaves 2006) and here it is shown that TLR2 and TLR7 are also expressed
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in neurons that innervate the rat tooth pulp, which are considered to be largely
nociceptive (Vang et al. 2012). Therefore bacteria such as P. gingivalis (TLR4)
and S. mutans (TLR2) as well as a range of enteroviruses (TLR7), e.g. cox-
sackievirus, may potentially interact with neuronal TLRs to directly activate or
sensitise nociceptors and contribute towards disease pathology. A range of tissue-
damage released endogenous molecules are now known to activate various TLRs
(see Yu et al. 2010) and neuronal TLR activation via endogenous ligands has been
demonstrated in the TG (Ohara et al. 2013) and DRG (Miller et al. 2014; Park
et al. 2014). Acute and chronic tissue damage associated with oral diseases, such
as later-stage gingivitis, may therefore also promote pain hypersensitivity directly
via the activation of neuronal TLRs.
This study is the first to demonstrate a co-localisation of TLR4, TLR2 and TLR7
with P2X3-expressing neurons. P2X3 activation, by ATP, causes rapid nociceptor
depolarisation and plays a prominent role in the sensitisation of nociceptors and
alteration of neuronal/non-neuronal cell communication following the onset of
inflammation (Oliveira et al. 2005; Fabbretti 2013) and nerve injury (Honore
et al. 2002; Hsieh et al. 2012). LPS has been shown to evoke an upregulation and
sensitisation of P2X3 receptors in primary trigeminal ganglion neuron cultures
however it is not known whether this is through a direct action on neurons or
secondary to the activation of non-neuronal cells and subsequent release of ATP
and inflammatory mediators (Franceschini et al. 2013). Here it is demonstrated
that a large proportion of P2X3-positive neurons co-express TLR4 suggesting
that LPS could directly modulate P2X3 receptor function. A large proportion of
P2X3-positive neurons co-express TLR4, TLR2 and TLR7 suggesting that other
bacterial (both Gram-negative and Gram-positive) and viral infection could also
directly modulate P2X3 receptor function. It is therefore reasonable to suggest
that the activation of neuronal TLRs could be sufficient to sensitise P2X3 in a
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similar manner to that of TLR4-dependent TRPV1 sensitisation.
The exact composition of the TLR4 co-receptor complex that is required for neu-
ronal TLR4 activation remains unclear. The co-localisation of TLR4 with the
co-receptor CD14 has been identified in capsaicin-responsive nociceptors within
the TG (Wadachi & Hargreaves 2006) and the involvement of CD14 in neuro-
pathic pain has been demonstrated (Cao et al. 2009). However there is conflicting
evidence as to whether MD-1 or MD-2 are involved in neuronal TLR4 signalling.
In innate immune cells the TLR4 receptor complex consists of TLR4, CD14 and
MD-2 (Akashi-Takamura & Miyake 2008). MD-1, a MD-2 homologue, normally
forms a complex with RP105, a TLR4 homologue that lacks an intracellular TIR
homology domain (Medzhitov 2001). One study has shown that neuronal TLR4
interacts with MD-1 rather than the conventional co-receptor MD-2 (Acosta &
Davies 2008). This latter study also showed a lack of MD-2 expression in DRG
sensory neurons. However more recent studies have identified both MD-1 and
MD-2 mRNA and protein expression in DRG nociceptors and shown a prefer-
ential co-localisation of TLR4 with MD-2 (Ochoa-Cortes et al. 2010; Tse et al.
2014a). Results presented in this chapter show that acutely dissociated TG sen-
sory neuron preparations express TLR4, CD14, MD-1, MD-2, MyD88 and TRAM
mRNA. This in agreement with Tse et al. (2014a) and Ochoa-Cortes et al. (2010)
that sensory neurons express both MD-1 and MD-2. MyD88 and TRAM expres-
sion suggests that both the MyD88-dependent and MyD88-independent branches
of the TLR4-signalling pathway are available following neuronal TLR4 activation.
MyD88-dependent signalling downstream of neuronal TLR4 and IL-1β receptor
activation has been shown (Davis et al. 2006; Qi et al. 2011; Tse et al. 2014a)
however the role of MyD88-independent signalling in peripheral sensory neurons
is yet to be demonstrated. The expression of all targets within the TG were much
lower than three common pain-associated genes (TRPV1, P2X3 and TrkA) al-
118
3. TLR expression in sensory neurons.
though this was expected given the primary function of neurons. The expression
of each target in the TG was lower than the corresponding expression in spleen
tissue. Again this was expected given that TLR signalling is an essential compo-
nent of innate immune cells that can be found in large numbers in the spleen. The
acutely dissociated sensory ganglia cell preparations used in this study contained
a proportion of non-neuronal cells and as we have shown that a small number of
satellite cells display TLR4-IR it is therefore not possible to directly assign this
gene expression purely to neurons. However, given the TLR expression patterns
observed in this study as well as the techniques used when dissociating ganglia
we believe that it is reasonable to suggest that the gene expression is largely neu-
ronal. It is worth noting that co-receptor components, such as MD-2 and CD14,
exist in soluble forms that are secreted from cells to actively participate in the
LPS response (Bazil et al. 1989; Visintin et al. 2001). Therefore co-receptor com-
ponents do not necessarily need to be expressed by neurons to mediate neuronal
TLR4 signalling, a phenomenon which has been demonstrated in lung epithelial
cells (Kennedy et al. 2004).
In summary, the results presented in this chapter demonstrate that a substan-
tial proportion of nociceptors within sensory ganglia express TLR4, TLR2 and
TLR7. It is also shown that TLR2 and TLR7 are expressed in peripheral nerve
fibres within the dental pulp. Therefore it is likely that these TLRs may be ac-
tivated by their respective agonists (see Table 1.1) under pathological conditions.
The activation of TLRs may be sufficient to induce an alteration in nociceptor
physiology and may contribute towards the initiation and maintenance of pain
hypersensitivity. Collectively these results support the hypothesis that nocicep-
tors possess the required molecular components to directly detect and respond to
ligands of bacterial, viral and endogenous origin independently from the innate
immune response.
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Chapter 4
The TLR-dependent induction of
cytokine gene expression in
trigeminal sensory neurons in
vitro.
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4.1 Introduction
TLR signalling in innate immune cells represents a critical component of the
first line of defence against invading pathogens. Following receptor activation,
downstream signalling cascades ultimately result in the production of various in-
flammatory mediators, such as cytokines and chemokines, and the up-regulation
of co-stimulatory molecules. TLR signalling is therefore a major driving factor for
the initiation and orchestration of the localised inflammatory response and the
subsequent development of a tailored adaptive immune response. An in-depth
review of TLR signalling pathways can be found in Chapter 1 of this thesis. TLR
signalling in non-neuronal cells, such as glial cells and immune cells within the
CNS and in peripheral tissues, is a critical component of a neuroimmune axis that
develops with inflammatory and neuropathic pain states. The activation of these
TLRs ultimately results in the indirect sensitisation of neurons associated with a
prolonged immune response (see Nicotra et al. 2012). Various pro-inflammatory
cytokines, for example, that are produced by innate immune cells at the site of
infection/injury can interact with specific receptors on peripheral sensory neurons
to directly activate and/or sensitise the cell. TNFα, IL-1β and IL-6 are perhaps
the most characterised cytokines that are known to induce neuronal plasticity (see
Miller et al. 2009) however some other novel cytokines such as IL-17 (Segond von
Banchet et al. 2013) and IL-33 (Han et al. 2013) have also been demonstrated to
directly alter sensory neuron responses.
As mentioned in previous chapters, TLRs have been implicated in various models
of chronic pain. The majority of these past studies, however, have suggested that
the activation of TLRs is likely to occur on non-neuronal cells and infiltrating
immune cells. More recently, it has been demonstrated that TLR activation may
occur directly on sensory neurons. For example, the activation of TLR3 (Liu
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et al. 2012) and TLR7 (Park et al. 2014) activation has been shown to directly
activate peripheral sensory neurons in the murine DRG. Further, the activation
of neuronal TLRs has also been shown to induce transcriptional, translational
and post-translational alterations to transduction channels and neuropeptide pro-
duction. The majority of past studies have been performed using DRG neurons
with only a limited number focussing on TG neurons. In the trigeminal system,
the activation of neuronal TLR4 by P. gingivalis LPS sensitises and up-regulates
TRPV1 and potentiates the capsaicin-induced release of the vasoactive neuropep-
tide CGRP (Diogenes et al. 2011; Ferraz et al. 2011). A role for neuronal TLR4
in mediating pain induced by endogenous compounds released following oral tis-
sue damage has also been demonstrated (Ohara et al. 2013). This latter study
showed that the administration of HSP70 or LPS to the rat tooth resulted in a
TLR4-dependent increase in mechanical and thermal hyperalgesia. The activa-
tion of neuronal TLR4 has been shown to induce inward currents (Ochoa-Cortes
et al. 2010; Due et al. 2012), nociceptin expression (Acosta & Davies 2008) and
the MyD88-dependent production of pro-inflammatory mediators (Ochoa-Cortes
et al. 2010; Tse et al. 2014a; Lin et al. 2015) in murine DRG neurons. Certain
DAMPs are also capable of activating TLR4 on DRG neurons to promote the pro-
duction of pro-inflammatory mediators (Miller et al. 2014). Activation of TLR3
and TLR7 directly activates DRG nociceptors and also induces an itch response
(pruritis) (Liu et al. 2010; 2012). More recently the activation of TLR7, by en-
dogenous microRNAs (miRNA), has been shown to rapidly activate DRG neurons
through mechanisms that involve TRPA1 (Park et al. 2014). Activation of TLR3,
7 and 9 also induces the production of pro-inflammatory mediators, up-regulates
TRPV1 expression and sensitises TRPV1 activation in DRG neurons (Qi et al.
2011). Given the unique location and developmental origin of the TG as well as
the specialist sensory organs that are innervated by trigeminal sensory neurons
it would be incorrect to assume that the properties of TLRs expressed on DRG
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neurons translate to those of TG neurons. Indeed many differences between TG
and DRG neurons have been documented (see Bereiter et al. 2009). Therefore
further characterisation of neuronal TLRs within the trigeminal system is essen-
tial in order to understand their role in the acute pain response and also in the
development of chronic pain following oral infection/injury.
A recent oral microbiome sequencing study showed that the oral flora associ-
ated with a healthy oral cavity consists of approximately 750 different microbial
species and the levels of roughly 200 of these species were significantly altered
in sub-gingival plaques found in periodontal disease (Ge et al. 2013). Three ‘red
complex’ bacteria have been identified in chronic periodontal disease that are
thought to play a key orchestrating role in tissue destruction and disease progres-
sion (Socransky et al. 1998). Porphyromonas gingivalis, Treponema denticola and
Tannerella forsythia can act in a synergistic fashion to cause the destruction of
periodontal tissue. It is now widely accepted that P. gingivalis has a central role
in the development of both chronic and aggressive periodontal disease. Although
P. gingivalis is capable of initiating an innate immune response it has recently
been suggested that the bacterium acts as a keystone pathogen to promote an
overall shift in microbiome behaviour and create a dysbiotic relationship with the
host (Hajishengallis et al. 2012). Multiple pathogenic species within the mature
plaque then contribute toward the development of a chronic inflammatory re-
sponse in sub-gingival tissue and the subsequent tissue damage that is associated
with the chronic disease. Although the majority of bacterial species implicated in
chronic periodontal disease are Gram-negative anaerobic bacteria a host of other
microbial species have been associated with the disease such as Gram-positive bac-
teria and also certain viruses and fungi (see Wade 2013). The polymicrobial and
chronic nature of periodontal disease means that there are an array of potential
PAMPs and DAMPs contained within the localised area of infection that could
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potentially interact with neuronal TLRs and other innate receptor families.
P. gingivalis possesses multiple virulence factors, including LPS, that promote
immune activation and tissue damage associated with periodontal disease (Bain-
bridge & Darveau 2001). The bacterium releases copious amounts of LPS, often
contained within vesicles coated in fimbriae, that are able to penetrate host tissue
and actively promote tissue destruction (Grenier & Mayrand 1987). LPS consists
of three major components; an outer polysaccharide, an oligosaccharide core and
an inner lipid A region (Dixon and Darveau, 2005). Lipid A is a phosphory-
lated glucosamine disaccharide that has multiple attached fatty acids and is the
crucial component of LPS that is responsible for the activation of TLR4 (Park
et al. 2009). P. gingivalis LPS is known to contain multiple, structurally differ-
ent, lipid A species with varying affinity for TLR4 and therefore a differing level
of inflammatory potency (Kumada et al. 1995; Darveau et al. 2004; Al-Qutub
et al. 2006; Herath et al. 2013). Whereas the immune response to canonical
LPS from E. coli is well characterised, that of P. gingivalis LPS and other non-
enterobacterial species has been the source of past debate. E. coli LPS is delivered
to CD14, either in the soluble form or expressed on the host cell membrane, by
LPS binding protein (LBP). The LPS is then transferred to a receptor complex
consisting of TLR4 and MD-2. LPS binding causes receptor dimerisation and
the subsequent activation of intracellular signalling cascades associated with host
defence mechanisms. P. gingivalis LPS however has previously been shown to
signal through both TLR2 (Bainbridge & Darveau 2001; Hirschfeld et al. 2001;
Martin et al. 2001) and TLR4 (Tabeta et al. 2000; Ogawa et al. 2002) with vary-
ing downstream effects. The ability of P. gingivalis LPS to activate TLR2 has
previously been attributed to lipopeptide contamination of isolated LPS however
it is now understood that the bacterium is indeed able to signal through TLR2
and TLR4 due to the heterogeneity of P. gingivalis lipid A structures (Darveau
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et al. 2004).
Specifically, P. gingivalis lipid A structures can vary in the composition of the
attached fatty acids and number of phosphorylation sites within the molecule
(Dixon & Darveau 2005). Di-, mono- and non-phosphorylated as well as penta-
and tetra-acylated isoforms of P. gingivalis lipid A have been identified (Ku-
mada et al. 1995). The bacterium is able to actively alter the phosphorylation
and acylation status of lipid A molecules in response to changes in the local en-
vironment (Al-Qutub et al. 2006; Curtis et al. 2011). It is these variations in
lipid A structure that ultimately determine the receptor affinity and inflamma-
tory potency of the LPS structure. For example synthetic di-phosphorylated,
penta-acylated is particularly potent TLR4 agonist (Kumada et al. 2008; Coats
et al. 2009). In addition, mono-phosphorylated, penta-acylated (LPS1690) also
displays strong TLR4 activity (Reife et al. 2006) whereas mono-phosphorylated,
tetra-acylated (LPS1435) is able to interact with both TLR2 and TLR4 although
it does not generate a strong host response (Darveau et al. 2004). In human
gingival fibroblasts P. gingivalis LPS1690 up-regulates the expression of IL-6 and
IL-8, whereas P. gingivalis LPS1435 does not (Herath et al. 2013). Interestingly
the non-phosphorylated isoform of P. gingivalis lipid A is a particularly weak
TLR4 agonist and both mono-phosphorylated and non-phosphorylated isoforms
display TLR4 antagonist activity (Coats et al. 2009). Therefore when examining
the biological roles of P. gingivalis LPS it is critically important to pay particular
attention to the individual isoforms of lipid A present.
The microbiology of periodontal disease, as detailed above, demonstrates the com-
plexity and multifactorial nature of many oral diseases. This, combined with the
dense innervation of oral tissues, makes the direct interaction between neurons and
the oral flora a likely, and regular, occurrence. In the case of orofacial diseases the
presence of more potent and pathogenic PAMPs, as well as DAMPs released fol-
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lowing tissue damage, is likely to be detected by neuronal TLRs. This interaction
may contribute towards the initiation of a local inflammatory response and pe-
ripheral sensitisation of nociceptors. Although significant progress has been made
over the past decade, since Wadachi and Hargreaves (2006) first demonstrated
that TG sensory neurons express TLR4, our understanding of the functional con-
sequences of neuronal TLR activation remains limited, particularly within the
trigeminal system. As mentioned previously, the detection of P. gingivalis LPS
by TG neurons expressing TLR4 has been demonstrated (Diogenes et al. 2011;
Ferraz et al. 2011) however the induction of pro-inflammatory cytokines following
TLR activation has not been demonstrated within the TG. In the previous chap-
ter we have demonstrated that trigeminal nociceptors express TLR4, TLR2 and
TLR7 under normal conditions. In this chapter it is hypothesised that these TLRs
are capable of detecting and responding to a range of pathogenic ligands. Using
primary neuronal cultures it is demonstrated that TG sensory neurons are capa-
ble of directly responding to acute stimulation by agonists of the aforementioned
TLRs resulting in the induction of pro-inflammatory cytokine gene expression.
The cytokine response of TG sensory neurons to multiple isoforms of P. gingivalis
LPS is also a focus of this chapter.
4.2 Results
4.2.1 Primary neuronal cell culture
Cell cultures were closely monitored during culture and assessed for cell viability
at 48 h in vitro. Visual checks of cell appearance were made at 2 h, 12 h, 24 h and
48 h in vitro with specific focus on the appearance of cytoplasm and membrane
integrity. Furthermore, neurite outgrowth within three separate culture prepara-
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Figure 4.1. An example of neurite outgrowth of TG sensory neurons after 48 h in vitro, demon-
strated by β-III-tubulin staining. Arrows show examples of neurons with extensive neurite
outgrowth whereas open arrows show an example of a neuron that did not display any visible
outgrowth. Image representative of 3 individual culture preparations. Scale bar 50 µm.
tions was assessed by ICC at 48 h in vitro, using β-III-tubulin as a neuron-specific
stain. All neurons were counted manually and the percentage of cells that dis-
played neurite outgrowth was expressed as a percentage of total neurons (Fig.
4.1). The calculated neuronal viability at 48 h in vitro was 91.5 ± 3.3% (n=3
separate cultures).
4.2.2 TLR co-receptor gene expression in vitro
Cultured primary neurons are not in a native state in vitro as they have un-
dergone axotomy during cell isolation. They may therefore demonstrate injury-
induced transcriptional alterations that could influence their response to exoge-
nous ligands. Prior to exposing cells to exogenous TLR ligands it was therefore
important to measure the change in the gene expression of TLR4 and associated
co-receptors/signalling molecules under normal culture conditions. TLR4, MD-1,
129
4. Cytokine gene expression.
Table 4.1. Summary of qPCR data showing the changes in TLR4, MD-1, MD-2, CD14, MyD88,
TRAM, TNFα, IL-1β, IL-6 and IFNβ mRNA over 48 h in vitro. All fold changes are relative
to the endogenous control genes GAPDH, ACTB and 18s. Data presented as mean ± S.E.M. n
= 3 individual culture preparations.
Target gene Relative fold change at
12 h in vitro
Relative fold change at
48 h in vitro
TLR4 1.21 ± 0.27 fold decrease 1.63 ± 0.5 fold increase
MD-1 1.71 ± 0.22 fold decrease 6.13 ± 0.07 fold decrease
MD-2 1.42 ± 0.02 fold increase 2.42 ± 0.46 fold increase
CD14 7.41 ± 1.64 fold increase 5.7 ± 1.63 fold increase
MyD88 1.73 ± 0.27 fold increase 1.82 ± 0.54 fold increase
TRAM 1.05 ± 0.03 fold decrease 1.29 ± 0.15 fold increase
TNFα 2.25 ± 0.67 fold increase 2.55 ± 0.96 fold increase
IL-1β 1.9 ± 0.57 fold increase 1.21 ± 0.25 fold decrease
IL-6 109.33 ± 50.82 fold increase 16.92 ± 5 fold increase
IFNβ 8.9 ± 2.77 fold increase 5.55 ± 1.89 fold increase
MD-2, CD14, MyD88 and TRAM mRNA levels were measured at 12 h and 48
h in vitro by qPCR, using acutely dissociated tissue (0 h) as a reference sample.
TLR4, MD-2, MyD88 and TRAM mRNA levels did not display any significant
changes in gene expression at either 12 h or 48 h. MD-1 mRNA expression was not
significantly different to control at 12 h (1.71 ± 0.22 fold decrease) however at 48
h MD-1 mRNA was significantly down-regulated by 6.13 ± 0.07 fold (p < 0.001,
48 h vs. 0 h). CD14 mRNA was significantly up-regulated by 7.41 ± 1.64 fold
and 5.7 ± 1.63 fold at 12 h (p < 0.001, 12 h vs. 0 h) and 48 h (p < 0.01, 48 h vs.
0 h), respectively. All fold changes are relative to the endogenous control genes
GAPDH, ACTB and 18s. See figure 4.2 and table 4.1 for summary data.
These data indicate that, at 12 h and 48 h in vitro, the gene expression of TLR4,
MD-2, MyD88 and TRAM are not significantly affected by axotomy whereas MD-
1 and CD14 are.
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Figure 4.2. Relative gene expression of TLR4, MD-1, MD-2, CD14, MyD88 and TRAM in
primary sensory neuron cultures over 48 h in vitro. TLR4, MD-2, MyD88 and TRAM mRNA
are not significantly altered at either 12 h or 48 h in vitro. MD-1 mRNA remains comparable
to control levels at 12 h but is down-regulated at 48 h (***, p < 0.001, 48 h vs. 0 h). CD14
mRNA is significantly up-regulated at both 12 h (***, p < 0.001, 12 h vs. 0 h) and 48 h in vitro
(**, p < 0.01, 48 h vs. 0 h). All statistical comparisons were made using one-way ANOVA with
a Dunnett’s post hoc analysis. Data presented as mean ± S.E.M.
4.2.3 Cytokine gene expression in vitro
Similar considerations were also taken into account with regard to the expression
of pro-inflammatory cytokines in vitro. Therefore changes in TNFα, IL-1β, IL-6
and IFNβ mRNA levels were measured at 12 h and 48 h in vitro by qPCR, again
using acutely dissociated tissue (0 h) as a reference sample (Fig. 4.3). TNFα and
IFNβ mRNA did not significantly differ from control levels at 12 h and 48 h in
vitro. IL-6 was significantly up-regulated by 109.33 ± 50.82 fold and 16.92 ± 5
fold at 12 h (p < 0.01, 12 h vs. 0 h) and 48 h (p < 0.01, 48 h vs. 0 h), respectively.
IFNβ was significantly up-regulated by 8.9 ± 2.77 fold and 5.55 ± 1.89 fold at 12
h (p < 0.01, 12 h vs. 0 h) and 48 h (p < 0.01, 48 h vs. 0 h), respectively. All fold
changes are relative to the endogenous control genes GAPDH, ACTB and 18s.
See figure 4.3 and table 4.1 for summary data.
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Figure 4.3. Relative gene expression of TNFα, IL-1β, IL-6 and IFNβ in primary sensory neuron
cultures over 48 h in vitro. A; IL-6 mRNA is significantly elevated at 12 h (**, p < 0.01, 12 h vs.
0 h) and begins to return towards control levels at 48 h, although it remains significantly elevated
compared to acutely dissociated tissue (**, p < 0.01, 48 h vs. 0 h). B; Replication of the same
graph as in A with a smaller scale to allow the differences in gene expression of other cytokines
to be examined in more detail. TNFα and IL-1β do not display any significant differences in
gene expression at 12 h or 48 h in vitro. IFNβ mRNA was significantly up-regulated at 12 h (**,
p < 0.01, 12 h vs. 0 h) and 48 h (**, p < 0.01, 48 h vs. 0 h) in vitro. All statistical comparisons
were made using one-way ANOVA with a Dunnett’s post hoc analysis. Data presented as mean
± S.E.M.
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These data indicate that axotomy significantly induces the increased gene expres-
sion of IL-6 and IFNβ whilst the gene expression of TNFα and IL-1β remain
unaltered at 12 h and 48 h in vitro.
4.2.4 PAMP-induced induction of cytokine gene expres-
sion in TG sensory neurons in vitro
4.2.4.1 E. coli LPS-dependent induction of cytokine gene expression
In order to demonstrate that TG neurons express functional TLR4, cultured neu-
rons were exposed to E. coli LPS (1µg/mL for 2 h) after 48 h in vitro. TNFα
and IL-1β mRNA were both significantly up-regulated by 8.08 ± 0.47 fold (p <
0.001, E. coli LPS treated vs. control) and 4.11 ± 0.45 fold (p < 0.01, E. coli LPS
treated vs. control), respectively (Fig. 4.4A). IL-6 (1.05 ± 0.06 fold increase) and
IFNβ (1.3 ± 0.22 fold increase) did not show significant change when compared
to control.
Pre-treatment with the TLR4-specific inhibitor CLI-095 (1 µg/mL, 2 h pre-treatment)
prior to LPS exposure significantly reduced the LPS-induced expression of both
TNFα (p < 0.01, control+LPS vs. CLI-095+LPS) and IL-1β (p < 0.01 control+LPS
vs. CLI-095+LPS)(Fig. 4.4B-C). TNFα remained significantly up-regulated by
3.37 ± 0.74 fold when exposed to LPS following pre-treatment with the inhibitor
(p < 0.01, CLI-095+control vs. CLI-095+LPS). No up-regulation of IL-1β was
observed in the presence of the inhibitor alone.
These data show that E. coli LPS is able to significantly induce the transcriptional
up-regulation of TNFα and IL-1β in a TLR4-dependent manner but has no effect
on IL-6 and IFNβ gene expression.
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Figure 4.4. E. coli-dependent induction of cytokine mRNA expression via TLR4. A; E. coli LPS
exposure (1 µg/mL, 2 h) resulted in a significant up-regulation in TNFα (***, p < 0.001, E.
coli LPS treated vs. control) and IL-1β mRNA (**, p < 0.01, E. coli LPS treated vs. control)
whilst IL-6 and IFNβ mRNA were unaltered. B; Pre-treatment with CLI-095, a TLR4-specific
inhibitor, significantly reduced the induction of TNFα by approximately 60% (**, p < 0.01, LPS
vs. CLI-095+LPS). TNFα remained significantly up-regulated in the presence of the inhibitor
(**, p < 0.01, CLI-095 vs. CLI-095+LPS). C; Pre-treatment with CLI-095 completely inhibited
the induction of IL-1β (**, p < 0.01, LPS vs. CLI-095+LPS). All statistical comparisons were
made using one-way ANOVA with a Tukey’s post hoc analysis. Data presented as mean ±
S.E.M.
4.2.4.2 P. gingivalis LPS-dependent induction of cytokine gene ex-
pression
In a series of further experiments, TG neurons were treated with two separate
isoforms of P. gingivalis LPS, LPS1690 and LPS1435. Changes in cytokine gene
expression were again measured by qPCR (Fig. 4.5). P. gingivalis LPS1690 treat-
ment did not have any significant effect upon the gene expression levels of either
TNFα (1.16 ± 0.11 fold decrease), IL-1β (1.23 ± 1.19 fold decrease), IL-6 (1.19 ±
0.3 fold increase) or IFNβ (1.2 ± 0.14 fold decrease). Similarly, following exposure
with P. gingivalis LPS1435, TNFα (1.25 ± 0.23 fold increase), IL-1β (1.04 ± 0.32
fold increase), IL-6 (1.25 ± 0.37 fold decrease) and IFNβ (1.42 ± 0.3 fold decrease)
gene expression levels were not significantly altered compared to control.
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Figure 4.5. Relative gene expression of TNFα, IL-1β, IL-6 and IFNβ following exposure to P.
gingivalis LPS1690 and LPS1435 (1 µg/mL, 2 h). Neither isoform of P. gingivalis LPS induced
a significant alteration in expression of any target gene compared to control expression. All
statistical comparisons were made using one-way ANOVA with a Tukey’s post hoc analysis.
Data presented as mean ± S.E.M.
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Figure 4.6. P. gingivalis LPS isoform-dependent (1 µg/mL, 4 h) induction of TNFα production
by M1 and M2 macrophages differentiated from THP-1 cells. P. gingivalis LPS1690 and LPS1435
both significantly induced the increased production of TNFα by M1 and M2 macrophages com-
pared to unstimulated cells (***, p < 0.001). All statistical comparisons were made using
one-way ANOVA with a Dunnett’s post hoc analysis. Data presented as mean ± S.E.M.
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Bio-activity of the P. gingivalis LPS isoforms were confirmed by exposing M1 and
M2 macrophages, differentiated from THP-1 cells, to each individual LPS isoform
(1 µg/mL, 4 h). The production of TNFα was then measured by ELISA (Fig.
4.6). P. gingivalis LPS1690 significantly induced the production and release of
8995.29 ± 971.18 pg/106 cells (p < 0.001, one-way ANOVA with Dunnett’s post
hoc analysis) and 1764.48 ± 19.17 pg/106 cells (p < 0.001, one-way ANOVA with
Dunnett’s post hoc analysis) by M1 and M2 macrophages, respectively. Similarly,
P. gingivalis LPS1435 significantly induced the production and release of 33545.9
± 811.65 pg/106 cells (p < 0.001) and 6566.6 ± 105.4 pg/106 cells (p < 0.001) by
M1 and M2 macrophages, respectively.
These data show that neither P. gingivalis LPS1690 or LPS1435 were able to signif-
icantly induce the transcriptional alteration in TNFα, IL-1β, IL-6 or IFNβ within
TG neurons in vitro. Both isoforms however were able to induce an expected
response in a macrophage cell line.
4.2.4.3 Pam3 CSK4-dependent induction of cytokine gene expression
P. gingivalis LPS has been previously shown to signal via both TLR4 and TLR2.
In the previous chapter it was also shown that a significant proportion of nocicep-
tors express TLR2. Therefore, in order to demonstrate the functionality of TLR2
in TG sensory neurons, cells were exposed to the TLR2/1 heterodimer-specific
synthetic agonist Pam3 CSK4 (500 ng/mL, 2 h). The relative gene expression of
pro-inflammatory cytokines were measured by qPCR (Fig. 4.7). TNFα mRNA
was significantly up-regulated by 18.21± 1.53 fold (p < 0.001, Pam3 CSK4 treated
vs. control). IL-1β mRNA was also significantly up-regulated by 4.6 ± 0.34 fold
(p < 0.001, Pam3 CSK4 treated vs. control). IL-6 (1.68 ± 0.24 fold increase)
and IFNβ (1.59 ± 0.43 fold increase) mRNA levels were not significantly altered
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Figure 4.7. Relative gene expression of TNFα, IL-1β, IL-6 and IFNβ following Pam3 CSK4
exposure (500 ng/mL, 2 h). Exposure to Pam3 CSK4 induced the significant up-regulation of
TNFα (***, p < 0.001, Pam3 CSK4 treated vs. control) and IL-1β mRNA (***, p < 0.001, Pam3
CSK4 treated vs. control). IL-6 and IFNβ mRNA expression were not statistically different
from the control group. All statistical comparisons were made using one-way ANOVA with a
Tukey’s post hoc analysis. Data presented as mean ± S.E.M.
compared to control.
These data suggest that TG sensory neurons express functional TLR2, the acti-
vation of which significantly induces the transcriptional up-regulation of TNFα
and IL-1β.
4.2.4.4 Imiquimod-dependent induction of cytokine gene expression
In addition to TLR4 and TLR2, the previous chapter identifies the expression of
TLR7 in trigeminal nociceptors. To test the functionality of neuronal TLR7, cells
were exposed to the synthetic TLR7 agonist imiquimod (5 µg/mL, 2 h). Relative
gene expression of cytokines were measured by qPCR (Fig. 4.8). TNFα mRNA
was significantly up-regulated by 12.34 ± 1.23 fold (p < 0.001, imiquimod treated
vs. control). IL-1β mRNA was also significantly up-regulated by 3.66 ± 0.53 fold
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Figure 4.8. Relative gene expression of TNFα, IL-1β, IL-6 and IFNβ following imiquimod
exposure (5 µg/mL, 2 h). Exposure to imiquimod induced the significant up-regulation of TNFα
(***, p < 0.001, imiquimod treated vs. control) and IL-1β mRNA (*, p < 0.05, imiquimod
treated vs. control). IL-6 and IFNβ mRNA expression were not statistically different from the
control group. All statistical comparisons were made using one-way ANOVA with a Tukey’s
post hoc analysis. Data presented as mean ± S.E.M.
(p < 0.05, imiquimod treated vs. control). Again IL-6 (2.11 ± 0.55 fold increase)
and IFNβ (1.47 ± 0.27 fold increase) mRNA levels were not significantly altered
compared to control.
These data suggest that TG sensory neurons express functional TLR7 and receptor
activation, similarly to TLR4 and TLR2, significantly induces the transcriptional
up-regulation of TNFα and IL-1β.
4.3 Discussion
The functional activation of neuronal TLR4, TLR2 and TLR7 is demonstrated
in this chapter through their capacity to induce the increased gene expression
of pro-inflammatory cytokines following ligand-induced receptor activation. The
activation of TLR4, TLR2 and TLR7 by well characterised agonists was suf-
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ficient to induce the transcriptional up-regulation of the pro-inflammatory and
pro-nociceptive cytokines TNFα and IL-1β.
Although the use of primary neuronal cultures is a powerful tool to determine cel-
lular signalling mechanisms, the technique has a number of limitations that must
be considered when interpreting results. First, it is important to understand that
neuronal cultures do not represent normal, uninjured neurons. The dissection and
dissociation process exposes the cell preparation to multiple sources of potential
stress and injury. The initial dissection and mechanical dissociation inflicts a com-
plete axotomy to peripheral and central axons which is associated with a distinct
set of transcriptional and translational changes. Additionally, the enzymatical dis-
sociation process could potentially contribute to cellular stress. Therefore a range
of transcriptional responses to such stress may alter cell physiology in vitro. Alter-
ations in gene/protein expression would also be expected in vitro as the neurons
initiate a regeneration programme. This is illustrated in the fact that neuronal
cultures display extensive neurite outgrowth after 48 h (see Fig. 4.1). Results in
the current study show however that the expression of the majority of receptor
components are not significantly altered at either time point. MD-1 is significantly
down-regulated at 48 h and CD14 is significantly up-regulated at both time points.
CD14 mRNA expression peaks at 12 h and begins to return toward control levels
at 48 h whereas MD-1 mRNA shows a progressive down-regulation over the 48 h.
The injury-dependent expression of TLR receptor components has not previously
been investigated in cultured sensory neurons, however CD14 is shown to be up-
regulated in spinal microglia following peripheral nerve injury (Tanga et al. 2004).
It is therefore not surprising therefore that the expression of CD14 in neurons is
also altered under the conditions encountered in the present study. Changes in
MD-1 expression has not been previously observed following nerve injury and the
functional consequences of this altered expression are currently unknown.
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Furthermore the present study shows that, following neuronal injury, the gene
expression of two of the cytokines that were central to this investigation (TNFα
and IL-1β) remain unaltered, whilst a further two (IL-6 and IFNβ) were sig-
nificantly up-regulated. The increase in IFNβ production is interesting as it is
associated with TRIF-dependent (MyD88-independent) signalling and this path-
way has yet to be demonstrated downstream from neuronal TLR activation. Al-
though the majority of cellular debris is removed during the Percoll gradient stage
of the dissociation process a small amount remains in culture. A range of tissue
damage-associated mediators, associated with the presence of cellular debris, may
therefore be able to interact with neurons in vitro and could potentially induce
the up-regulation of IFNβ mRNA expression. IL-6 mRNA is substantially up-
regulated at 12 h but, similarly to IFNβ, this induction is greatly reduced at 48 h.
The induction of IL-6 gene expression is expected as it is well accepted that IL-6
production is induced following nerve injury (Murphy et al. 1995) and contributes
toward the regeneration of injured neurons (Zhong et al. 1999) and the activa-
tion of non-neuronal cells (Klein et al. 1997). The time course of IL-6 mRNA
expression in the present study is comparable to previous in vivo experiments
(Murphy et al. 1995) as an increase in IL-6 gene expression was identified within
1 day of neuronal injury. This increase in IL-6 gene expression, combined with
the extensive neurite outgrowth, also demonstrates the viability of the neuronal
cultures used in the present study. Since there were no major changes in the gene
expression of TLR receptor components or cytokines at 48 h in vitro, with the
exception of IL-6, and any changes observed in gene expression levels that did
vary from control levels were generally less pronounced at 48 h, this time point
was chosen for exposure to TLR agonists.
The second major limitation of the use of primary neuronal cultures is the diffi-
culty to identify the specific cellular origin of ligand-induced cytokine expression.
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The neuronal cultures used in the present study contain a small proportion of
non-neuronal cells and cellular debris. The majority of non-neuronal cells and de-
bris are removed by the Percoll gradient spin however a small proportion of each
remain and are present in vitro. Further, the dissociation process does not favour
one particular size or functional sub-type of neuron. Therefore both nociceptor
and non-nociceptor populations of TG sensory neurons are represented. It can-
not therefore be shown that the increased cytokine gene expression measured in
this study is specifically occurring in nociceptors. In the previous chapter it was
demonstrated that the expression of neuronal TLR4, 2 and 7 is exclusive to noci-
ceptor populations of sensory neurons however the possibility that the expression
patterns of these TLRs may be altered in vitro cannot be discounted. Indeed,
satellite cells from the DRG have been shown to display increased expression of
TLR4 following the loss of neuronal communication in vitro (Tse et al. 2014b).
In the previous chapter the expression of TLR4 is identified in a small propor-
tion of cells that morphologically resemble satellite cells under naïve conditions.
Therefore it is possible that the increased expression of cytokine mRNA may be
partly due to the activation of TLR4 on non-neuronal cells. However, given the
percentage of nociceptors that express each individual TLR and the lack of an
induction of TLR4 gene expression under normal culture conditions it is reason-
able to suggest that the induction of gene expression following TLR activation is
primarily occurring within neurons and more specifically nociceptors.
This is the first study, to our knowledge, to investigate the TLR activation-
induction of pro-inflammatory cytokine gene expression in TG sensory neurons.
The up-regulation of TNFα and IL-1β mRNA in DRG sensory neurons has previ-
ously been demonstrated following acute E. coli LPS-dependent TLR4 activation
(Tse et al. 2014a). Results from this present study show that TG sensory neurons
respond to acute E. coli LPS exposure in a similar manner. Both TNFα and
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IL-1β mRNA are significantly up-regulated however the the induction of IL-1β is
not as pronounced as that observed in DRG neurons (Tse et al. 2014a). Using the
TLR4-specific inhibitor, CLI-095, it is also shown that the induction of these cy-
tokines is primarily dependent upon TLR4 activation. LPS has also been shown to
activate certain non-canonical receptors including TRPA1 (Meseguer et al. 2014)
and various caspases (Shi et al. 2014). Whilst IL-1β mRNA up-regulation was
predominantly TLR4-dependent, the reduction of TNFα induction was limited
to approximately 60%. This suggests that the E. coli LPS-induced gene expres-
sion of TNFα may also be mediated by receptors other than TLR4 on sensory
neurons.
Previous studies have shown that P. gingivalis LPS interacts with neuronal TLRs
to sensitise TRPV1 and facilitate the rapid release of CGRP in TG neurons (Dio-
genes et al. 2011; Ferraz et al. 2011). In the present study, mono-phosphorylated,
penta-acylated (LPS1690) and mono-phosphorylated, tetra-acylated (LPS1435) lipid
A-containing LPS isoforms were able to induce an expected response in macrophages,
differentiated from a monocyte cell line (THP-1), but in our hands did not alter
cytokine gene expression in cultured TG neurons. It is somewhat expected that
the mono-phosphorylated, tetra-acylated isoform did not induce a response as it
has previously been shown to be a relatively weak TLR4 agonist and can also act
as a TLR4 antagonist under certain circumstances (Darveau et al. 2004; Coats
et al. 2009; Herath et al. 2013). The penta-acylated isoform however is considered
relatively immunologically potent compared to other isoforms. The results from
the present study, combined with those of past reports, would suggest that TG
sensory neurons are able to detect the presence of P. gingivalis LPS via TLRs
but do not mount a significant cytokine response. P. gingivalis LPS is generally
considered to be less potent than that of enterobacterial species such as E. coli
(Holden et al. 2014) and it has been suggested that this is one reason why the
142
4. Cytokine gene expression.
activated host immune response is often insufficient for clearence of the infection.
The inability of sensory neurons to mount a cytokine response to P. gingivalis
LPS may also contribute to this as the release of cytokines in the periphery would
have major implications for the innate immune response and subsequent bacterial
clearance.
In addition to the involvement of TLR4, the present study also shows that the
activation of TLR2 in TG sensory neurons induces the up-regulation of TNFα and
IL-1β. In the previous chapter it was discussed that the expression of TLR2 in
primary sensory neurons, prior to this study, had not been identified. The results
presented in this chapter demonstrate the functional activation of TLR2 in TG
sensory neurons suggesting that this receptor is present and able to detect the
presence of Gram-positive bacteria as well as a wide range of endogenous ligands
(see Table 1.1). The TLR2 agonist used in this study, Pam3 CSK4, is a specific
agonist for the TLR2/1 heterodimer. Therefore results suggest that TG sensory
neurons may also express TLR1. Gram-positive bacteria are frequently identified
in the healthy oral flora (Dewhirst et al. 2010) however many are also associated
with the diseased state. For example, a range of Streptococcus spp. and Actino-
myces spp. within the oral cavity are commonly associated with carious tooth
decay and pulpitis (Tanzer et al. 2001) and some less common oral pathologies
such as osteomyelitis of the jaw (see Hudson 1993). Tissue damage associated with
physical trauma or chronic inflammation within oral tissues causes the release of
multiple endogenous factors that may also activate TLR2. TMJ disorders, carious
tooth decay and chronic periodontal disease, for example, are all associated with
a gradual and progressive tissue destruction. The expression and direct activation
of TLR2 on TG sensory neurons by Gram-positive species and endogenous fac-
tors may therefore contribute towards the inflammation and pain associated with
various orofacial disorders.
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A previous study has shown that the activation of TLR3, 7/8 and 9 in DRG neu-
rons results in the up-regulation of IL-1β, IL-1α, CCL5 and CXCL10 (Qi et al.
2011). Here it is shown that TLR7 activation in TG sensory neurons not only
induces the up-regulation of IL-1β but also TNFα. The previous study used
a dual agonist of TLR7 and TLR8 however, here, a TLR7 specific agonist is
used to demonstrate the functionality of TLR7 in TG sensory neurons. TLR7
is commonly associated with ssRNA viral infections, a major class of which are
enteroviral strains, with Cocksackie virus being particularly relevant to the oral
cavity (see McCullough & Savage 2005). Also relevant to this study is the abil-
ity of TLR7 to recognise multiple miRNAs. miRNAs are endogenous factors that
post-transcriptionally regulate gene expression (Bartel 2004) however recent stud-
ies have shown that certain microRNAs can activate TLR7 (Fabbri et al. 2012)
and play a role in the regulation of neuronal growth (Liu et al. 2015), neurodegen-
eration (Lehmann et al. 2012) and pain (Zhao et al. 2010; Park et al. 2014). The
direct activation of TLR7 by certain miRNAs is also sufficient to rapidly depolarise
DRG neurons to elicit a pain response (Park et al. 2014). TLR7 activation on TG
sensory neurons by viral ssRNA and/or endogenous microRNAs may therefore be
sufficient to directly activate neurons in addition to the transcriptional alteration
detailed in the present study.
Although the current study shows that the activation of multiple neuronal TLRs
results in the transcriptional up-regulation of TNFα and IL-1β it does not demon-
strate whether these changes were also replicated at the protein level. The major
limitation of working with TG sensory neurons compared to those of the DRG is
the sample size. Whilst there are numerous DRG located along the entire length
of the spinal cord, only two TG are found in each rodent. This, combined with a
loss of cells during tissue dissociation, results in a limited cell harvest. Assuming
that the observed transcriptional alterations were matched at the translational
144
4. Cytokine gene expression.
level, both TNFα and IL-1β are able to promote neuronal sensitisation both in
the periphery and spinal cord through multi-cellular mechanisms.
Cytokine signalling is critical for the initiation and maintenance of pain hypersen-
sitivity (Uceyler et al. 2007). In many conditions associated with chronic pain, an
increase in pro-inflammatory cytokines is observed (see Uceyler et al. 2009) and
treatment with anti-inflammatory cytokines or inhibitors of pro-inflammatory cy-
tokines is often sufficient to reduce this pain (Sommer et al. 1999; 2001; Milligan
et al. 2005a; 2005b). An increased expression of TNFα and IL-1β are associated
with multiple models of inflammatory and neuropathic pain (see Uceyler et al.
2009). Both exhibit a broad range of effects on neurons, non-neuronal cells and
immune cells that can alter the pain phenotype through multiple peripheral and
central mechanisms (Junger & Sorkin 2000; Ozaktay et al. 2006). Both are able
to directly activate peripheral neurons to produce acute, spontaneous firing which
is associated with the development of hyperalgesia and allodynia (Fukuoka et al.
1994; Sorkin et al. 1997; Obreja et al. 2002; Murata et al. 2006; Ozaktay et al.
2006; Schafers et al. 2008). This rapid activation of neurons is also associated
with a potentiation of CGRP and SP release in a manner that is independent
from transcriptional alterations (Fukuoka et al. 1994; Opree & Kress 2000; Hou
et al. 2003).
TNFα and IL-1β, signalling in an autocrine or paracrine manner, can induce
long-lasting alterations to neuronal excitability through transcriptional, transla-
tional and post-translational mechanisms mediated by the activation of TNFR1
and IL1R1 expressed by nociceptors. Another TNF receptor, TNFR2, is silent
under normal conditions however it is suggested that it contributes to TNF sig-
nalling following the induction of neuronal sensitisation (Schafers et al. 2008).
Activation of NF-κB, p38 MAPK, ERK, JNK and PI3K pathways downstream
from receptor activation (Pollock et al. 2002; Takahashi et al. 2006; Wei et al.
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2007) can induce the up-regulation of PGE2 (Cunha et al. 1992), the bradykinin
receptor B1 (Marceau 1995), BDNF (Lin et al. 2011), TrkB (Lin et al. 2011),
TRPV1 (Khan et al. 2008), TRPA1 (Wu et al. 2015) and TRPV4 (Wu et al.
2015). Protein kinases such as PKA and PKC are also activated resulting in the
post-translational sensitisation of TRPV1 (Nicol et al. 1997; Obreja et al. 2002),
TRPA1 (see Lapointe & Altier 2011), P2X3 (Zhang et al. 2007) and NaV channels
(Jin & Gereau 2006; Binshtok et al. 2008). In the superficial dorsal horn, both
can promote central sensitisation by increasing the activity of NMDA and AMPA
receptor activation as well as reducing inhibitory current induced by GABA and
glycine (Kawasaki et al. 2008).
Further to their actions on neurons, cytokines can activate non-neuronal cells to
indirectly promote pain hypersensitivity (see Hanisch 2002). The activation of
peripheral neurons by cytokines can also indirectly promote the activation of non-
neuronal cells via the release of glutamate and neurotransmitters. Activated glial
cells display an increased production of many pro-nociceptive factors including
NGF, NO, ATP and other pro-inflammatory cytokines following activation of re-
ceptors and signalling cascades that have been previously mentioned (see Milligan
& Watkins 2009). TNFα can also inhibit the activity of glutamate transporters
(Sitcheran et al. 2005) and potassium channels (Koller et al. 1998) in spinal cord
glial cells to promote activation of AMPA and NMDA receptors on spinal neu-
rons.
Both TNFα and IL-1β are key orchestrators of the innate immune response and
can therefore indirectly promote pain hypersensitivity by potentiating the local
inflammatory response. Neuronal production of these cytokines would promote
the local accumulation and activation of immune cells including macrophages,
neutrophils, mast cells and T lymphocytes. For example, TNFα and IL-1β pro-
mote the production of NGF, prostaglandins, bradykinin, histamine, matrix met-
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allopeptidase (MMP)-9, NO and further promote their own synthesis by immune
cells (see Moalem & Tracey 2006; Watkins et al. 2007). These, and other, pro-
inflammatory mediators have a range of direct and indirect effects on neuronal
and glial function, as detailed in chapter 1.2 of this thesis.
Despite the absence of an acute response to P. gingivalis LPS, the activation
of neuronal TLRs represent an important mechanism in the development and
maintenance of multiple orofacial pain states. Results presented in this chapter
demonstrate the functional activation of TLR4, 2 and 7 expressed by TG sen-
sory neurons and further support the hypothesis that primary nociceptors can
directly detect and respond to bacterial and viral infection as well as a range
of endogenous ligands. The most prevalent orofacial pain disorders, including
TMJ disorders and carious tooth decay, are associated with the presence of mul-
tiple PAMPs and DAMPs. The dense innervation and unique location of many
orofacial tissues mean that the activation of neuronal TLRs has the potential
to occur rapidly and frequently during the progression of multiple orofacial dis-
eases/disorders. The acute activation of neuronal TLRs and the subsequent induc-
tion of pro-inflammatory and pro-nociceptive cytokines may therefore contribute
towards the initiation of an altered state of neuroimmune signalling to promote
neuronal hypersensitivity.
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Chapter 5
LPCAT1 & LPCAT2 expression
in trigeminal ganglion sensory
neurons
Published in part as:
Helley, M.P., Abate, W., Jackson, S.K., Bennett, J.H., Thompson, S.W. (2015)
The expression of Toll-like receptor 4, 7 and co-receptors in neurochemical sub-
populations of rat trigeminal ganglion sensory neurons. Neuroscience 310, 686-
698. (see Appendix A).
149
150
5. LPCAT expression in TG neurons.
5.1 Introduction
The plasma membrane is a dynamic, fluid structure that undergoes constant re-
modelling in response to extracellular and intracellular signals. The general con-
sensus on membrane organisation has moved on from that of a random homoge-
neous assortment of lipids towards that of an ordered and controlled assortment of
multiple microdomains each with a specific structure and order of phospholipids
and membrane proteins. Specific cholesterol- and sphingolipid-rich membrane
microdomains, known as lipid rafts, possess a particularly ordered lipid structure
that allows for controlled lateral trafficking of various membrane components (see
Simons & Ikonen 1997). The high percentage of cholesterol, for example, within
raft domains provides an increased thickness and stiffness of the phospholipid
bilayer to optimise protein sorting. Lipid rafts are associated with a range of
cell functions including cell signalling (see Simons & Toomre 2000). Lipid rafts
are not only rich in receptor proteins but also facilitatory proteins such as co-
receptors, enzymes and intracellular signal transduction molecules (see Anderson
1998). Therefore raft microdomains provide a highly ordered compartment to
allow for the clustering and physical interaction of the necessary molecular com-
ponents to generate a signalling response to a particular activatory stimulus.
Lipid rafts have been shown to play a vital role in numerous neuronal cell func-
tions such as cell adhesion (Kasahara et al. 2000), synaptic transmission (Pato
et al. 2008) and cellular signalling. Multiple membrane-bound receptors in sensory
neurons cluster in lipid raft domains in order to initiate a signalling response. For
example, P2X receptors (Garcia-Marcos et al. 2009), multiple TRP channels (Liu
et al. 2006; Morenilla-Palao et al. 2009), TrkA (Limpert et al. 2007) and NaV 1.8
(Pristera et al. 2012) have all been either identified in lipid rafts or their function
has shown to be dysregulated following the removal of lipid raft components from
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the membrane.
TLRs, and other immune receptors (see Triantafilou et al. 2011), localise to lipid
raft domains in a number of cell types in response to a range of stimuli (Triantafilou
et al. 2004; citealpWong2009). All identified TLRs are type I transmembrane
proteins with an intracellular TIR domain that associate with intracellular adaptor
molecules such as TIRAP, MyD88, TRAM and TRIF, that are also clustered in
raft domains, to initiate multiple signalling cascades (see Kawai & Akira 2007b).
Bacterial recognition, via TLR2 and TLR4, is a complex process that involves
interactions between multiple membrane proteins and also various serum proteins
(see Park & Lee 2013). Upon ligand recognition by LBP-mediated LPS delivery to
CD14 in raft domains, TLR4 is recruited into lipid rafts (Triantafilou et al. 2002)
where it interacts with MD-2 and forms a homodimer to transduce a signal. TLR4
has also been shown to interact with atypical receptor components under certain
circumstances (Byrd et al. 1999; Triantafilou et al. 2001; Heine et al. 2003). The
dynamics of TLR2 activation are markedly different to those of TLR4 as TLR2
pre-exists as a heterodimer, with either TLR1 or TLR6. Ligand recognition then
causes TLR2 heterodimers to translocate to lipid rafts where they interact with
the resident raft proteins CD14 and CD36 to initiate MyD88-dependent signalling
(Gupta et al. 1996; Soong et al. 2004; Hoebe et al. 2005). The involvement of raft
domains in intracellular TLR signalling has not been shown however cholesterol-
enriched endosomal raft-like domains have been identified (Nada et al. 2009).
It has also been demonstrated that raft associated TLR7 enhances macrophage
phagocytosis by interacting with HSP70 (Wang et al. 2006).
Currently the mechanisms of receptor movement within membranes are largely
unknown however it has been shown that many proteins are targeted to raft do-
mains via lipid modifications such as acyl and glycosylphosphatidylinositol (GPI)
anchoring (see Levental et al. 2010). Members of a family of phospholipid remod-
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elling enzymes, known as lysophosphatidylcholine acyltransferases (LPCATs), reg-
ulate membrane structure and fluidity by converting lysophosphatidylcholine to
phosphatidylcholine using a diverse range of acyl-coenzyme A (CoA) donors (Ya-
mashita et al. 1997). Changes to the lysophospholipid/phospholipid ratio within
the membrane are known to affect lipid raft mircodomains (Stulnig et al. 2001) and
therefore LPCATs are suggested to modulate lateral movement of proteins within
the membrane. Indeed it has been shown that LPCATs are essential for the LPS
response in inflammatory cells and inhibition of LPCATs prevents the translo-
cation of TLR4 into lipid rafts and subsequent signalling (Schmid et al. 2003;
Jackson & Parton 2004; Jackson et al. 2008). LPCAT1 mediates the calcium-
dependent palmitoylation of histone proteins (Zou et al. 2011) and LPCAT2 has
recently been shown to directly modify TLR4 and TLR2 proteins (Abate & Jack-
son 2015). It is thought that these modifications facilitate targeting of these
receptors to lipid raft domains prior to the initiation of cell signalling (Abate &
Jackson 2015).
To date four LPCAT isoforms have been identified, LPCAT1-4. LPCAT1 and LP-
CAT2 are from the 1-acylglycerol-3-phosphate O-acyltransferase (AGPAT) fam-
ily of enzymes and contain LPAAT motifs whereas LPCAT3 and LPCAT4 lack
these motifs and are both from the membrane-bound O-acyltransferase (MBOAT)
family of acyltransferases. LPCAT1 and LPCAT2 are located on the endoplas-
mic reticulum and possess both acyltransferase and acetyltransferase activity as
demonstrated by their roles in membrane homeostasis and platelet activating fac-
tor (PAF) synthesis, respectively (Nakanishi et al. 2006; Shindou et al. 2007).
LPCAT1 has been identified in a wide range of tissues and cell types although its
function remains largely unclear (Cheng et al. 2009). It displays acyltransferase
activity for lysophosphatidylcholine and lysophosphatidylethanolamine and has
a preference for saturated acyl-CoA donors. It has been shown to play a ma-
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jor role in pulmonary surfactant production in lung alveolar cells by generating
dipalmitoyl phosphatidylcholine (Bridges et al. 2010). LPCAT1 displays both
acyltransferase and acetyltransferase activity in the non-immune biosynthesis and
inactivation of PAF, respectively (Harayama et al. 2008; Cheng et al. 2009). LP-
CAT1 has also been shown to be overexpressed in multiple cancers (Mansilla et al.
2009; Zhou et al. 2011), play a role in retinal photoreceptor homeostasis (Cheng
et al. 2009) and may also regulate mRNA synthesis (Zou et al. 2011). LPCAT2 is
perhaps the best characterised LPCAT isoform. It is an inducible enzyme linked
to inflammatory mechanisms due to its high expression levels in macrophages
and neutrophils (Morimoto et al. 2010). Under normal conditions LPCAT2 par-
ticipates in membrane remodelling by the acylation of lysophosphatidylcholine,
lysophosphatidylserine and lysophosphatidylethanolamine with a preference for
polyunsaturated fatty CoA donors. Following inflammatory stimuli such as LPS,
PAF and ATP the acetyltransferase activity of LPCAT2 is induced which medi-
ates the production of PAF from its pre-cursor lyso-PAF (Shindou et al. 2007;
Morimoto et al. 2010; 2014). The enzyme is activated by phosphorylation fol-
lowing TLR4 (Morimoto et al. 2010) and PAF receptor (PAFR) (Morimoto et al.
2014) activation and the TLR4-dependent cytokine response in macrophages has
been demonstrated to be dependent on LPCAT2 (Jackson et al. 2008; Abate &
Jackson 2015).
LPCAT3 and LPCAT4 are poorly characterised in comparison to the previously
mentioned isoforms. LPCAT3 expression has been ubiquitously identified in the
mouse with particularly high expression in the testis, liver, adipose and pancreas
(Hishikawa et al. 2008; Zhao et al. 2008). LPCAT4 expression is also widely
distributed within the mouse however it shows particularly high levels of expres-
sion in brain, testis, ovary and epididymis (Hishikawa et al. 2008). The biolog-
ical functions of LPCAT3 and LPCAT4 are unknown however LPCAT3 knock-
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down results in liver inflammation (Rong et al. 2013). LPCAT3 displays acyl-
transferase activity for lysophosphatidylcholine, lysophosphatidylethanolamine,
and lysophosphatidylserine with broad unsaturated-CoA specificity whereas LP-
CAT4 displays acyltransferase activity for lysophosphatidylcholine and lysophos-
phatidylethanolamine with a preference for oleoyl-CoA (Hishikawa et al. 2008;
Gijon et al. 2008; Matsuda et al. 2008). When combined, LPCAT isoforms ex-
hibit a broad substrate and donor specificity to provide phospholipid diversity
within the cellular membrane (Harayama et al. 2014).
Previous chapters have demonstrated that neuronal TLR activation leads to in-
flammatory cytokine production however the mechanisms surrounding neuronal
TLR activation are largely unknown. LPCAT2 has been demonstrated to regulate
TLR4-dependent cytokine production in immune cells and it is therefore hypoth-
esised that a similar mechanism may exist in sensory neurons. The expression of
LPCAT isoforms within neuronal tissue and sensory neurons in particular has not
been sufficiently described. LPCAT1 has been identified in the brain and spinal
cord sensory neurons whereas LPCAT2 has been identified in spinal cord sensory
neurons and microglia (Kihara et al. 2008; Cheng et al. 2009; Okubo et al. 2012).
LPCAT2 is the only isoform to be identified in peripheral sensory neurons to
date however this was only demonstrated following nerve injury (Hasegawa et al.
2010). The specific aim of this chapter was to describe the expression patterns of
LPCAT1 and LPCAT2 in naïve sensory ganglia and in primary sensory neurons
in vitro.
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5.2 Results
5.2.1 Antibody characterisation
Antibodies specific for LPCAT1 and LPCAT2 were characterised using similar
techniques to those in chapter 3. As the expression of LPCAT is identified in a
wide range of tissues and cell types, western blotting was used to demonstrate
the specificity of LPCAT antibodies. This was performed on tissues known to
express LPCAT1 (cortex) and LPCAT2 (RAW 264.7 cells) as well as the specific
tissues of interest, the TG and DRG. When LPCAT antibodies were used for
western blotting a single, specific band was observed at the expected molecular
weight (see Fig. 5.2). Antibody specificity was also determined by use in positive
control tissues known to express LPCAT1 (lung) and LPCAT2 (spleen). Multiple
positively stained cells were seen in the lung (LPCAT1, Fig. 5.1A-B) and spleen
(LPCAT2, Fig. 5.1C-D). All other control experiments for primary and secondary
antibodies have been detailed in Chapter 3.2.1.
5.2.2 Expression of LPCAT isoforms in naïve trigeminal
ganglia
In order to investigate the expression of LPCAT1 and LPCAT2 within TG and
DRG sensory neurons western blotting was performed followed by indirect single-
labelling IHC. Co-expression of LPCAT1 and LPCAT2 with neurochemical mark-
ers of functional sensory neuron sub-populations was then demonstrated using
dual-labelling IHC. LPCAT1 and LPCAT2 were identified in whole tissue lysates
of the TG, DRG, cortex and RAW 267.4 cells (control). Cortex tissue and
RAWcells were included as controls given that LPCAT1 and LPCAT2 are highly
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Figure 5.1. Fluorescent micrograph showing the distribution of LPCAT1 (green, A-B) and LP-
CAT2 (green, C-D) expression in lung and spleen tissue, respectively. Combined images include
a DAPI counterstain to identify nuclear profiles (blue, B, D) Multiple positively stained profiles
can be identified for both LPCAT1 and LPCAT2. Scale bar 50 µm and 15 µm, respectively.
Figure 5.2. Western Blot analysis for LPCAT isoform expression across multiple tissue types.
LPCAT1 (A; 1:1000, ProteinTech) and LPCAT2 (B; 1:500, Novus Biologicals) expression in TG,
DRG and cortex. 20µg protein was run in each lane. RAW264.7 cells were used as a positive
control. β-III tubulin was used as a loading control. Images representative of three separate
experiments.
157
5. LPCAT expression in TG neurons.
expressed in brain and immune cells, respectively. A band just above 50 kDa was
observed for LPCAT1 and LPCAT2 (Fig. 5.2). Whilst western blotting demon-
strated the expression of LPCAT within the ganglia as a whole, immunofluores-
cence staining allowed for the description of the specific cellular localisation of
expression for each isoform. LPCAT1-IR was identified in 50.4 ± 4.5% of total
TG neurons (Fig. 5.3A-B). 14.1 ± 2.8% of total neurons displayed a more intense
level of LPCAT1-IR; these were classed as high expressors (HE) of LPCAT1 as
defined by fluorescent intensity. A proportion of non-neuronal cells also displayed
weak LPCAT1-IR (Fig. 5.3A-B).
Further, the co-expression of LPCAT1 with common neurochemical markers was
examined using dual-labelled IHC. Within the TG, LPCAT1 was expressed by
86.3 ± 4.7%, 67 ± 7.9% and 47.7 ± 5.3% of TRPV1-, P2X3- and NF200-IR
neurons, respectively (Fig. 5.5). HE LPCAT1-IR was identified in 29.9 ± 3.3%,
19.4 ± 3% and 14.7 ± 2.7% of TRPV1-, P2X3- and NF200-expressing neurons,
respectively.
LPCAT2 expression patterns were markedly different than that of LPCAT1. All
neuronal profiles were negative for LPCAT2 however the majority of non-neuronal
cells within the ganglia displayed strong positive LPCAT2-IR (Fig. 5.3C-D).
These data show that LPCAT1 is expressed by a sub-population of TG sen-
sory neurons and co-localises with populations likely to be both nociceptors and
non-nociceptors. LPCAT2 however is expressed exclusively by non-neuronal cells
within the naïve TG.
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Figure 5.3. Images show fluorescent micrographs of rat TG and DRG labelled with antibodies specific for LPCAT1
and LPCAT2. Multiple neuronal profiles within the TG (green, A) and DRG (green, B) displayed LPCAT1-IR,
arrows show selected examples. A small proportion of neuronal profiles displayed high intensity of LPCAT1-IR,
asterisks show selected examples. A proportion of non-neuronal cells also displayed weak LPCAT1-IR, arrowheads
show selected examples. All neurons were negative for LPCAT2 but the majority of non-neuronal cells displayed strong
LPCAT2-IR within the TG (green, C) and DRG (green, D), arrowheads show selected examples. Areas contained
within the indicated borders (dashed lines) have been magnified in Fig. 5.4. Scale bar 50 µm. Images representative
of three biological replicates.
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Figure 5.4. Images show selected areas of Fig. 5.3 that have been magnified to give a more detailed representation of
LPCAT isoform staining within the TG (A, C) and DRG (B, D). Similarly to the previous figure, arrows show selected
examples of neuronal profiles that display positive LPCAT1-IR whilst asterisks show neuronal profiles that display
high intensity of LPCAT1-IR, in the TG (A) and DRG (B). Arrowheads show selected examples of non-neuronal cells
that display positive IR for LPCAT1 (A-B) and LPCAT2 (C-D). Scale bar 50 µm. Images representative of three
biological replicates.
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Figure 5.5. Images show fluorescence micrographs of rat TG double labelled for LPCAT1-IR (green, A, D, G) plus
either TRPV1- (red, B), P2X3- (red, E) or NF200-IR (red, H). The combined images (C, F, I) show co-localisation of
LPCAT1-IR with neurochemical markers. LPCAT1-IR shows co-expression with a substantial proportion of TRPV1-
IR neurons, examples of co-expressing neurons are indicated by filled arrows (A, B) and by asterisks in the combined
image (C). Not all neurons displaying TRPV1-IR neurons express LPCAT1-IR, examples indicated by open arrows
(A, B, C). The majority of LPCAT1-IR neurons also co-express P2X3-IR, examples of co-expressing neurons are
indicated by filled arrows (D, E) and by asterisks in the combined image (F). A proportion of LPCAT1-IR neurons
also co-express NF200-IR, examples of co-expressing neurons are indicated by filled arrows (G, H) and by asterisks
in the combined image (I). There were also a population of NF200-IR neurons that did not co-express LPCAT1-IR,
examples indicated by open arrows (G, H, I). Scale bar 50 µm. Images representative of three biological replicates.
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5.2.3 LPCAT isoform gene expression in trigeminal sen-
sory neurons in vitro
To assess whether LPCAT1 and LPCAT2 expression is altered following tissue
dissociation qPCR was performed primary neuronal cultures at 12 h and 48 h in
vitro, using acutely dissociated tissue as a reference sample (Fig. 5.6). LPCAT1 is
detectable in the acutely dissociated sample (CT value = 25.7 ± 0.6) and shows no
significant change in gene expression at both 12 h (-2.2 ± 0.4 fold change) and 48 h
(-1 ± 1.2 fold change) in culture (one-way ANOVA with Dunnett’s post-hoc test).
LPCAT2 is undetectable in the acutely dissociated sample (CT >40) however
LPCAT2 gene expression is induced by approximately 35 ± 2.7 fold at 12 h post-
plating (p < 0.001, one-way ANOVA with Dunnett’s post-hoc test. LPCAT2
reference CT > value was set at 40 for the purposes of statistical analysis.). At
48 h post-plating the level of LPCAT2 gene expression falls to 7.1 ± 0.6 fold but
remains significantly increased compared to the acutely dissociated sample (p <
0.05, one-way ANOVA with Dunnett’s post-hoc test).
These data show that an increase in LPCAT2 gene expression is induced following
nerve injury whereas LPCAT1 gene expression is not significantly different to
control levels.
5.2.4 LPCAT isoform protein expression in TG sensory
neurons in vitro
To assess changes in LPCAT isoform protein expression in vitro dual-labelling
ICC was performed on primary neuron cultures 48 h post-plating, using β-III
tubulin as a neuron-specific stain. Neurons from three individual culture prepara-
tions were manually counted and those displaying positive LPCAT1-/LPCAT2-IR
162
5. LPCAT expression in TG neurons.





	




























   
!!!
!
Figure 5.6. LPCAT gene expression in cultured primary TG neurons. qPCR was performed on
primary sensory neuron cultures pre-plating (0 h, control) as well as 12 h and 48 h post-plating.
LPCAT1 gene expression is not induced at either time point compared to control. LPCAT2
gene expression is induced at 12 h (*** p < 0.001 compared to 0 h) and 48 h post-plating (* p
< 0.05 compared to 0 h). Data are means ± S.E.M. from three independent cell cultures.
were expressed as a percentage of total neuronal profiles. There was no significant
change in LPCAT1 expression in neurons after 48 h in culture compared to naïve
tissue (Student’s t-test). LPCAT1 is expressed by 49.3 ± 5.4% of neurons 48 h
post-plating (Fig. 5.7). In contrast to LPCAT1, LPCAT2 expression was sig-
nificantly up-regulated in neurons after 48 h in culture compared to naïve tissue.
LPCAT2-IR was entirely non-neuronal in naïve TG but following dissociation and
48 h in culture LPCAT2-IR was detected in 15.6 ± 3.8% of neurons (p < 0.05
compared to naïve tissue, Student’s t-test; Fig. 5.8).
These data show that LPCAT2 protein expression is induced in a proportion of
neurons following nerve injury whereas LPCAT1 protein expression is not signifi-
cantly different from control tissue. This is in accordance to the gene expression
data and, collectively, these results suggest that the expression of LPCAT2 in
TG sensory neurons is inducible whereas the expression of LPCAT1 is constitu-
tive.
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Figure 5.7. Images show fluorescence micrographs of cultured primary TG neurons at 48 h in vitro dual-labelled for
LPCAT1-IR (green, A, D, G) plus β-III-tubulin-IR (red, B, E, H). The combined images (C, F, I) show co-localisation
of LPCAT1-IR with the neuronal marker and includes a DAPI stain to identify nuclear profiles. Similarly to naïve
neurons, positive LPCAT1-IR was detected in approximately half of all neurons after 48 h in vitro; arrows show
positive neurons whilst open arrows show neurons that were considered to be negative. Images are representative of
3 independent cell cultures. Scale bar 15 µm.
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Figure 5.8. Images show fluorescent micrographs of cultured primary TG neurons at 48 h in vitro dual-labelled for
LPCAT2-IR (green, A, D, G) plus β-III-tubulin-IR (red, B, E, H). The combined images (C, F, I) show co-localisation
of LPCAT2-IR with the neuronal marker and includes a DAPI stain to identify nuclear profiles. In contrast to
naïve neurons, a small number of neurons displayed LPCAT2-IR after 48 h in vitro, arrows show LPCAT2-positive
neurons whilst open arrows show LPCAT2-negative neurons. The majority of non-neuronal cells also display positive
LPCAT2-IR, arrowheads show selected examples. Images are representative of 3 independent cell cultures. Scale bar
15 µm.
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5.3 Discussion
The group of phospholipid modifying enzymes known as lysophosphatidylcholine
acyltransferases are essential for a number of biochemical events at the membrane
level. LPCAT2 in particular has been shown to mediate the TLR2 and TLR4 sig-
nalling capabilities of monocytes (Schmid et al. 2003; Jackson et al. 2008; Abate
& Jackson 2015). Inhibiting this enzyme prevents TLR4 translocation to lipid raft
domains within the cell membrane and causes a down-regulation of TLR4- and
TLR2-mediated inflammatory cytokine production (Jackson et al. 2008; Abate &
Jackson 2015). Here we have investigated whether the LPCAT isoforms, LPCAT1
and LPCAT2, are present in mammalian sensory ganglia in vivo and TG sensory
neurons in vitro. Both isoforms are indeed present within naïve sensory ganglia
however each have a distinct pattern of expression within the tissue. Approxi-
mately half of all sensory neurons were positive for LPCAT1; a small proportion
of non-neuronal cells also displayed LPCAT1-IR. LPCAT1 expression was not re-
stricted to a specific sub-population of cells given that it co-localised with all three
of the neurochemical markers used suggesting that it is expressed by both nocicep-
tor and non-nociceptor sub-populations. LPCAT2 was not expressed by neurons
in either the TG or DRG. LPCAT2 was however expressed by non-neuronal cells
that surrounded neurons, the morphology of which closely resemble satellite cells.
The expression patterns of LPCAT1 and LPCAT2 in naïve tissue are intriguing
as it would be expected that all neurons express one LPCAT isoform given their
phosphatidylcholine remodelling properties and that phosphatidylcholine is a ma-
jor phospholipid component of sensory neuron membranes (Calderon et al. 1995).
Other, recently identified isoforms of LPCAT (LPCAT3 and LPCAT4) exist that
possess phosphatidylcholine remodelling properties have not been included in this
study due to antibody unavailability. LPCAT3 displays broad substrate and acyl-
CoA donor specificity and has been suggested to be a key regulator of membrane
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remodelling in certain tissues, particularly in the liver (Hishikawa et al. 2008; Gi-
jon et al. 2008; Matsuda et al. 2008). LPCAT3 and LPCAT4 expression have not
been characterised in sensory neurons and it is entirely feasible that they may be
expressed. It is also possible that, given the variable staining intensity observed
with LPCAT1, some neurons that were classed as negative may express a very low
level of LPCAT1 that was not distinguishable above background staining.
The expression patterns of LPCAT1 and LPCAT2 in vivo are supported by the
protein and gene expression of each respective isoform in TG sensory neurons in
vitro. LPCAT1 gene expression was abundant in acutely dissociated neurons (CT
value) whereas LPCAT2 gene expression was undetectable (CT > 40). This was
expected given that the majority of non-neuronal cells are removed during the
Percoll gradient spin of the dissociation process. As previously mentioned, the
dissociation process inflicts an acute axotomy on sensory neurons as the periph-
eral and central processes are removed, first by dissection from the animal and
second by enzymatic and mechanical digestion. Such an insult initiates a range
of well documented cellular changes that mediate changes in membrane protein
and neuropeptide expression (Bradbury et al. 1998; Shi et al. 2001; Kim et al.
2008). LPCAT1 gene expression remains comparable to control (pre-plating) at
12 and 48 h post-plating whereas LPCAT2 gene expression is significantly in-
duced at both time points, with the greatest induction seen at 12 h. This is also
demonstrated by a significant increase in LPCAT2 protein expression in sensory
neurons after 48 h although the specific sub-populations of sensory neuron that
this induction occurs in were not determined in this study. These data reflect
previous studies performed on immune cells that show LPCAT1 to be constitu-
tively expressed whereas LPCAT2 is inducible in response to LPS (Shindou et al.
2007). Okubo et al. (2012) have previously demonstrated these findings in spinal
neurons using the SNI model of peripheral nerve injury. LPCAT1 and LPCAT2
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mRNA were expressed by a proportion of spinal cord neurons in naïve animals
and LPCAT2 mRNA expression increased following nerve injury whilst LPCAT1
mRNA remained unchanged (Okubo et al. 2012). It has also been shown that
LPCAT2 is expressed by murine DRG neurons and non-neuronal cells 7 days post
spinal nerve transection (Hasegawa et al. 2010). Therefore it appears that neu-
ronal LPCAT1 and LPCAT2 share certain properties to those characterised in
immune cells. Although nerve injury is sufficient to induce LPCAT2 expression,
it is currently unknown whether an inflammatory stimulus, such as LPS, is also
sufficient.
The results presented in this chapter do not provide any clear indications that
either isoform may be associated with neuronal TLR signalling. In immune cells
LPCAT2 mediates the translocation of TLR2 and TLR4 monomers into lipid
raft domains of the phospholipid membrane that allow for intracellular signalling
(Abate & Jackson 2015). The expression pattern of LPCAT1 overlaps somewhat
with that of TLR4 (see Chapter 2) although, unlike TLR4, the expression of
LPCAT is not specific to nociceptors. It is therefore likely that LPCAT1 has a
more general function in these cells rather than one specifically related to noci-
ception.
The observed pattern of LPCAT2 expression in naïve tissue initially suggests that
the enzyme is not associated with TLR4. It was however shown that LPCAT2
expression is induced in neurons in vitro following nerve injury. This suggests that
LPCAT2 may indeed be associated with a range of nerve-injury related signalling
pathways. Due to antibody incompatibility it was not possible to demonstrate
whether LPCAT2-expressing neurons co-localised with TLR4. It is not known
whether the expression of LPCAT2 in neurons is up-regulated following PAMP-
exposure or TLR activation and therefore the possibility of LPCAT2 playing a
role in neuronal TLR4 activation can not be dismissed.
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Current studies on neuronal LPCAT isoforms, including the present study, have
focussed on enzyme expression rather than enzyme activity. Although determining
enzyme expression is a necessary pre-cursor for further characterisation, investi-
gating enzyme activity within neurons is key to further understanding their role
in specific physiological and pathological processes. Indeed, in immune cells, an
inflammatory stimulus such as LPS induces LPCAT2 activity as well as increased
expression. LPS exposure also causes TLR4 to translocate to lipid rafts and it
is now thought that LPCAT2 could mediate this movement (Jackson et al. 2008;
Abate & Jackson 2015). The specific functions of both LPCAT1 and LPCAT2
in neurons are poorly understood. One function of LPCAT1 and LPCAT2 that
is particularly relevant when discussing pain and inflammation is their ability to
synthesis PAF, a lipid mediator which has been shown to contribute towards in-
flammatory and neuropathic pain (see Tsuda et al. 2011). LPCAT1 synthesises
PAF in a constitutive, non-inducible manner whereas LPCAT2-dependent PAF
synthesis is inducible (Shindou et al. 2007). Although the PAF-synthesising ac-
tivity of neuronal LPCAT2 has not been directly demonstrated, LPCAT2 mRNA
expression as well as PAFR mRNA is increased following nerve injury (Okubo
et al. 2012). The contribution of PAF signalling to neuronal sensitisation and the
generation of pain has been discussed (see Tsuda et al. 2011) and the application
of a PAFR antagonist in this latter study suppressed mechanical allodynia follow-
ing nerve injury. This study, and past studies, show that LPCAT2 is expressed
by neurons and non-neuronal cells following nerve injury. Neuronal LPCAT2 may
therefore increase the production of PAF by both neurons and tissue macrophages
following a priming event such nerve injury, and possibly inflammation, leading to
neuronal sensitisation via indirect mechanisms involving inflammatory cytokine
production by tissue macrophages. The specific mechanism that mediates the
induction of LPCAT2 following nerve injury is currently unknown however it is
known that LPCAT2 function is Ca2+ dependent (Shindou et al. 2007). Calcium
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ion influx is essential for normal neuronal function as well as the induction of neu-
ronal plasticity and Tsuda et al. (2011) suggest a mechanism whereby LPCAT2
activity and PAF production is mediated by purinergic receptor and calcium chan-
nel activation. Following neuronal TLR activation, TRPV1 sensitisation has been
demonstrated (Diogenes et al. 2011; Ferraz et al. 2011) and it is possible that
TRPV1 activation-dependent calcium influx may also be sufficient to induce LP-
CAT2 activity and up-regulation.
This study, to the best of our knowledge, is the first to examine LPCAT1 and
LPCAT2 expression in naïve TG sensory neurons and cultured sensory neurons
in vitro. LPCAT1, but not LPCAT2, is shown to be expressed by trigeminal sen-
sory neurons under normal conditions. Following nerve injury LPCAT1 expression
levels remain unchanged whilst a small percentage of neurons begin to express LP-
CAT2. The calcium-dependent inducibility of LPCAT2 activity combined with its
PAF-synthesising activity suggests that neuronal LPCAT2 is potentially involved
in neuropathic and inflammatory pain. The involvement of LPCAT2 in neuronal
TLR signalling should be explored further and a recent study has identified a range
of potential LPCAT2-specific inhibitors which would greatly aid the field (Tarui
et al. 2014). LPCAT2 specific inhibitors may also represent a potential future clin-
ical target for pain management due to their antagonism of LPCAT2-dependent
PAF synthesis and subsequent PAF-dependent pain hypersensitivity.
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6.1 Discussion
Traditionally it was thought that pathogens interact with sensory neurons through
indirect mechanisms involving the activation of an innate immune response and
production of pro-inflammatory mediators. It is now understood that sensory
neurons can directly detect and respond to pathogenic challenge independently
of the innate immune system through the activation of neuronal TLRs. The
present study set out to investigate how the activation of neuronal TLRs within
the trigeminal system alters neuronal signalling with the following core aims:
• To describe the degree of expression of TLR4, TLR2 and TLR7 within
sensory ganglia and their distribution within functionally-identified neuronal
sub-populations.
• To investigate pro-inflammatory cytokine production by trigeminal sensory
neurons following exposure to agonists of the aforementioned TLRs.
• To investigate the potential involvement of LPCAT isoforms in the activation
of neuronal TLRs.
Prior research has identified the expression of multiple TLRs in sensory neu-
rons and the co-expression of certain TLRs with neurochemical markers such as
TRPV1, NF200, CGRP and IB4 (Wadachi & Hargreaves 2006; Diogenes et al.
2011; Due et al. 2012; Lin et al. 2015; Xu et al. 2015). The majority of these past
studies however do not attempt to quantify this expression of TLRs in neurons
or the degree of co-expression of TLRs with neurochemical markers. A detailed,
quantitative description of receptor expression is a pre-requisite for subsequent
functional studies in order to fully understand the different functional cell types
that may respond to TLR activation. Results presented in chapter 3 and in Hel-
ley et al. (2015) demonstrate that the expression of TLR4, TLR2 and TLR7 are
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specific to C fibre nociceptor populations within the adult rat TG and DRG.
The activation of these TLRs is therefore likely to primarily impact nocicep-
tor signalling rather than that of non-nociceptor populations. The activation of
these TLRs may however be able to indirectly alter the properties of larger non-
nociceptors through paracrine signalling mechanisms downstream from receptor
activation in nociceptors. TLR4, 2 and 7 shared similar patterns of expression
and co-expression suggesting that C fibre nociceptors express a range of different
TLRs and are therefore able to detect and respond to a range of exogenous and
endogenous agonists. Indeed, results presented in chapter 4 demonstrate that the
activation of the above TLRs in TG sensory neurons induces a transcriptional up-
regulation of pro-inflammatory cytokines that are known to contribute towards
peripheral and central sensitisation (see Fig. 6.1 for proposed mechanisms). An
alteration in cytokine gene expression was observed in response to E. coli LPS
but not to LPS isolated from the oral pathogen P. gingivalis. This suggests that
neuronal TLRs may generate a differential response to agonists of varying potency
as is the case for TLRs expressed by innate immune cells.
The lack of a neuronal cytokine response induced by exposure to P. gingivalis
LPS provides an interesting insight into potential mechanisms of pathology as-
sociated with chronic periodontitis. Although the disease is associated with a
chronic inflammatory response a majority of patients do not report a change in
pain experienced (Abd El-Aleem et al. 2004). This is somewhat surprising given
that the presence of an inflammatory response is often associated with peripheral
sensitisation. This is indeed the case for some prevalent orofacial pain including
acute conditions such as pulpitis and mucositis as well as chronic conditions af-
fecting the TMJ (see Sessle 2011). The peripheral mechanisms of inflammatory
pain are well established and the contribution of specific immune factors have
been discussed in chapter 1 of this thesis. Many of these factors, including IL-1β
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and TNFα, are found in increased concentrations within the GCF of periodontitis
patients and actively contribute to tissue damage (see Gupta 2013). Despite this,
the majority of pain reported with chronic periodontitis is associated with more
advanced stages of the disease possibly due to more pronounced tissue damage
to tooth supporting structures and abscess formation (see LeResche & Dworkin
2002).
Previous studies have demonstrated that the activation of neuronal TLR4 by P.
gingivalis LPS sensitises TRPV1 and facilitates the associated release of CGRP
(Diogenes et al. 2011; Ferraz et al. 2011). This would suggest that P. gingivalis
promotes neuronal sensitisation however this does not appear to be replicated in
the clinical setting. One potential explanation for this difference may involve the
relatively high concentration of P. gingivalis LPS used in previous reports. This is
in contrast to many immunological studies that routinely expose cells to concen-
trations in the nanogram range. Although a high concentration of agonist ensures
a strong degree of receptor activation and is therefore useful for describing down-
stream mechanisms, it may not accurately represent the situation in vivo. This is
also the case for the use of other agonists of neuronal TLRs. For example, exclud-
ing some preliminary data presented by Tse et al. (2014a) which shows that DRG
neurons up-regulate COX-2 mRNA following 4 h exposure to 0.1 µg/mL of E. coli
LPS, the lowest concentration of LPS used to activate neuronal TLR4 is 1 µg/mL.
This study, and past studies, have also primarily used synthetic agonists to acti-
vate certain neuronal TLRs. Synthetic agonists are often used when investigating
specific receptor signalling pathways as their receptor specificity and potency are
well characterised. They cannot however be directly related to a pathological con-
dition. Future research must therefore expand on these initial studies and utilise
specific, pathologically relevant agonists at relevant concentrations to investigate
their effects on nociceptor physiology.
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Figure 6.1 – Summary of proposed mechanisms. The results presented in this
thesis suggest that TNFα and IL-1β are produced by nociceptors, downstream
from TLR activation. These cytokines exert a range of actions at multiple loca-
tions within the sensory nervous system to promote neuronal sensitisation. (A)
TNFα and IL-1β may be released from the peripheral terminals of nociceptors
and can act in an autocrine and paracrine fashion. The activation of TNFR1
and IL1R1 expressed by nociceptors is sufficient to induce spontaneous firing and
also activate intracellular signalling pathways associated with mechanisms of pe-
ripheral sensitisation (see Fig. 1.1). The peripheral release of these cytokines
can also stimulate innate immune cells such as macrophages to promote the in-
flammatory response. Inflammation is associated with the increased production of
multiple factors that are known to directly increase neuronal excitability. (B) The
release of TNFα and IL-1β by neuronal soma and satellite cells within the trigem-
inal ganglion can also promote neuronal sensitisation. Activation of TNFR1 and
IL1R1 on neurons produces similar alterations to neuronal function as described
above. These alterations are not limited to the neuron that initially releases
the cytokines. Paracrine signalling may also promote neuronal sensitisation in
neighbouring neurons which results in a more diffuse hyperalgesia. Satellite cells
may also be activated resulting in the production of pro-inflammatory and pro-
nociceptive factors which can further promote neuronal sensitisation. This can
also promote a mild inflammatory response within the ganglion resulting in the
sensitisation of neighbouring neurons. (C) TNFα and IL-1β may also be released
from the central terminals of nociceptors to activate receptors expressed by second
order neurons and non-neuronal cells. The activation of these receptors on neurons
is sufficient to induce spontaneous firing but may also induce transcriptional and
post-translational changes associated with central sensitisation (see Fig. 1.2). Ac-
tivation of glial cells results in the production of factors that can further promote
central sensitisation and an altered state of intercellular communication.
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Specific cellular mechanisms that attempt to explain the apparent absence of pain
hypersensitivity associated with periodontitis are lacking. One possible explana-
tion for this relates to the microbiological aetiology of the disease. The keystone
pathogen hypothesis states that no individual species of pathogen is responsible
for the majority of tissue damage/immune activation (Hajishengallis et al. 2012).
It is in fact the overall shift in plaque behaviour and breakdown of the symbiotic
relationship with the host to a state of dysbiosis that promotes tissue destruction.
The individual species of bacteria contained within the plaque are considered less
potent when compared to the dysbiotic plaque as a whole. This is demonstrated
by the relative potency of P. gingivalis LPS isoforms compared to that of enter-
obacterial pathogens such as E. coli. Generally P. gingivalis LPS is considered less
immunologically potent than E. coli LPS (Bainbridge & Darveau 2001). Results
presented in chapter 4 of this thesis suggest that this may also be the case for the
activation of neuronal TLRs. Whilst E. coli LPS induced an increased expres-
sion of pro-inflammatory cytokine mRNA, two individual isoforms of P. gingivalis
LPS did not. Therefore P. gingivalis alone may not possess sufficient TLR agonist
activity in order to induce intracellular signalling pathways in neurons.
The relatively low potency of P. gingivalis LPS is suggested to be a host evasion
mechanism employed by the pathogen to promote survival and plaque matura-
tion (see Hajishengallis & Lamont 2014). The bacterium is able to actively alter
its LPS isoforms in response to changes in the local environment that are asso-
ciated with the diseased state (Al-Qutub et al. 2006; Curtis et al. 2011). Less
potent isoforms of LPS, containing mono-phosphorylated, tetra-acylated lipid A
for example, are more prevalent in the disease setting (Al-Qutub et al. 2006).
This isoform has relatively weak TLR agonist activity compared to other isoforms
(Darveau et al. 2004) and this is mirrored by the strength of the host immune
response initiated in periodontitis. A strong cytokine response would promote
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immune activation and subsequent clearance of the bacteria whereas a low level
of immune activation is beneficial to bacterial survival. Tissue damage caused by
the low level immune response releases essential molecules that can be utilised as
nutrients by opportunist species within the plaque, termed inflammophillic bac-
teria, to promote plaque maturation and disease progression (see Hajishengallis
2014). Therefore an absence of cytokine induction in neurons could promote bac-
terial survival by dampening the host response. The absence of neuronal cytokine
production in response to P. gingivalis LPS may also contribute to the lack of
clinical pain reported by chronic periodontitis patients.
The heterogeneity of bacterial species within sub-gingival plaques however means
that may be possible for one or more of these other species to alter nociceptor
physiology through the activation of TLRs. The contribution of many different
microbial species to the pathogenesis of periodontitis have not been described
due to the large number of implicated species in recent microbiome studies (De-
whirst et al. 2010; Abusleme et al. 2013). The importance of previously under-
appreciated microbial species in periodontal diseases are only just beginning to be
explained (see Hajishengallis 2014). For example, Filifactor alocis, has recently
been shown to induce a pro-inflammatory response (Moffatt et al. 2011) and it
is therefore possible that it may also directly interact with sensory neurons. The
focus of this study was on TLR activation however P. gingivalis and other peri-
odontal pathogens also possess a range of other virulence factors. α-haemolysin
and N -formylated peptides, for example, are able to directly induce calcium in-
flux and action potential generation in nociceptors (Chiu et al. 2013). Periodontal
pathogens, including P. gingivalis, secrete proteases such as gingipains (Guo et al.
2010) and express a range of different peptides on fimbriae (Hajishengallis 2007)
that contribute towards tissue damage and these may also exert effects on noci-
ceptors, similar to those demonstrated by Chiu et al. (2013).
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Although P. gingivalis LPS was not sufficient to induce a transcriptional response
in terms of the specific inflammatory cytokines within the time-frame studied, it is
possible that alterations to other pro-nociceptive and/or pro-inflammatory factors
may occur. As mentioned, P. gingivalis LPS is able to induce post-transcriptional
alterations that are known to contribute towards peripheral and central sensiti-
sation (Diogenes et al. 2011; Ferraz et al. 2011). A broad range of factors and
mechanisms have been implicated in the development and maintenance of pe-
ripheral and central sensitisation (summarised in Chapter 1.2) and the effect of
neuronal TLR activation on the expression of the majority of these factors has yet
to be investigated. For example, in chapter 3, it is shown that TLR4, 2 and 7 all
display a substantial amount of co-localisation with P2X3 in the TG and DRG. It
is therefore possible that activation of these receptors, including the activation of
TLR4 by P. gingivalis LPS, may alter P2X3 receptor function. P2X3 activation
and sensitisation is central to the development and maintenance of both inflamma-
tory and neuropathic pain states, including those induced by LPS (Franceschini
et al. 2013). Activation of neuronal TLRs has been shown to activate signalling
pathways such as p38 MAPK and ERK1/2 (Tse et al. 2014a) and it is well ac-
cepted that the activation of such pathways induces the sensitisation of P2X3 as
well as multiple other receptors and ion channels on the neuronal membrane (see
Fig. 1.1). Therefore the activation of TLRs may have implications for a wider
range of receptors and channels than has been previously described.
A mechanistic role for neuronal TLRs in the initiation of pain associated with
chronic periodontitis may still be proven by their ability to recognise DAMPs.
Blocking TLR signalling in pain models associated with sterile inflammation,
such as cancer pain and nerve injury, has been shown to reduce pain-like be-
haviour (Raghavendra et al. 2004; Tanga et al. 2005; Kim et al. 2007; Cao et al.
2009). This suggests that DAMPs may trigger a cycle of signalling events that
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contributes to the potentiation of persistent pain. As previously mentioned, pain
experienced in periodontitis patients is often associated with advanced disease
and this, in turn, is associated with increasing amounts of DAMPs in the local
micro-environment. In support of this, the ability of the specific DAMPs, S100
calcium-binding protein A8 (S100A8) and α2-macroglobulin, to directly activate
sensory neurons has been demonstrated in DRG neurons innervating the knee
joint (Miller et al. 2014). A role for HSP70, signalling via TLR4, has also been
demonstrated in TG neurons in a model of tongue-referred pain associated with
tooth pulp inflammation (Ohara et al. 2013). S100A8, α2-macroglobulin and
HSP70, are often identified at increased levels within the GCF of periodontitis
patients compared to healthy controls (Chen et al. 1998; Kojima et al. 2000; Kido
et al. 2012), as have a wide range of other endogenous molecules (Kido et al. 2012)
that are known to contribute towards pain (see Kato & Svensson 2015). There-
fore neuronal TLRs may be activated by their respective endogenous agonists (see
Table 1.1) and contribute to pain experienced in advanced periodontitis.
The activation of neuronal TLRs also remains relevant for the development of in-
flammatory and neuropathic pain in other orofacial pain conditions. This has been
demonstrated for nociception associated with acute and chronic pulpitis (Ohara
et al. 2013; Lin et al. 2015) and could also potentially be extended to include
infectious conditions such as burning mouth syndrome, stomatitis and pericoro-
nitis (see Drangsholt & LeResche 2009). Additionally, TMJ disorders associated
with chronic tissue damage result in the release of endogenous TLR agonists in-
cluding fibrinogen, HSP60, HSP70, hyaluronic acid and HMGB1 (see Haseeb &
Haqqi 2013) some of which are associated with pain (see Kato & Svensson 2015).
Further, the dense sensory neuron innervation of oral tissues means that a neu-
ropathic component of an increasing number of orofacial pain conditions, such
as idiopathic facial pain and burning mouth pain, is being identified. In these
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situations, nerve injury, like other tissue damage, is associated with the release of
endogenous TLR agonists. Sensory neurons express the necessary TLRs to detect
the exogenous and endogenous TLR agonists associated with these conditions and
the activation of these TLRs may directly contribute to the pain response.
In conclusion, the results presented in this thesis support the hypothesis that
the activation of TLRs, expressed by trigeminal nociceptors, may contribute to
the initiation and maintenance of pain hypersensitivity in a range of orofacial
disorders. Superficial nerve endings within peripheral tissues are ideally placed
to detect infection or tissue damage through the activation of TLRs. This is
particularly relevant for many unique orofacial tissues given their relatively high
density of innervation. The activation of these neuronal TLRs represents an in-
nate sensing ability of nociceptors that not only has implications for neuronal
excitability but also the orchestration of an inflammatory immune response. Neu-
ronal TLR signalling has the potential to be exploited by pathogens to modify the
host response, as is the case for TLRs expressed by immune cells (Hajishengallis
& Lamont 2014). In addition, better understanding of the expression patterns
of TLRs in sensory neurons has the potential for novel therapeutic approaches
to pain control. For example, a recent study has utilised the specific expression
of TLR5 on A-fibres to reduce the mechanical allodynia associated with nerve
injury through the application of TLR5-targeted Na+ channel blockers (Xu et al.
2015).
The key findings and contributions of the present study to the greater research
area report that:
• TG sensory neurons express TLR4, TLR2 and TLR7.
• This expression is exclusive to nociceptor populations as demonstrated by a
significant degree of co-localisation with the neurochemical markers TRPV1
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and P2X3, but not NF200.
• TLR4 and TLR2 are expressed by a proportion of non-neuronal cells within
sensory ganglia, whereas TLR7 is only expressed by neurons.
• TG sensory neurons constitutively express a range of TLR-associated co-
receptor and signalling adapter genes.
• TG sensory neurons in vitro up-regulate the TLR4-dependent expression of
TNFα and IL-1β mRNA, but not IL-6 or IFNβ mRNA, in response to E.
coli LPS.
• TG sensory neurons in vitro up-regulate the expression of TNFα and IL-1β
mRNA, but not IL-6 or IFNβ mRNA, in response to synthetic TLR2 and
TLR7 agonists.
• No cytokine induction was observed in response to two structurally different
isoforms of P. gingivalis LPS.
• TG sensory neurons constitutively express LPCAT1 but not LPCAT2 under
naïve conditions.
• LPCAT1 expression may not be specific to one sub-population of sensory
neuron as it co-localises with TRPV1, P2X3 and NF200.
• LPCAT2 is expressed by the majority of satellite cells within sensory ganglia
whereas LPCAT1 is expressed by a smaller proportion of non-neuronal cells.
• LPCAT2 gene and protein expression is induced in TG sensory neurons
following nerve injury.
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6.2 Future perspectives
The expression of TLR4 in sensory neurons has been previously shown to be in-
ducible by tissue damage. As mentioned previously, it has been demonstrated that
19% of neurons in the maxillary region of the TG and 29% of neurons innervating
the gingivomucosa express TLR4 under normal conditions (Vindis et al. 2014).
Following ligature induced periodontitis this expression increased to 32% and 41%
respectively. Similarly, TLR4 is up-regulated in peptidergic neurons within the
TG in the setting of acute pulpitis following dental injury (Lin et al. 2015). The
inducibility of other neuronal TLRs has not been demonstrated following tissue
damage. The alteration in neuronal expression following the onset of infection,
such as periodontitis, has not been investigated. The expression of TLR1-10,
excluding TLR7 and 8, are all increased in epithelial cells in patients with peri-
odontitis (Beklen et al. 2008). Therefore investigating the periodontitis-induced
alteration in neuronal TLR expression represents an interesting avenue of future
research.
Despite recent advances in the field, the specific mechanisms of TLR activation
in neurons remain poorly understood. For example, the specific mechanisms that
govern receptor activation in neurons have not been described. In immune cells,
TLR4 undergoes dimerisation and translocation to lipid raft domains within the
cell membrane in order to activate intracellular signalling pathways following lig-
and binding. It is not known whether neuronal TLRs localise to lipid raft domains
however a functional association between TLR7 and TRPA1, which is thought to
be clustered in raft domains (Saghy et al. 2015), has recently been demonstrated
(Park et al. 2014). Therefore it is likely that neuronal TLRs may also cluster
in lipid raft domains to activate intracellular signalling cascades. Describing the
specific mechanisms of TLR activation at the neuronal membrane may provide
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an interesting insight into the interaction of TLRs with other receptors and ion
channels such as TRPV1 and P2X3. Previous studies have identified a central role
for LPCAT2 in the activation and translocation of TLR4 and TLR2 within the
phospholipid membrane (Abate & Jackson 2015). Chapter 5 of this thesis demon-
strates that the expression of LPCAT2 in TG sensory neurons is not detectable
under normal circumstances however the up-regulation of LPCAT2 mRNA and
protein is induced by nerve damage. A potential role for LPCAT2 upstream of
neuronal TLR activation therefore remains a possibility following nerve injury,
however this requires further research. For example, the specific neuronal sub-
populations that express LPCAT2 under these conditions and whether these cells
also co-express TLRs needs to be demonstrated. Investigation into the expression
of LPCAT2 in neurons under the setting of chronic inflammation is also needed in
order to determine a potential role for LPCAT2 in inflammatory pain states.
Significant voids in current knowledge remain that are also particularly relevant
for the transition to and maintenance of chronic pain. The current study focusses
on the acute activation of neuronal TLRs however, in the setting of many chronic
pain states, sensory neurons are exposed to multiple TLR agonists over time. This
is indeed the case for common orofacial pain disorders associated with chronic in-
flammation and tissue damage such as TMJ disorders and carious tooth decay.
Neuronal TLRs may therefore face repeated activation by the same or different
agonists during the course of these disorders. The repeated activation of TLRs
expressed by immune cells can either lead to a heightened sensitivity or a damp-
ened response, through processes known as priming and tolerance, respectively.
This is dependent on a range of factors including cell type, the agonist used and
the agonist concentration. Repeated activation of nociceptors often results in a
decreased activatory threshold and therefore increased excitation and neuronal
sensitisation. Whether neuronal TLRs share this capacity for priming and toler-
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ance with immune cells and how this may integrate with the multiple mechanisms
responsible for neuronal plasticity is not currently known. Understanding this
would significantly advance the knowledge of neuronal TLRs and may provide a
valuable insight into potential mechanisms of the maintenance of chronic pain.
This may also be particularly relevant in the case of chronic periodontitis. The
acute application of P. gingivalis LPS isoforms does not induce a transcriptional
up-regulation of inflammatory cytokines in sensory neurons however the priming
effect of this initial exposure is unknown. It is therefore possible that repeated
exposure to LPS or subsequent exposure to a different ligand, such as an en-
dogenous ligand associated with tissue damage, may indeed induce a different
response.
Finally, it is also important to consider the recent findings that LPS may acti-
vate neurons through TLR-independent mechanisms. As previously mentioned,
LPS has been shown to activate certain non-canonical receptors including TRPA1
(Meseguer et al. 2014) and various caspases (Shi et al. 2014). TRPA1 is consid-
ered to be a key transducer of a wide range of chemical stimuli associated with
inflammation so it is perhaps not surprising that it may also directly detect for-
eign molecules such as LPS. Interestingly, TRPA1 has also been demonstrated to
regulate the activation of TLR7 in sensory neurons (Park et al. 2014). Therefore,
whilst TRPA1 may directly detect certain PAMPs or DAMPs, it may also play a
key role in regulating the activity of neuronal TLRs. Further research is required
to provide a more detailed description of the potential innate surveillance function
of TRPA1. A broader study investigating the co-expression of TRPA1 and multi-
ple neuronal TLRs as well as the ability of TRPA1 to directly detect other TLR
agonists would provide an insight into this. Future work should also focus on the
interaction between TRPA1 and neuronal TLRs in order to better understand the
molecular mechanisms of neuronal TLR activation and regulation.
188
189
190
Appendix A
Publications
191
192
THE EXPRESSION OF TOLL-LIKE RECEPTOR 4, 7 AND
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Abstract—The recent discovery thatmammalian nociceptors
express Toll-like receptors (TLRs) has raised the possibility
that these cells directly detect and respond to pathogenswith
implications for either direct nociceptor activation or sensiti-
zation. A range of neuronal TLRs have been identified, how-
ever a detailed description regarding the distribution of
expression of these receptors within sub-populations of
sensory neurons is lacking. There is also some debate as to
the composition of the TLR4 receptor complex on sensory
neurons. Here we use a range of techniques to quantify the
expression of TLR4, TLR7 and some associated molecules
within neurochemically-identified sub-populations of trigem-
inal (TG) and dorsal root (DRG) ganglion sensory neurons.
We also detail the pattern of expression and co-expression
of two isoforms of lysophosphatidylcholine acyltransferase
(LPCAT), a phospholipid remodeling enzyme previously
shown to be involved in the lipopolysaccharide-dependent
TLR4 response in monocytes, within sensory ganglia.
Immunohistochemistry shows that both TLR4 and TLR7pref-
erentially co-localize with transient receptor potential valli-
noid 1 (TRPV1) and purinergic receptor P2X ligand-gated
ion channel 3 (P2X3), markers of nociceptor populations,
within both TG and DRG. A gene expression profile shows
that TG sensory neurons express a range of TLR-associated
molecules. LPCAT1 is expressed by a proportion of both
nociceptors and non-nociceptive neurons. LPCAT2
immunostaining is absent from neuronal profiles within both
TGandDRGand is confined to non-neuronal cell types under
naı¨ve conditions. Together, our results show that nocicep-
tors express the molecular machinery required to directly
respond to pathogenic challenge independently from the
innate immune system.  2015 IBRO. Published by Elsevier
Ltd. All rights reserved.
Key words: pain, cell signaling, sensory neuron, trigeminal
ganglion, dorsal root ganglion, Toll-like receptor.
INTRODUCTION
Traditionally it is thought that pathogens interact with
sensory neurons through indirect mechanisms involving
the activation of an innate immune response and
production of pro-inﬂammatory mediators (see Ren and
Dubner, 2010 for review). These indirect mechanisms
involve the release of inﬂammatory mediators and the
peripheral sensitization of high-threshold sensory neu-
rons, nociceptors, increasing excitability to threshold
and sub-threshold stimuli and contributing toward the
transition from acute to chronic pain states (for reviews
see Marchand et al., 2005; Ren and Dubner, 2010). A
complex web of interactions between neurons, non-
neuronal cells and immune cells develops to maintain a
state of pain hypersensitivity (Milligan and Watkins,
2009; Austin and Moalem-Taylor, 2010; Grace et al.,
2011; Nicotra et al., 2012). Previous work on the impact
of inﬂammatory mediators on nociceptor sensitization
and pain generation has suggested that the degree of
pain associated with infection is heavily inﬂuenced by
the degree of immune activation (Marchand et al., 2005;
Ren and Dubner, 2010). It is now understood that sensory
neurons can directly detect and respond to pathogenic
challenge independent of the innate immune system.
Toll-like receptors (TLRs) are a family of innate
pattern recognition receptors that detect a wide range of
exogenous pathogenic and endogenous damage-
released ligands. Since the discovery by Wadachi and
Hargreaves (2006) of TLR4 expression on trigeminal sen-
sory neurons, a range of functional TLRs have been
shown to be expressed by neurons in both the peripheral
and central nervous system (Lafon et al., 2006; Mishra
et al., 2006; Wadachi and Hargreaves, 2006; Cameron
et al., 2007; Acosta and Davies, 2008; Barajon et al.,
2009; Ochoa-Cortes et al., 2010; Diogenes et al., 2011;
Ferraz et al., 2011; Qi et al., 2011; Due et al., 2012;
http://dx.doi.org/10.1016/j.neuroscience.2015.09.069
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Abbreviations: AF, alexa-ﬂuor; DAMP, damage-associated molecular
pattern; DAPI, 40,6-diamidino-2-phenylindole; DRG, dorsal root
ganglion; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; IHC,
immunohistochemistry; IL-1b, Interleukin-1b; LPS, lipopolysaccharide;
LPCAT, lysophosphatidylcholine acyltransferase; MD, myeloid
diﬀerentiation protein; mRNA, messenger ribonucleic acid; MyD88,
myeloid diﬀerentiation primary response protein 88; NF200,
neuroﬁlament 200; P2X3, purinergic receptor P2X ligand-gated ion
channel 3; PBS, phosphate-buﬀered saline; qPCR, real-time
polymerase chain reaction; RP105, radioprotective 105; TG,
trigeminal ganglion; TLR, Toll-like receptor; TRAM, TRIF-related
adapter molecule; TRPV1, transient receptor potential vallinoid 1.
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Park et al., 2014; Tse et al., 2014a). The expression of
TLRs in neurons, particularly primary sensory neurons,
has uncovered a potential innate surveillance function
with implications for both the acute nociceptive response
and the maintenance of chronic pain states.
TLR4 and the co-receptor CD14 are expressed on rat
and human transient receptor potential vanilloid 1
(TRPV1)-positive and TRPV1-negative nociceptors
within the trigeminal ganglion (TG) (Wadachi and
Hargreaves, 2006; Diogenes et al., 2011). Activation of
TLR4, by Porphyromonas gingivalis lipopolysaccharide
(LPS), on TG sensory neurons both sensitizes TRPV1
and potentiates capsaicin-induced calcitonin gene-
related peptide (CGRP) release (Diogenes et al., 2011;
Ferraz et al., 2011). A role for TLR4, expressed by TG
neurons, in mediating pain induced by tissue damage
has also been demonstrated (Ohara et al., 2013; Miller
et al., 2014). The activation of TLR4, by Escherichia coli
LPS, on murine dorsal root ganglion (DRG) neurons has
been shown to increase neuronal excitability (Ochoa-
Cortes et al., 2010; Due et al., 2012), nociceptin
expression (Acosta and Davies, 2008) and the myeloid
diﬀerentiation primary response protein 88 (MyD88)-
dependent production of pro-inﬂammatory mediators
(Ochoa-Cortes et al., 2010; Tse et al., 2014a). The ability
of TLRs to inﬂuence the nociceptive response is not lim-
ited to TLR4. Activation of TLR3, 7 and 9 expressed by
DRG neurons induces the production of pro-
inﬂammatory mediators, up-regulates TRPV1 expression
and sensitizes TRPV1 activation (Qi et al., 2011). Activa-
tion of TLR3 and TLR7 induces an itch response (pruritus)
and directly activates DRG nociceptors (Liu et al., 2010,
2012). More recently the activation of TLR7, by endoge-
nous microRNAs, has been shown to rapidly activate
DRG neurons through mechanisms that involve TRPA1
(Park et al., 2014).
In the DRG, the reported percentage of total TLR4-
positive neurons varies widely (28–60%; Acosta and
Davies, 2008; Due et al., 2012; Tse et al., 2014a,b). While
it has been shown that 19% of neurons in the maxillary
region of the TG and 29% of neurons innervating the gin-
givomucosa express TLR4, mainly in small- to medium-
sized neurons (Vindis et al., 2014), there are currently
no quantitative data for TLR4 expression within the TG
as a whole. Previous studies have suggested that the
expression of TLR7 is limited to small/medium sized neu-
rons that express TRPV1 and TRPA1 although no quan-
titative analysis has been performed (Liu et al., 2010; Qi
et al., 2011; Park et al., 2014).
There is also some debate regarding the composition
of the TLR4 receptor complex expressed by sensory
neurons. In innate immune cells a functional TLR4-
signaling complex consists of TLR4, CD14 and myeloid
diﬀerentiation protein (MD)-2 (Akira and Takeda, 2004).
DRG neurons reportedly express CD14 and MD-1
messenger ribonucleic acid (mRNA) and protein but little
MD-2 and no radioprotective 105 (RP105) mRNA or pro-
tein (Acosta and Davies, 2008). Upon activation, neuronal
TLR4 is reported to form an atypical co-receptor complex
with CD-14 and MD-1 (Acosta and Davies, 2008).
MD-1 classically interacts with the TLR4 homolog,
RP105 to regulate TLR4 signaling (Ohto et al., 2011).
More recent studies however have shown that DRG neu-
rons do express MD-2 and RP105 mRNA and protein in
addition to MD-1 and CD14 mRNA and protein (Ochoa-
Cortes et al., 2010; Tse et al., 2014a). Additionally it
was shown that the majority of TLR4-positive neurons
co-localize with CD14 and MD-2, rather than MD-1 (Tse
et al., 2014a).
Lysophosphatidylcholine acyltransferase 1 and 2
(LPCAT1 and LPCAT2) are two isoforms of a
phospholipid-modifying enzyme that participate in
membrane remodeling by mediating the acylation of
lysophosphatidylcholine (see Shindou and Shimizu,
2009). The phospholipid/lysophospholipid composition of
cellular membranes aﬀects membrane function, including
lipid raft functions (Stulnig et al., 2001), and therefore may
impact upon multiple cellular signaling pathways including
TLR4 signaling (see Triantaﬁlou et al., 2011). In macro-
phages, LPCAT2 is activated by phosphorylation follow-
ing TLR4-dependent LPS recognition (Morimoto et al.,
2010) and LPCAT activity is essential for the translocation
of TLR4 to lipid rafts and subsequent generation of a
TLR4 signaling response (Jackson et al., 2008). LPCAT1
and LPCAT2 have been identiﬁed in a range of tissues
although a high level of expression has been demon-
strated in lung alveolar cells and immune cells for
LPCAT1 and LPCAT2, respectively (Nakanishi et al.,
2006; Shindou et al., 2007; Morimoto et al., 2010). Both
LPCAT1 and LPCAT2 expression have been demon-
strated in a sub-set of spinal neurons (Okubo et al.,
2012). Whereas LPCAT1 expression is constitutive,
LPCAT2 is an inducible form of the enzyme (Shindou
et al., 2005). Indeed, LPCAT2 is up-regulated in microglia
following nerve injury while LPCAT1 expression remains
unchanged (Okubo et al., 2012). LPCAT2 expression
has also been identiﬁed in peripheral sensory neurons
as well as non-neuronal cells within the DRG following
nerve injury (Hasegawa et al., 2010). While previous stud-
ies have identiﬁed the expression of LPCAT isoforms in
injured DRG neurons, the expression of LPCATs naı¨ve
peripheral sensory neurons and the subsequent role they
might play in the neuronal TLR response is unknown.
While it has been shown that nociceptors express a
range of TLRs, a detailed analysis of TLR expression
within multiple sensory neuron sub-populations has not
been performed, particularly within the TG. A detailed
analysis of TLR4 and TLR7 expression patterns within
primary sensory neurons is a pre-requisite for further
functional analysis of receptor activation. In the current
study we explore the hypothesis that nociceptors
possess the required molecular components to directly
detect and respond to ligands of bacterial, viral and
endogenous origin. Using well-deﬁned neurochemical
markers, we provide a semi-quantitative analysis of the
expression of TLR4 and TLR7 within sensory neuron
sub-populations. We also detail a gene expression
proﬁle of TLR signaling-associated components within
the TG. Lastly, we describe the distribution of
expression of two isoforms of a lysophosphatidylcholine
acyltransferase (LPCAT) enzyme, LPCAT1 and
LPCAT2 within sensory ganglia.
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EXPERIMENTAL PROCEDURES
Materials
All materials, unless otherwise stated, were purchased
from Sigma–Aldrich (Gillingham, UK). All real-time
polymerase chain reaction (qPCR) reagents were
purchased from Life Technologies (Carlsbad, CA, USA).
Animal care
Age-matched, adult male Sprague–Dawley rats
(>3 months of age, 250–350 g, Charles River, UK)
were group-housed in a temperature and humidity-
controlled environment with a 12-h light/dark cycle
(lights on at 8:00 A.M.) with food and water available
ad libitum. All experiments adhered to guidelines
described by Schedule 1 of the UK 1986 Animals
(Scientiﬁc Procedures) Act. A total number of 6 animals
were used in this study: 3 for TLR and LPCAT
immunohistochemistry and 3 for qPCR analysis of TLR-
associated gene expression.
Immunohistochemistry
Indirect single- and dual-labeled immunohistochemistry
(IHC) was performed to determine the distribution of
expression of TLR4, TLR7, LPCAT1 and LPCAT2 and
their co-expression with the functional neurochemical
markers neuroﬁlament 200 (NF200), thermo-transducer
TRPV1 and purinergic receptor P2X3 in the rat TG and
DRG. Adult male Sprague–Dawley rats were euthanized
with a lethal dose of sodium pentobarbital (100 mg/kg)
and animals were conﬁrmed as being dead by
conﬁrming the permanent cessation of the circulation.
Animals were then transcardially perfused with 0.1 M
phosphate-buﬀered saline (PBS, pH 7.4) followed by 4%
paraformaldehyde in 0.1 M phosphate buﬀer (pH 7.4).
TG, L4/L5 DRG, lung and spleen tissues were rapidly
removed and post-ﬁxed in 4% paraformaldehyde (pH
7.4) for 2 h at 4 C then cryoprotected overnight in 20%
sucrose in 0.1 M phosphate buﬀer (pH 7.4) at 4 C.
Tissue samples were snap-frozen in optimal cutting
temperature compound (Tissue Tek, UK) and
sequentially cryo-sectioned at 9 lm (CM1100, Leica
Biosystems, Milton-Keynes, UK). Mounted sections
were washed in PBS and blocked/permeabilized with
donkey serum (10% in PBS, 0.2% Triton-X-100, 0.1%
azide) for 1 h in a humidity chamber at room
temperature. Primary antibodies against TLR4 (1:200,
Abcam, Cambridge, UK), TLR7 (1:500, Novus
Biologicals, Littleton, CO, USA), LPCAT1 (1:200,
ProteinTech, Chicago, IL, USA) or LPCAT2 (1:200,
Novus Biologicals, Littleton, CO, USA) were pooled with
primary antibodies against either NF200 (1:4000,
Sigma–Aldrich, Gillingham, UK), TRPV1 (1:200,
Neuromics, Edina, MN, USA) or P2X3 (1:1000, Novus
Biologicals, Littleton, CO, USA) and incubated with
tissue sections for 24 h, with the exception of TLR4
which required a 48-h incubation, in a humidity chamber
at 4 C. After washing with PBS, tissue sections were
incubated with a combination of species-speciﬁc alexa-
ﬂuor (AF) 488 (10 lg/mL, Life Technologies, Carlsbad,
CA, USA), AF555 (10 lg/mL, Life Technologies,
Carlsbad, CA, USA) or AF594 (10 lg/mL, Jackson
ImmunoResearch, West Grove, PA, USA) conjugated
secondary antibodies for 3 h in a dark humidity
chamber at room temperature. After washing with PBS,
tissue sections were incubated with 40,6-diamidino-2-phe
nylindole (DAPI) (100 ng/mL, Sigma–Aldrich,
Gillingham, UK) for 1 h in a humidity chamber at room
temperature. Tissue sections were then mounted in
FluorSave reagent (EMD Millipore, Watford, UK) for
imaging.
A series of control experiments were performed to
verify the speciﬁcity of the antibodies used in this study.
The antibodies/antisera used for the neurochemical
markers have been categorized elsewhere (Vulchanova
et al., 1997; Guo et al., 1999; Michael and Priestley,
1999; Kiasalari et al., 2010). These antibodies/antisera
performed as previously described when used in this
study. Primary rat spleen tissue was used as a positive
control for the TLR and LPCAT2 antibodies because of
the high proportion of immune cells found in the spleen.
Primary rat lung tissue was used as a positive control
for LPCAT1. No blocking peptides were available for the
primary antibodies used in this study. For the TLR anti-
bodies we therefore performed staining on tissue known
to be negative for the antigen in question. Peripheral rat
red blood cells were used as negative controls for the
TLR antibodies. Western blotting performed on whole
TG samples was used to verify the speciﬁcity of the
LPCAT antibodies and both displayed single bands at
the expected weights. To test the speciﬁcity of the sec-
ondary antibodies TG sections were incubated with sec-
ondary antibodies in the absence of primary antibodies.
Unstained TG sections were used to observe any auto-
ﬂuorescence within the tissue. No labeling was observed
under the negative control conditions (control images not
shown).
Image acquisition & analysis
Images were captured using a Nikon Eclipse 80i
epiﬂuorescence microscope equipped with a Nikon DS-
Qi1Mc camera using NIS-Elements software (BR 3.2,
Nikon, New York, NY, USA). All images were taken
using 20X or 60X objectives coupled with a 10X
eyepiece. At least 2000 neuronal proﬁles from each
tissue type and each animal were counted on randomly
chosen tissue sections. Only neuronal proﬁles with a
visible nuclear DAPI counterstain were included in the
counting process. Image analysis and quantiﬁcation
were performed on monochrome images by a single
investigator who was blinded to the slide identity.
Subjective visual criteria were used to determine
positive TLR4/TLR7/LPCAT1 immunoreactivity (IR). A
threshold for positive counting was set using mean
ﬂuorescence intensity units, determined by two
independent investigators for each antibody. Co-
expression of TLR4, TLR7 and LPCAT with phenotypic
markers was determined by positive identiﬁcation of
markers in individual images obtained by switching
between TRITC and FITC ﬁlters. Following identiﬁcation
of positive proﬁles in individual images, co-expression
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was conﬁrmed in merged images. Co-expression was
expressed as a percentage of target markers
expressing phenotypic markers and vice-versa.
TG dissociation
To investigate TLR-associated gene expression in TG
sensory neurons, dissociated TG, rather than whole
tissue samples were used in order to remove the
majority of non-neuronal cells and non-cellular
components. The protocol used for TG dissociation in
this study was adapted from Malin et al. (2007). Brieﬂy,
male Sprague–Dawley rats were euthanized by exposure
to rising concentrations of CO2. Animals were transcar-
dially perfused with ice-cold HBSS (Calcium and
Magnesium-free), TG were rapidly removed and cut into
10–12 small pieces. Tissue was incubated with papain
solution (60 units papain, 1 mg L-cysteine in HBSS) for
20 min at 37 C with gentle mixing halfway. Tissue was
pelleted by centrifugation at 800g for 3 min and the super-
natant discarded. The tissue was resuspended in collage-
nase/dispase solution (12 mg collagenase type II and
14 mg dispase type II in HBSS) and incubated for
20 min at 37 C with gentle mixing halfway. Pre-warmed
trypsin inhibitor (1 mg/mL in HBSS) was added to stop
enzymatic digestion and tissue was then pelleted by cen-
trifugation at 800g for 3 min. Mechanical disruption by trit-
uration with a sterile ﬁre-polished, silicon-coated glass
pipette in pre-warmed L15 medium created a single-cell
suspension which was then passed through a 12.5/28%
Percoll gradient at 1800g for 10 min to yield a neuron-
enriched cell pellet which was immediately processed
for RNA isolation.
Real-time polymerase chain reaction (qPCR)
Total messenger RNA (mRNA) from dissociated TG
neurons and whole spleen tissue was isolated using
RNAqueous-Micro kit according to the manufacturer’s
instructions. Isolated RNA was treated with DNase I for
20 min at 37 C to remove any genomic DNA
contamination. Total RNA concentration was determined
using a Qubit 2.0 Fluorometer with the Qubit RNA
Assay Kit. Sample purity was assessed using a
nanodrop 2000 (Thermo-Fisher Scientiﬁc, Waltham, MA,
USA). Only samples with a 260/280 ratio of >1.8 were
used for reverse transcription. First-strand cDNA was
synthesized from 100 ng RNA using the SuperScript
VILO cDNA Synthesis Kit which contained SuperScript
III reverse transcriptase (Reaction conditions: 25 C for
10 min, 42 C for 2 h, 85 C for 5 min). cDNA was stored
at 20 C until used for qPCR. Relative quantiﬁcation
was achieved with qPCR using TaqMan Gene
Expression Assays for TLR4 (Rn00569848_m1), MD-1
(Rn01434815_m1), MD-2 (Rn01448830_m1), CD14
(Rn00572656_m1), MyD88 (Rn01640049_m1) and
TRIF-related adapter molecule (TRAM) (Rn02082
474_s1) with glyceraldehyde 3-phosphate dehydrogen
ase (GAPDH, Rn01775763_g1) as the endogenous
control. All qPCR experiments used TaqMan Fast
Advanced Master Mix and were performed in triplicate
on a QuantStudio 12 k Flex system with a Fast 96-well
Block using 2.5 ng of template cDNA in a total reaction
volume of 10 lL per well. The reaction parameters were
as follows – 50 C for 2 min, 95 C for 20 s, 40 cycles of
95 C for 1 s and 60 C for 20 s. An initial no RT control
for each sample type was performed to assess the
eﬀectiveness of the DNAse treatment used which
returned an undetectable result. No template controls
were also included in every run and returned
undetectable results. A gene expression proﬁle from
each tissue type was created using DCT values, with
GAPDH set at 100. Analysis of gene expression data
between tissue types was performed using the 2DDCT
method (Livak and Schmittgen, 2001) with target gene
expression in each sample normalized against the
endogenous control gene GAPDH.
Statistical analysis
Data are displayed as mean ± SEM, n= 3.
Comparisons between groups were made using a
Student’s t-test, as appropriate, performed on IBM
SPSS statistics software version 21.0 (1 animal = 1 unit
for statistical analysis). Diﬀerences were considered
statistically signiﬁcant when p< 0.05.
RESULTS
Expression of TLR4 & TLR7 within the adult
mammalian TG & DRG
Indirect single-labeling IHC was used to investigate the
expression of TLR4 and TLR7 within the naı¨ve adult rat
TG and DRG. Multiple neuronal proﬁles displayed
TLR4- and TLR7-IR in the TG and DRG (Fig. 1).
Fig. 1. TLR4 and TLR7 expression within the TG and DRG. Multiple
neuronal proﬁles display intracellular granular IR for TLR4 within the
TG (A) and DRG (B), arrows show selected examples of positive
neurons. A proportion of non-neuronal cells that were morphologically
identiﬁed as satellite cells also display a positive stain for TLR4 within
both TG and DRG, indicated by asterisks (A, B). Multiple neuronal
proﬁles also display positive IR for TLR7 within the TG (C) and DRG
(D), arrows show selected examples. All non-neuronal cells within the
tissue are negative for TLR7. Scale bar 50 lm.
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Whereas the expression of TLR7 was strictly neuronal, a
proportion of non-neuronal cells that were
morphologically identiﬁed as satellite cells (elongated
fusiform cells that envelope neuronal soma) also
expressed TLR4 (Fig. 1A, B). Non-neuronal staining
was diﬀerentiated from neuronal membrane staining by
carefully examining the co-expression patterns with
neuronal markers and also by identifying the non-
neuronal cell nucleus. No overlap of staining with
neuronal markers was observed and clear,
distinguishable nuclei were identiﬁed hence we
characterized this staining as non-neuronal.
TLR4 was expressed by 29.3 ± 3.4% and 32 ± 2.9%
of total sensory neurons in the TG and DRG, respectively.
TLR7 was expressed by 32.4 ± 1.8% and 35 ± 3.9% of
sensory neurons in the TG and DRG, respectively.
There was no signiﬁcant diﬀerence in expression levels
of TLR4 and TLR7 between the TG and DRG (Student’s
t-test). TLR4-/TLR7-IR neurons are expressed as a
percentage of total neuronal proﬁles as deﬁned using a
DAPI counterstain. Rat spleen tissue was used as a
positive control and displayed multiple TLR4- and TLR7-
IR cells, respectively (Fig. 2). Red blood cells were used
as a negative control tissue as they do not express
TLR4 or TLR7. No staining was observed in the
negative control tissue (Fig. 3). Spleen tissue was
stained in the absence of primary antibodies to assess
the speciﬁcity of the secondary antibodies used. No
staining was observed under these conditions (Fig. 4).
Co-expression of TLR4 & TLR7 with neurochemical
markers of functional sensory neuron populations
Indirect dual-labeling IHC was used to characterize the
degree of co-expression of TLR4 and TLR7 with
neurochemical markers that are indicative of functional
sensory neuron populations within the naı¨ve adult rat
TG and DRG. TLR4-IR was commonly observed in
TRPV1- and P2X3-expressing neurons, respectively
(Fig. 5A–F). However, in contrast to TRPV1 and P2X3,
TLR4 was virtually absent from all NF200-expressing
neurons (Fig. 5G–I).
Similar to TLR4, TLR7-IR was identiﬁed in a large
proportion of TRPV1- and P2X3-expressing neurons,
respectively (Fig. 6A–F). TLR7 and NF200 expression
was also mutually exclusively (Fig. 6G–I). Similar
patterns of co-expression were observed for TLR4 and
TLR7 within the TG and DRG. A full characterization of
TLR4 and TLR7 co-localization within the TG and DRG
is shown in Table 1.
There was a signiﬁcant diﬀerence between TLR4 and
TLR7 in their relative levels of co-expression with the
nociceptor markers used. TLR4 co-localized more
frequently with P2X3-positive neurons compared to
TRPV1-positive neurons (TLR4/TRPV1 co-expression
vs. TLR4/P2X3 co-expression, p< 0.0001 for TG and
DRG, Student’s t-test). In the TG, TLR7 co-localized
more frequently with TRPV1-positive neurons compared
to P2X3-positive neurons (TLR7/TRPV1 co-expression
vs. TLR7/P2X3 co-expression, p< 0.05 for TG,
Student’s t-test.
Expression of TLR4 signaling-associated molecules
in TG sensory neurons
We performed qPCR on dissociated TG sensory neurons
in order to create a gene expression proﬁle for TLR4
signaling-associated components. We evaluated the
gene expression of TLR4 and three TLR4 co-receptor
molecules, MD-1, MD-2 and CD14, as well as two
intracellular signaling molecules that represent two
pathways of the TLR4 intracellular signaling cascade,
MyD88 and TRAM. The MyD88 pathway is also
downstream from all other TLRs, with the exception of
TLR3. For reference purposes, we have also included
the pain-associated genes TRPV1, P2X3 and TrkA. The
expression of these target genes relative to the
housekeeping gene GAPDH (set at 100) is shown for
TG sensory neurons (Fig. 7A) and control (spleen
tissue, Fig. 7B), respectively. All target genes are
expressed in TG sensory neurons (CT < 35) albeit at
lower levels than TRPV1, P2X3 and TRKA expression,
respectively (Fig. 7A). Gene expression levels of the
Fig. 2. Positive control staining of primary antibodies. Multiple
positively stained proﬁles can be identiﬁed for TLR4 (A, B), TLR7
(C, D) and LPCAT2 (E, F) in the spleen and LPCAT1 (G, H) in the
lung. Scale bar 15 lm and 50 lm for spleen and lung images,
respectively.
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Fig. 3. TLR expression in red blood cells as a negative control. Phase-contrast microscopy was used to identify red blood cells (A). No positive
staining was observed in red blood cells for TLR4 (B) or TLR7 (C) antibodies. Scale bar 50 lm.
Fig. 4. Secondary antibody control staining in spleen tissue. Tissue staining was performed in the absence of primary antibody in order to observe
non-speciﬁcity of secondary antibodies. Minimal levels of non-speciﬁc background staining were observed for Donkey anti-Rabbit AF488 (A),
Donkey anti-Mouse AF555 (B) and Donkey ant-Guinea Pig AF594 (C). Scale bar 50 lm.
Fig. 5. Fluorescence micrograph of rat TG dual-labeled for TLR4-IR (green, A, D, G) plus either TRPV1- (red, B), P2X3- (red, E) or NF200-IR (red,
H). The combined images (C, F, I) show co-localization of TLR4-IR with neurochemical markers. A substantial proportion of TLR4-IR neurons co-
express TRPV1-IR, examples of co-expressing neurons are indicated by ﬁlled arrows (A, B) and by asterisks in the combined image (C). Not all
TRPV1-IR neurons express TLR4, examples indicated by open arrows (A, B, C). A substantial proportion of TLR4-IR neurons also co-express
P2X3-IR, examples of co-expressing neurons are indicated by ﬁlled arrows (D, E) and by asterisks in the combined image (F). Also however, not all
P2X3-IR neurons express TLR4, examples indicated by open arrows (D, E, F). There was minimal co-localization between TLR4-IR and NF200-IR;
examples of co-expressing neurons are indicated by ﬁlled arrows (G, H) and by asterisks in the combined image (I). The majority of NF200-IR
neurons did not express TLR4-IR, examples indicated by open arrows (G, H, I). A similar pattern of expression and co-expression was observed in
the DRG (images not shown). Scale bar 50 lm. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web
version of this article.)
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TLR-associated components within TG sensory neurons
were also compared to those of the primary spleen
tissue which is known to contain a broad range of TLR-
expressing immune cells. All genes are expressed at
lower levels in TG sensory neurons than in the spleen
tissue (Fig. 7C). MD-1 was expressed 290.1 ± 36.3-fold
lower in TG sensory neurons compared to primary
spleen tissue although this is not surprising given the
high B lymphocyte content of the spleen tissue (Cesta,
2006). TLR4 gene expression was the most comparable
between the diﬀerent tissue types with a 9.1 ± 1.1-fold
lower expression in TG sensory neurons. The remaining
targets were expressed 9.8 ± 2.1 (TRAM), 13 ± 2.1
(MD-2), 24.5 ± 3.1 (MyD88) and 40 ± 8.2 (CD14) fold
lower in TG sensory neurons than the spleen.
Expression of LPCAT isoforms in the TG
We performed indirect single- and dual-labeling IHC to
investigate the expression of LPCAT1 and LPCAT2
within the TG and DRG and their co-expression with
neurochemical markers. LPCAT1-IR was identiﬁed in
Fig. 6. Fluorescence micrograph of rat TG double labeled for TLR7-IR (green, A, D, G) plus either TRPV1- (red, B), P2X3- (red, E) or NF200-IR
(red, H). The combined images (C, F, I) show co-localization of TLR7-IR with neurochemical markers. A substantial proportion of TLR7-IR neurons
co-express TRPV1-IR, examples of co-expressing neurons are indicated by ﬁlled arrows (A, B) and by asterisks in the combined image (C). Some
neurons expressing low levels of TRPV1-IR neurons do not display TLR7-IR, examples indicated by open arrows (A, B, C). A substantial proportion
of TLR7-IR neurons also co-express P2X3-IR, examples of co-expressing neurons are indicated by ﬁlled arrows (D, E) and by asterisks in the
combined image (F). Also however, not all P2X3-IR neurons display TLR7-IR, examples indicated by open arrows (D, E, F). There was minimal co-
localization between TLR7-IR and NF200-IR; examples of co-expressing neurons are indicated by ﬁlled arrows (G, H) and by asterisks in the
combined image (I). The vast majority of NF200-IR neurons did not express TLR7-IR, examples indicated by open arrows (G, H, I). A similar pattern
of expression and co-expression was observed in the DRG (images not shown). Scale bar 50 lm. (For interpretation of the references to colour in
this ﬁgure legend, the reader is referred to the web version of this article.)
Table 1. Summary of TLR4 and TLR7 co-localization with the neurochemical markers TRPV1, P2X3 and NF200 within the naı¨ve adult rat TG and DRG.
Co-expression was expressed as a percentage of target markers expressing phenotypic markers and vice-versa
Neurochemical
label
% of labeled cells that
express TLR4
% of TLR4-positive cells that
express label
% of labeled cells that
express TLR7
% of TLR7-positive cells that
express label
TG
TRPV1 53.7 ± 0.9 57.8 ± 0.9 75.7 ± 2.5 42.6 ± 8.1
P2X3 76.6 ± 0.4 58.2 ± 2 61.6 ± 2.1 33.4 ± 3.1
NF200 3.5 ± 0.7 9.2 ± 1.5 – –
DRG
TRPV1 56.1 ± 1.4 68.2 ± 4.7 78.6 ± 2.6 45.5 ± 10.5
P2X3 81.9 ± 0.6 76.5 ± 2.5 54.8 ± 9.4 32.5 ± 4.8
NF200 4 ± 1.3 6.9 ± 2.1 – –
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50.4 ± 4.5% of total neurons (Fig. 8A, B). A proportion of
non-neuronal cells that were morphologically identiﬁed as
satellite cells also displayed weak IR for LPCAT1 (Fig. 8A,
B).
LPCAT1 was expressed by 86.3 ± 4.7%, 67 ± 7.9%
and 47.7 ± 5.3% of TRPV1-, P2X3- and NF200-
expressing neurons, respectively (Fig. 9).
All neuronal proﬁles were negative for LPCAT2 but the
majority of non-neuronal cells displayed strong LPCAT2-
IR (Fig. 8C, D).
Rat lung and spleen tissue were used as positive
control tissues for LPCAT1 and LPCAT2, respectively.
Multiple positively stained cells can be identiﬁed
(Fig. 2E–H). As LPCAT isoforms are expressed across
a range of tissue types we used western blotting to
demonstrate the speciﬁcity of the primary antibodies. A
single band at the expected molecular weight was
identiﬁed for both LPCAT1 and LPCAT2 in the TG,
DRG, cortex and RAW264.7 cells (Fig. 10).
DISCUSSION
Previous studies have shown both TLR4 and TLR7 to be
expressed by nociceptors within mammalian sensory
ganglia (Wadachi and Hargreaves, 2006; Liu et al.,
2010; Qi et al., 2011; Due et al., 2012; Park et al.,
2014) however this is the ﬁrst quantitative description of
TLR4 and TLR7 expression within adult mammalian
A B C
Fig. 7. TLR4 signaling-associated component gene expression in dissociated TG sensory neurons (A) and spleen tissue (B) as determined by
qPCR. All genes are expressed relative to GAPDH levels (set at 100). Three pain-associated genes are also included in (A) for reference purposes.
All targets are expressed in sensory neurons (CT < 35). All TLR-associated genes are expressed at noticeably lower levels than each of the three
pain-associated genes, respectively. The diﬀerence in gene expression between TG sensory neurons and spleen tissue is calculated using the
DDCT method (C). All targets are expressed in TG sensory neurons at lower levels compared to spleen tissue. Data are displayed as mean ± S.E.
M., n= 3.
Fig. 8. LPCAT1 and LPCAT2 expression within the TG and DRG. Approximately half of the total neuronal proﬁles within the TG displayed LPCAT1-
IR, arrows show selected examples (A). A similar pattern of expression was seen in the DRG (B). A proportion of non-neuronal cells that were
morphologically identiﬁed as satellite cells also displayed weak LPCAT1-IR, examples indicated by asterisks (A, B). LPCAT2-IR was not detected
above threshold levels within any neuronal proﬁle in either TG or DRG. However the majority of non-neuronal cells identiﬁed morphologically as
satellite cells, displayed strong LPCAT2-IR within both TG (C) and DRG (D). Scale bar 50 lm.
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sensory ganglia in relation to functional neuronal phenotype.
Here we show that TLR4 and TLR7 are expressed by
both capsaicin- and ATP-responsive nociceptors due to
a high degree of co-expression with TRPV1 and P2X3,
respectively. We show that dissociated sensory neurons
from the TG express a range of TLR4-associated genes
that are required for a full TLR4 signaling response. We
also show that LPCAT1 and LPCAT2 are expressed
within sensory ganglia although only LPCAT1 displays
neuronal expression in naı¨ve tissue.
Our TLR4 expression data fall within the range of
expression observed in previous studies on DRG tissue
sections (28–34% of total neurons; Due et al., 2012;
Tse et al., 2014b). Previous studies have reported that
non-neuronal cells do not express TLR4 (Due et al.,
2012; Tse et al., 2014a) however here we show that a
proportion of satellite cells do indeed display TLR4-IR.
There was no diﬀerence in expression levels of TLR4
and TLR7 between the TG and DRG. Interestingly how-
ever there was a signiﬁcant diﬀerence between TLR4
and TLR7 in their relative levels of co-expression with
the nociceptor markers used. TLR4 co-localized more fre-
quently with P2X3-positive neurons whilst TLR7 co-
localized more frequently with TRPV1-positive neurons.
Fig. 9. Fluorescence micrograph of rat TG double labeled for LPCAT1-IR (green, A, D, G) plus either TRPV1-(red, B), P2X3-(red, E) or NF200-IR
(red, H). The combined images (C, F, I) show co-localization of LPCAT1-IR with neurochemical markers. LPCAT1-IR shows co-expression with a
substantial proportion of TRPV1-IR neurons, examples of co-expressing neurons are indicated by ﬁlled arrows (A, B) and by asterisks in the
combined image (C). Not all neurons displaying TRPV1-IR neurons express LPCAT1-IR, examples indicated by open arrows (A, B, C). The majority
of LPCAT1-IR neurons also co-express P2X3-IR; examples of co-expressing neurons are indicated by ﬁlled arrows (D, E) and by asterisks in the
combined image (F). A proportion of LPCAT1-IR neurons also co-express NF200-IR, examples of co-expressing neurons are indicated by ﬁlled
arrows (G, H) and by asterisks in the combined image (I). There were also a population of NF200-IR neurons that did not co-express LPCAT1-IR,
examples indicated by open arrows (G, H, I). A similar pattern of expression and co-expression was observed in the DRG (images not shown).
Scale bar 50 lm. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
Fig. 10. Western Blot control for LPCAT isoform expression across multiple tissue types. LPCAT1 (A; 1:1000) and LPCAT2 (B; 1:500) expression in
TG, DRG and cortex. 20 lg of protein was run in each lane. RAW 264.7 cells were used as a positive control. b-III tubulin was used as a loading
control. Images representative of three separate experiments (n= 3).
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The functional signiﬁcance of this observation is currently
unknown although Park et al. (2014) have recently shown
that TLR7 interacts with TRPA1, expressed by a propor-
tion of TRPV1-positive neurons, to directly activate sen-
sory neurons. We found minimal co-localization between
TLR4/TLR7 and NF200 suggesting that TLR4 and TLR7
selectively localize to C-ﬁber nociceptors. Preferential
and direct activation and/or sensitization of C-ﬁber noci-
ceptors by pathogens and damage-released endogenous
molecules (DAMPs) via TLR4 and TLR7 is therefore
potentially possible.
There is now extensive evidence for the involvement
of neuroimmune signaling in the development and
maintenance of chronic pain states (reviewed by Nicotra
et al., 2012). TLRs are an important receptor family
involved in the complex intercellular signaling network
that develops in the setting of chronic inﬂammatory pain.
TLR4 is the most widely studied member of the receptor
family in this regard and it is rapidly up-regulated following
the onset of both inﬂammatory and neuropathic pain
(DeLeo et al., 2004; Raghavendra et al., 2004; Zhao
and Zhang, 2015). TLR4 deletion (Tanga et al., 2005)
and pharmacological inhibition have both been shown to
prevent (Bettoni et al., 2008) and reverse behavioral
hypersensitivity (Hutchinson et al., 2007, 2008, 2010;
Lan et al., 2010; Wu et al., 2010) and decrease the pro-
duction of pro-inﬂammatory mediators in models of neuro-
pathic pain (Tanga et al., 2005; Lan et al., 2010).
Importantly, the involvement of TLR4 in the development
and maintenance of chronic pain has also been demon-
strated in a human model. A low intravenous dose of
LPS sensitized nociceptors to a subsequent capsaicin
challenge and participants experienced an increase in
capsaicin-dependent ﬂare, allodynia and hyperalgesia
however the eﬀect of LPS on neurons in this study is likely
to be mainly indirect (Hutchinson et al., 2013). These ﬁnd-
ings have been extended to include the contribution of
TLR2 and TLR3 to central nervous system preclinical pain
models (Kim et al., 2007; Obata et al., 2008; Mei et al.,
2011). TLR3 (Liu et al., 2012) and TLR7 (Park et al.,
2014) activation has also been shown to directly activate
peripheral sensory neurons in the murine DRG. Early
research in this ﬁeld has focussed mainly on TLR4 how-
ever more TLRs are emerging as important mediators of
pain hypersensitivity. Whilst the role, for example, of
TLR7 in clinical pain models has yet to be studied, periph-
eral blood mononuclear cells from chronic pain patients
display increased responsiveness to TLR7 ligand stimula-
tion, as well as TLR2 and TLR4 (Kwok et al., 2012).
Based on the ﬁndings of the current study, plus others,
it is likely that TLR activation may occur directly and
preferentially on nociceptors without the necessary
intervention of the innate immune system. The ability of
neurons to directly detect and respond to pathogenic
ligands represents a rapid response mechanism that
has signiﬁcant consequences for acute nociceptor
activation, sensitization and altered neuronal/non-
neuronal cell communication. There is also potential for
sensory neurons to detect DAMPs (Goh and Midwood,
2011) and this has been demonstrated in TG (Ohara
et al., 2013) and DRG (Miller et al., 2014; Park et al.,
2014) sensory neurons. Following TLR4 activation, for
example, peripheral sensory neurons display increased
excitability (Ochoa-Cortes et al., 2010; Due et al., 2012),
sensitization of TRPV1 and potentiation of TRPV1-
dependent neuropeptide production (Diogenes et al.,
2011; Ferraz et al., 2011). Various pro-inﬂammatory
mediators are also induced downstream from TLR4 acti-
vation (Ochoa-Cortes et al., 2010; Tse et al., 2014a).
Neuronal TLR7 activation induces rapid inward currents
and action potentials to increase neuronal excitability
through mechanisms involving TRPA1 (Liu et al., 2010,
2012; Park et al., 2014). An up-regulation and sensitiza-
tion of TRPV1 and induction of pro-inﬂammatory media-
tors is also observed following neuronal TLR7 activation
(Qi et al., 2011). It is likely that these mediators can fur-
ther act through autocrine and/or paracrine mechanisms
to further alter nociceptive responses and contribute to
the local inﬂammatory response (Opree and Kress,
2000; Sommer and Kress, 2004; Binshtok et al., 2008;
Milligan and Watkins, 2009; Uceyler et al., 2009; Zhang
et al., 2011; Ji et al., 2013).
This study is the ﬁrst to demonstrate a co-localization
between TLR4 and TLR7 with P2X3-expressing neurons.
P2X3 activation, by ATP, induces rapid nociceptor
depolarization which plays a prominent role in the
sensitization of nociceptors and alteration of neuronal/
non-neuronal cell communication following the onset of
neuroinﬂammation (Fabbretti, 2013). It is known that
LPS evokes an up-regulation and sensitization of P2X3
receptors in primary TG neuron cultures although it is
not known whether this is through a direct action on neu-
rons or secondary to the activation of non-neuronal cells
and subsequent release of ATP and inﬂammatory media-
tors (Franceschini et al., 2013). Here we show that a large
proportion of P2X3-positive neurons co-express TLR4
and TLR7 suggesting that bacterial and viral infection,
respectively, could directly modulate P2X3 receptor func-
tion. We suggest that the activation of TLR4 and TLR7
could be suﬃcient to sensitize P2X3 in a similar manner
to that of TLR4-dependent TRPV1 sensitization.
The exact composition of the TLR4 co-receptor
complex that is required for neuronal TLR4 activation
remains unclear. The co-localization of TLR4 with the
co-receptor CD14 has been identiﬁed in capsaicin-
responsive nociceptors within the TG (Wadachi and
Hargreaves, 2006) and the involvement of CD14 in neuro-
pathic pain has been demonstrated (Cao et al., 2009).
However there is conﬂicting evidence as to whether MD-
1 or MD-2 is involved in neuronal TLR4 signaling. In
innate immune cells the TLR4 receptor complex consists
of TLR4, CD14 and MD-2 (Akashi-Takamura and Miyake,
2008). MD-1, a MD-2 homolog, normally forms a complex
with RP105, a TLR4 homolog that lacks an intracellular
Toll/Interleukin-1 receptor (TIR) homology domain
(Medzhitov, 2001). One study has shown that neuronal
TLR4 interacts with MD-1 rather than the conventional
co-receptor MD-2 (Acosta and Davies, 2008). This latter
study also showed lack of MD-2 expression in DRG sen-
sory neurons. However more recent studies have identi-
ﬁed both MD-1 and MD-2 mRNA and protein expression
in DRG nociceptors and shown a preferential co-
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localization of TLR4 with MD-2 (Ochoa-Cortes et al.,
2010; Tse et al., 2014a). The present study shows that
acutely dissociated TG sensory neuron preparations
express TLR4, CD14, MD-1, MD-2, MyD88 and TRAM
mRNA. This in agreement with Tse et al. (2014a) and
Ochoa-Cortes et al. (2010) that sensory neurons express
both MD-1 and MD-2. MyD88 and TRAM are also
expressed by sensory neurons suggesting that both the
MyD88-dependent and MyD88-independent branches of
the TLR4-signaling pathway are available following neu-
ronal TLR4 activation. MyD88-dependent signaling down-
stream of neuronal TLR4 and Interleukin-1b (IL-1b)
receptor activation has been shown (Davis et al., 2006;
Qi et al., 2011; Tse et al., 2014a) however the role of
MyD88-independent signaling in peripheral sensory neu-
rons is yet to be demonstrated. Given that the acutely dis-
sociated sensory ganglia cell preparations used in this
study contain a proportion of non-neuronal cells and we
have shown that a small number of satellite cells display
TLR4-IR it is therefore not possible to directly assign this
expression purely to neurons. However, given the TLR
expression patterns observed in this study as well as
the techniques used when dissociating ganglia we believe
that it is reasonable to suggest that the gene expression is
largely neuronal. It is worth noting that co-receptor com-
ponents, such as MD-2 and CD14, exist in soluble forms
that are secreted from cells to actively participate in the
LPS response (Bazil et al., 1989; Visintin et al., 2001).
Therefore co-receptor components do not necessarily
need to be expressed by neurons to mediate neuronal
TLR4 signaling, a phenomenon which has been demon-
strated in lung epithelial cells (Kennedy et al., 2004).
In monocytes, the group of phospholipid modifying
enzymes known as lysophosphatidylcholine
acyltransferases (LPCAT) is essential for the TLR4
response (Schmid et al., 2003; Jackson et al., 2008).
TLR4 associates with lipid raft membrane domains, in
an LPCAT-dependent manner, in order to activate intra-
cellular signaling cascades (Triantaﬁlou et al., 2002;
Jackson et al., 2008). We have investigated whether
speciﬁc isoforms of this enzyme, LPCAT1 and LPCAT2,
are present in mammalian sensory ganglia and may
therefore be involved in neuronal TLR signaling. Although
multiple studies show that neuronal TLRs are functional, it
is yet to be demonstrated that neuronal TLRs associate
with lipid raft microdomains, as is seen in innate immune
cells, to initiate these responses. Both isoforms are
expressed within sensory ganglia however each displays
a distinct expression pattern within the tissue. Approxi-
mately half of all TG sensory neurons counted in this
study expressed LPCAT1. The expression of LPCAT1
was not exclusive to any one particular sub-population
of sensory neuron; LPCAT1 co-localized to a proportion
of TRPV1-, P2X3- and NF200-positive neurons within
the TG. This suggests that LPCAT1 does not speciﬁcally
mediate TLR4 signaling in sensory neurons and we sug-
gest that LPCAT1 may play a role in more general mem-
brane physiology common to all sensory neuron
populations. Interestingly, we demonstrate a complete
absence of LPCAT2 expression in sensory neurons within
the naı¨ve TG, suggesting little/no LPCAT2 activity in neu-
rons under normal conditions. Therefore, based on the
results presented in this study, we cannot suggest a role
for LPCATs in neuronal TLR signaling. It has however
been shown that, unlike LPCAT1, LPCAT2 is an inducible
enzyme and both the expression and PAF synthesizing
activity of LPCAT2 is up-regulated following LPS priming
in monocytes (Shindou et al., 2005). Indeed, the expres-
sion of LPCAT2 has been identiﬁed in sensory neurons
and non-neuronal cells in the DRG and spinal cord follow-
ing nerve injury (Hasegawa et al., 2010; Okubo et al.,
2012). Therefore nerve injury appears suﬃcient to provide
a priming signal that increases LPCAT2 expression within
peripheral and spinal sensory neurons. It is not known
whether LPS exposure is suﬃcient to induce LPCAT2
expression in neurons and understanding this may be
key to uncovering an association of LPCAT2 with neu-
ronal TLR4 signaling.
CONCLUSIONS
The full extent of direct pathogen-neuron interactions is
unknown and recently a mechanism for direct activation
of nociceptors by bacterial N-formylated peptides and
the pore-forming toxin a-hemolysin was identiﬁed (Chiu
et al., 2013). Pain experienced in a murine model of Sta-
phylococcus aureus skin infection correlated with bacte-
rial load rather than immune involvement (Chiu et al.,
2013). Therefore, direct pathogen-neuron interactions
may play a more prominent role in the onset of pain
hypersensitivity and may not be as reliant on immune cell
involvement as was previously thought. A growing body of
evidence suggests that TLRs expressed by nociceptors
are able to directly inﬂuence nociceptor function and con-
tribute to a neuroimmune signaling network involving neu-
rons, non-neuronal and immune cells that act both
centrally and peripherally to maintain chronic pain hyper-
sensitivity. In this study we have described in detail the
expression of TLR4, TLR7 and other TLR-associated
molecules within the adult mammalian TG and DRG.
Our results support a mechanism whereby nociceptors
can directly detect and respond to pathogenic challenge
independent of innate immune activation.
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Conferences attended
Conference presentations:
2015:
September: Cardiff, UK. British Society for Oral and Dental Research Biennial
Meeting.
Poster presentation: (Commendation - Unilever Poster Prize)
Direct bacteria-neuron interaction via Toll-Like Receptors: consequences for oro-
facial pain.
September: Plymouth, UK. Biomedical and Healthcare Science Research Day
Poster presentation:
TLR2-dependent production of pro-inflammatory cytokines in trigeminal sensory
neurons.
May: Edinburgh, UK. British Neuroscience Association Annual Meeting
Poster presentation:
Lipopolysaccharide-induced production of pro-inflammatory cytokines in trigem-
inal ganglion neurons via Toll-like receptor activation.
February: Amsterdam, Netherlands. Oral Microbiology and Immunology Group
Postgraduate Prize Meeting
Oral presentation:
Lipopolysaccharide-induced production of pro-inflammatory cytokines in trigem-
inal ganglion neurons via Toll-like receptor activation.
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Conferences attended
2014:
September: Dubrovnik, Croatia. Pan European Regional Congress of the Interna-
tional Association for Dental Research.
Poster presentation:
Toll-like Receptor & Co-receptor Expression in Trigeminal Sensory Neurons.
September: Plymouth, UK. Systems Biology Suite Open Day.
Poster presentation:
Toll-like Receptor & Co-receptor Expression in Trigeminal Sensory Neurons.
July: Plymouth, UK. PU PSMD Research Day.
Poster and Oral presentation: (Winner - Best Poster Prize)
Expression of Toll-like Receptors & Associated Molecules in Trigeminal Ganglion
Sensory Neurons.
February: Plymouth, UK. Transfer Presentation
Oral presentation:
Expression of Toll-like Receptors & Associated Proteins in Dorsal Root and Trigem-
inal Ganglion Sensory Neurons.
2013:
September: Bath, UK. British Society for Oral and Dental Research Biennial
Meeting
Oral presentation:
Expression Patterns of TLR Complex Components Within Trigeminal Sensory
Neurons
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Conferences attended
July: Plymouth, UK. Centre for Research in Translational Biomedicine Research
Day
Poster presentation:
Expression Patterns of Toll-like Receptor 4 Complex Components within Trigem-
inal Sensory Neurons.
March: Torquay, UK. Peninsula Schools of Medicine and Dentistry Annual Re-
search Event
Oral presentation:
Neuronal Toll-like Receptors: Mediators of Nociceptor Sensitisation?
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C. Neuronal culture optimisation
Purpose
As stated in the main methods section of this thesis, the protocol used to isolate
and culture sensory neurons was adapted from Malin et al. (2007). Multiple
adaptions were made to this original protocol in order to meet the requirements
of the experiments performed. These are detailed below.
Percoll spin
As stated in the original protocol, the procedure for isolating rat TG is slightly
different to that regarding murine TG. The recommended Percoll gradient for
murine tissue is 12.5%/28% whereas, for rat tissue, it is 30%/60% (Eckert et al.
1997). Therefore this latter composition was selected for use. Following the first
Percoll spin, neurons are mainly located at the 30%/60% interface as well as
within the 30% layer. A thick ‘axon matt’ is formed on top of the 30% layer (see
Fig. 2.1. Eckert et al. (1997) also recommend harvesting this ‘axon matt’ and
performing a second Percoll spin in order to maximise the final neuronal yield.
Initially this was performed however the neuronal cultures performed using this
method contained a large proportion of cellular debris. In order to remove this
debris an optimisation experiment was performed whereby individual layers of
harvested cells were isolated and cultured individually.
The 30%/60% interface from the first Percoll spin, the 30% layer from the first
Percoll spin and the 30%/60% interface from the second Percoll spin were isolated,
cultured under the same conditions as previously described and examined using
phase contrast microscopy. Both the first interface (Fig. C.1) and 30% layer (Fig.
C.2) contained a larger neuron:debris ratio compared to the second interface (Fig.
C.3). The second interface also added an extra 30 min to the protocol. Given
the extra time required for the second Percoll spin and the low yield of neurons
obtained, the second Percoll spin was removed from the protocol.
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Figure C.1. Phase micrograph of the 30%/60% interface harvested from the first Percoll spin.
Figure C.2. Phase micrograph of the 30% layer harvested from the first Percoll spin.
Figure C.3. Phase micrograph of the 30%/60% interface harvested from the second Percoll spin.
Culture media
The original protocol recommends the use of F12 culture media, supplemented
with foetal calf serum and Pen/Strep, for the maintenance of isolated neurons.
This was used initially however a very limited amount of neurite outgrowth was
observed (see Fig. C.4). Therefore this media was replaced with NBA media
supplemented with 2% v/v B-27, 0.5 mM GlutaMAX, 1% v/v Pen/Strep. A
further reason for this change in media was to eliminate the need to use serum.
Serum is known to contain multiple substances, including NGF for example, that
216
C. Neuronal culture optimisation
can alter neuronal function. B-27 serum-free supplement was therefore used in
combination with extra glutamine in order to support neuronal survival in vitro.
The observed amount of neurite outgrowth using NBA media was much higher
than previously observed (see Fig. C.5).
Figure C.4. Phase micrograph of neurons maintained in complete F12 media.
Figure C.5. Phase micrograph of neurons maintained in complete NBA media.
Conclusions
From these optimisation experiments it was concluded that the second Percoll
spin should be removed from the isolation protocol and that NBA, serum-free
culture medium better supports the survival and regeneration of primary sensory
neurons in vitro. The final protocol for the isolation and culture of rat TG neurons
is detailed below.
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Protocol for the isolation and culture of rat primary sensory neurons.
Stocks required for culture:
• Laminin stock (200 µg/mL). Reconstitute 5 mg laminin powder in 5 mL
HBSS and mix thoroughly. Aliquot at 100 µL and store at -20 °C.
• Poly-D-lysine stock (2 mg/mL). Reconstitute 5 mg poly-D-lysine powder in
2.5 mL sterile water and mix thoroughly. Aliquot at 20 µL and store at -20
°C.
• Papain stock (5 mg/mL). Reconstitute 50 mg papain powder in 10 mL
sterile water and mix thoroughly. Calculate the volume equivalent of 60 U
depending on the specifications of the batch. Aliquot and store at -20 °C.
• L-cysteine stock (6.67 mg/mL). Weigh out 20 mg of L-cysteine powder and
add 1.5 mL HBSS. Mix thoroughly, aliquot at 150 µL and store at -20 °C.
• Collagenase stock (50 mg/mL). Reconstitute 50 mg collagenase type II pow-
der in 1 mL HBSS and mix thoroughly. Aliquot at 200 µL and store at -20
°C.
Materials preparation:
• Soak glass coverslips in 1% v/v phosphate-free detergent for approximately
3 h. Wash 5x 10 min in sterile water and allow to air dry in a fume hood.
Wrap 7 coverslips in a small amount of foil and sterilise in the hot air oven
overnight.
• Fire polish the tips of glass pipettes using a bunsen burner until the bore
is visibly rounded but a clear hole is still visible. Allow to cool to room
temperature. Silicon coat the pipettes by pipetting RepelCote solution 3
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times. Expel as much of the solution as possible and allow to dry with the
fine tip facing upwards in a fume hood. Sterilise in a hot air oven overnight.
Day prior to culture:
• Thaw one aliquot of laminin and poly-D-lysine on ice. Add 100 µL of laminin
stock and 10 µL of poly-D-lysine stock to 890 µL HBSS and mix thoroughly.
This coating solution must be used within 10 min.
• Add one coverslip to each well of a 6 well plate and add 100 µL of coating
solution to each coverslip, ensuring that the entire coverslip is covered.
• Incubate the coverslips overnight at 4 °C.
Day of primary culture:
Solution preparation (For 1 animal, 2x TG)
1. Add 500 µL Pen/Strep stock and 1 mL HEPES stock to a final volume of
50 mL L15 medium.
2. Add 400 µL B27 stock, 200 µL Pen/Strep stock and 50 µL GlutaMAX stock
to a final volume of 20 mL NBA medium.
3. Prepare papain solution by adding 923 µL papain stock (amount equivalent
to 60 U, changes with each new batch), 150 µL L-cysteine stock and 3 µL
saturated sodium bicarbonate to 424 µL HBSS.
4. Prepare collagenase/dispase solution by adding 14 mg dispase and 200 µL
collagenase stock to 2.8 mL HBSS. Mix thoroughly.
5. Prepare trypsin inhibitor solution by adding 7 mg trypsin inhibitor to 7 mL
HBSS. Mix thoroughly.
6. Incubate L15, NBA, papain and collagenase/dispase at 37 °C. Incubate
219
C. Neuronal culture optimisation
trypsin inhibitor at 4 °C.
7. For each animal that is to be dissected, fill a 15 mL tube with 1.5 mL HBSS
and keep on ice.
8. Fill small Petri dish with HBSS and keep on ice.
Tissue dissection
9. Perform schedule 1 on adult rat by rising concentration of CO2 and confirm
the permanent cessation of a heartbeat.
10. Transcardially perfuse with chilled HBSS for approximately 5 mins.
11. Dissect the two trigeminal ganglia and place in the Petri dish on ice.
12. Repeat the above process if more tissue is required.
13. Chop tissue into approximately 10 pieces and transfer to 15 mL tubes con-
taining HBSS on ice.
Tissue dissociation
14. During the below enzyme incubation stages make the Percoll gradient. Make
one complete gradient per animal. For the 30% layer, add 1.2 mL Percoll
to 2.8 mL warm L15 media in 15 mL tube. For the 60% layer, add 2.4 mL
Percoll to 1.6 mL warm L15 media in 15 mL tube.
15. Gently layer 30% layer on top of the 60% layer using a plastic Pasteur
pipette. This should be done slowly and carefully to ensure the two layers
do not mix. A clear interface between the two layers should be visible. Store
at room temperature.
16. Add 1.5 mL of pre-warmed papain solution to each 15 mL tube and mix
thoroughly.
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17. Incubate at 37 °C for 20 min with vigorous mixing halfway.
18. Centrifuge at 800 x g for 5 min.
19. Remove supernatant and resuspend pellet in 3 mL collagenase/dispase so-
lution.
20. Incubate at 37 °C for 20 min with vigorous mixing halfway.
21. Remove trypsin inhibitor from the fridge and warm to 37 °C during this
incubation.
22. Add 3 mL warm trypsin inhibitor to the tissue to inactivate the enzymes.
23. Centrifuge at 800 x g for 5 min.
24. Remove supernatant and add 500 µL of warm L15 media.
25. Pre-wet a silicon-coated, flame-polished glass pipette with L15 media.
26. Triturate tissue 8-10 times being careful not to introduce air bubbles. The
solution should become cloudy but small tissue chunks may still be visible.
27. Gently layer this cloudy suspension onto the Percoll gradient and centrifuge
at 1800 x g for 10 min.
28. During this spin, remove the coverslips and cell culture-grade water from
the fridge and warm to room temperature.
29. Following the Percoll spin a cloudy layer should be discernible at the 30%/60%
layer interface. A thick, white layer will be located on top of the 30% layer
(see Fig. 2.1). Discard this first layer, trying to remove as much of the
debris as possible.
30. Collect the cloudy layer at the 30%/60% layer interface and dilute into 12
mL L15 media. Mix thoroughly.
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31. Centrifuge at 1800 x g for 6 min to pellet the cells.
32. During this spin remove coating solution from the coverslips and wash 2x
with cell culture-grade water. Remove final wash and air dry coverslips.
33. Remove supernatant and resuspend pellet in 75 µL NBA medium per cov-
erslip.
34. If processing multiple animals, pool the final cell pellets together before
plating.
Cell culture
35. Add 75 µL of cell suspension to each coverslip in a ring or doughnut shape.
This will prevent cells from grouping together on the middle of the coverslip.
Mix cells thoroughly before adding to coverslip.
36. Incubate at 37 °C, 5% CO2 for 2 h to allow cells to adhere.
37. Add 3 mL of warm NBA media to each well.
38. Maintain cells in culture at 37 °C, 5% CO2.
222
223
224
Appendix D
Real-time PCR optimisation
225
226
D. Real-time PCR optimisation
Quantity of template
Before performing the main qPCR experiments in it was necessary to optimise
the amount of template (cDNA) that was loaded into each reaction so that the
CT values of each target were within a suitable range. Further, due to the limited
amount of RNA obtained from one culture preparation (roughly 18 µL of RNA at
a concentration of 10 µg/mL) optimisation was required to determine a suitable
number of target genes and total reactions performed for each sample. The master
mix and PCR run conditions were pre-optimised by the supplier as probe (either
TaqMan or geNORM) sets were used. Therefore, using the reaction conditions
detailed in chapter 2.11, the CT values of CD14 and MD-1 were determined when
loading 1.25 ng, 2.5 ng and 5 ng of template into each reaction. Reactions were
run in duplicate.
For both target genes the CT values increased as the amount of template was
decreased (see Fig. D.1). CD14 had a higher CT value when compared to MD-
1 for each of the three conditions. From these optimisation experiments it was
decided that 2.5 ng of template cDNA would be loaded into each reaction. This
allowed each of the 7 target genes (4 genes of interest and 3 control genes) to be run
in triplicate with enough sample remaining to repeat the run if necessary.
Probe efficiencies
For the cytokine gene expression experiments performed in chapter 4 the am-
plification efficiencies of the primer and probe sets were considered. Efficiencies
were calculated using an algorithm based on the kinetics of each individual re-
action without the need for a standard curve (Zhao & Fernald 2005). This was
performed on PCR miner online software. Efficiencies were calculated for each ex-
periment and the mean efficiency updated accordingly. Efficiencies can be found
below in table D.1.
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(a) CD14
(b) MD-1
Figure D.1. Amplification graph showing the CT values of CD14 (a) and MD-1 (b) when loading
1.25 ng (green), 2.5 ng (yellow) and 5 ng (red) of template into the reaction.
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Table D.1. Calculated efficiencies for primer/probe sets used for qPCR.
Target Mean
efficiency
n Standard
deviation
Standard
error
TNFα 1.7997 27 0.0114 0.0022
IL-1β 1.8911 27 0.0239 0.0046
IL-6 1.8726 27 0.026 0.005
IFNβ 1.8481 27 0.0123 0.0024
GAPDH 1.7723 27 0.0082 0.0016
ACTB 1.7658 27 0.0169 0.0033
18s 1.7051 27 0.0348 0.0067
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E. E. coli LPS positive control
Purpose
The bio-activity of the E. coli LPS, used in chapter 4.2.4, was demonstrated by
exposing the murine macrophage cell line RAW 264.7 cells to LPS and measuring
the change in TNFα gene expression.
Methods
RAW 264.7 cells were plated at a density of 1 ×105 cells per well in a 6 well
plate in DMEM culture medium (10% foetal calf serum, 1mM L-glutamine) and
allowed to adhere overnight. The following day, culture media was removed and
cells were exposed to 1 µg/mL of LPS for 2 hours. Cells were then processed for
qPCR as described previously in chapter 2.11.
qPCR was then performed to measure the gene expression of TNFα relative to
the endogenous control gene GAPDH. 12.5 ng of template (in 3 µL) and 9 µL of
master mix (containing 6 µL Fast SyBr Green master mix, 0.5 µL of primer mix
(containing 10 µM of each the forward and reverse primers) and 2.5 µL water) were
loaded into each reaction (TNFα forward: AGGACCCAGTGTGGGAAGCT, re-
verse: AAAGAGGAGGCAACAAGGTAGAGA. GAPDH forward: CCTCGTC-
CCGTAGACAAAATG, reverse: TCTCCACTTTGCCACTGCAA). Each reac-
tion was run in duplicate. Run conditions: 95 °C for 10 min, 40 cycles of 95 °C
for 30 s and 60 °C for 1 min. Melt curve: 95 °C for 15 s, 60 °C for 1 min, 95 °C
for 15 s.
Analysis was performed as described in chapter 2.11.4. The calculated efficiencies
for the TNFα and GAPDH primers were 1.792 and 1.669, respectively.
Results
TNFα was up-regulated by 33.92 fold following exposure to E. coli LPS (Fig. E.1).
Melt curve analysis for each primer pair produced a single peak (Fig. E.2).
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Figure E.1. Relative gene expression of TNFα in RAW 264.7 cells induced by E. coli LPS (1
µg/mL, 2 h). TNFα mRNA is up-regulated by exposure to E. coli LPS. Data is presented as
mean of reactions run in duplicate, n = 1.
(a) TNFα
(b) GAPDH
Figure E.2. Melt curve analysis of TNFα and GAPDH primers. A single peak is observed for
each primer pair.
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Conclusions
This preliminary experiment shows that the E. coli LPS used is able to induce
an expected response in a well characterised cell line. This suggests that the
results presented in chapter 4.2.4.1 are a true reflection on the physiological situ-
ation.
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